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Abstract 
 
Malaria, caused by Plasmodium spp., causes ~1 million deaths each year and there are 
ever present problems due to drug resistance. In this work, I used drug-repositioning 
strategy with bisphosphonates to discover a lead that is active against malaria in vivo. The 
developmental procedures include, in vitro high throughput screening, x-ray 
crystallography and other biophysical techniques. First, a computational method was 
developed to elucidate the target of bisphosphonate in malaria parasite and, second, in-
house synthesized library of prenyl synthase inhibitors was used to find the lead, an 
analog of zoledronate, against the parasite, which the x-ray structure bound to target 
enzyme, farnesyl diphosphate synthase (FPPS), was solved. Also, the effect of lipophilic 
bisphosphonate against liver stage malaria parasite was investigated. Lastly, I studied the 
mechanism and inhibition of IspH, the last enzyme of nonmevalonate pathway, for 
discovery of a novel target for infectious disease.  
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Chapter 1 
Isoprenoid Biosynthesis Pathway as Drug Target 
 
1.1 Isoprenoid Pathway  
Isoprenoids are the largest class of natural products consisted by more than 50,000 distinct small 
molecules(1), and among numerous enzymes that are involved in isoprenoid biosynthesis are 
validated drug targets. One of the most well known example is statin (Lipitor), which targets the 
early step of cholesterol biosynthesis. Bisphosphonates, such as Fosamax, are used to treat bone 
resorption disease and targets the enzyme farnesyl diphosphate synthase (FPPS) in the middle 
stage of isoprenoid biosynthesis, while anti-infectives such as Lamisil targets downstream 
enzyme of sterol biosynthesis in yeasts and fungi. The initial step of isoprenoid pathway is the 
formation of isopentenyl diphosphate (1, 
IPP) and dimethylallyl diphosphate (2, 
DMAPP). Pathogenic bacteria and 
protozoan such as Mycobacterium 
tuberculosis and Plasmodium falciparum uses the Rohmer or nonmevalonate pathway to produce 
IPP and DMAPP(2), but incase of humans and bacteria such as Staphylococcus aureus, they are 
formed by the mevalonate pathway(3)(Figure 1.1). In the nonmevalonate pathway, the last two 
enzymes are IspG (GcpE) and IspH (LytB), containing Fe4S4 clusters(4, 5) to carry out reduction 
reactions from 2-C-methyl-D-erythritol-2,4-cyclo-diphosphate (MEcPP) to E-1-hydroxyl-2-
methyl-but-2-enyl 4-diphosphate (HMBPP) and HMBPP to IPP and DMAPP (shown in Figure 
1.1). 
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After IPP and DMAPP are formed, condensation of two products via a “head-to-tail” mechanism 
produces geranyl diphosphate (GPP) and farnesyl diphosphate (FPP) by FPPS and further 
reaction with IPP catalyzed by the enzyme geranylgeranyl diphosphate synthase (GGPPS) yields 
the C20 species, geranylgeranyl diphosphate (GGPP)(6, 7), shown in Figure 1.1. After FPP and 
GGPP are formed, they are used in protein prenylation, known to be important for cell survival 
and signaling pathway. FPP and GGPP can also condensed to form squalene via presqualene 
diphosphate(8) or phytoene via prephytoene diphosphate. 
In many organisms, squalene is converted to squalene epoxide by squalene epoxidase (SE) 
which then cyclized to form lanosterol and amiodrone targets the site as inhibition of action, 
shown in Figure 1.1. After couple of additional steps, lanosterol is converted to cholesterol in 
humans and ergosterol or episterol in yeasts, fungi, and protozoa. In S. aureus, dehydrosqualene, 
cis form of squalene, is converted to a carotenoid pigment, staphyloxanthin(9), a virulence factor 
responsible for protecting the organism from reactive oxygen species from its host. In Figure 1.1, 
several additional enzymes in the isoprenoid pathway that are known to be important targets of 
well-known inhibitors are depicted. By elucidating their structures, mechanism of action and 
inhibition, designing of novel inhibitors can take place in knowledge-based fashion. 
 
1.2 FPPS and GGPPS: Structure, Mechanism and Inhibition 
Through the nonmevalonate or mevalonate pathway, IPP and DMAPP are produced and further 
condensed by FPPS and GGPPS to form FPPS and GGPPS, as shown in scheme below.  
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In the pathway, the bisphosphonate class of drugs targets FPPS to treat bone resorption disease, 
but for over decades the target enzyme and their mechanism of action were unknown. The 
interest from our group in the system was drawn from couple of unexpected observations.  First, 
with collaborations with Urbina and Docampo(10), we discovered that Trypanosoma cruzi 
contained very high levels of condensed phosphate, such as diphosphate, shown below. Such 
discovery led us to explore nonhydrolysable PPi analogs such as pamidronate and risedronate 
(Actonel) could possibly inhibit parasite cell growth. In fact, this turns out to be the case(10, 11), 
but the enzyme target for these inhibitors were still unknown. The second observation was that 
nitrogen-containing analogs of 
GPP such as 4, was found to be a 
potent inhibitor of terpene 
cyclases and the overall structure 
resembles that of ibandronate. 
This observation suggests that cationic bisphosphonates could act as carbocation/diphosphate 
isosteres, blocking isoprenoid biosynthesis(12). The last of initial observation was that 
compound such as 3 was a herbicide developed by Zeneca(13) and was found to be a low 
nanomolar inhibitor of a daffodil FPPS(13). Since 3 was previously known to be active against 
bone resorption(14), we concluded that the bone-resorption(15) drugs would act by mimicking a 
carbocation reaction intermediate. The target for such compounds were soon confirmed 
crystallographically by Hosfield et al(16). Fallowing work in our group showed that pamidronate 
is active against cutaneous leishmaniasis(17), Figure 1.2, by inhibiting FPPS which lead to 
blocking ergosterol biosynthesis(11), opening up the new era of clinical use of bisphosphonates 
as anti-infectives(18).  
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Further discovery of bisphosphonates showed killing of tumor cells(19) and activation of 
γδ T cells(20), which also targets to kill tumor cell(21). As a result, the interest on killing tumor 
cells resulted in small clinical trials on pamidronate(22) and zoledronate(23). Recent large scale 
clinical study of 1803 patients with breast cancer showed3 30% of reduction of recurrence of 
disease in patients treated with postsurgery plus zoledronate(24). Such drug-repositioning 
strategies are now under rigorous investigation in various fields of disease for further 
development and protozoa including malaria is now one of disease of interest. 
 
1.3 LytB (IspH): a Novel Target Containing Fe4S4-Cluster 
The nonmevalonate pathway is attractive site for drug development, since the pathway is not 
present in human but is essential for survival of pathogen, including Plasmodium falciparum and 
Mycobacterium tuberculosis, and currently fosmidomycin, targeting DXP reductoisomerase in 
the pathway (Figure 1.1), is under Phase III clinical trial. In the pathway, the last reaction of the 
pathway is carried out by the enzyme IspH(25, 26). Our collaborations with Jomaa and Ermler, 
we reported(27) that the overall structure of the enzyme is a unique, trefoil-like fold with Fe3S4 
cluster positioned at the center of the protein (Figure 1.3A, B) and a similar structure was again 
reported by Grawert et al(28). Both the reported structures contained 3Fe and not 4Fe, incoherent 
with the spectrum of electron paramagnetic resonance (EPR), chemical analysis, and activity 
results, which all pointed to an Fe4S4 cluster, so we carried out computational modeling approach 
to construct an Fe4S4 model and performed docking of HMBPP substrate to unique fourth Fe in 
oxidized IspH, via its 1-OH group(27), Figure 1.3C. 
Interestingly, recent X-ray crystallographic structure of LytB(29) shows that HMBPP does 
actually bind to 4Fe cluster via O-1 as proposed in our group, and the binding mode of HMBPP 
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to Fe4S4 generated from docking(27) is almost identical to that determined by X-ray 
crystallography, Figure 1.3D, with lignad RMSD of 0.3Å. But the catalytic mechanism of Fe4S4 
with 2H+/2e- reduction, the removal of the 1-OH oxygen to form the IPP and DMAPP, is not 
elucidated. Based on our crystallographic and bioinformatics investigation, we proposed(27) that 
E126 it the critical residue in catalysis, providing the H+ required for activity. The essential 
nature of E126 was then observed by other groups(28), and also by creating E126A mutant we 
though to “trap” the reaction intermediate which could be informative for drawing out the 
enzyme involved in catalytic mechanism. So we carried out EPR and electron-nuclear double 
resonance (ENDOR) spectroscopy(30). With extensive investigation on the LytB, we were able 
to understand in details on the catalytic mechanism, which could lead us to develop novel 
inhibitors against the enzyme that are known to be essential for deleterious pathogens.  
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1.4  Figures 
 
Figure 1.1. Drug targets and their inhibitors in the isoprenoid pathway 
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Figure 1.2. Effect of pamidronate on cutaneous leishmaniasis in mice (A) dose dependent 
inhibition on lesion progression; (B) cure of infection in treated mouse 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
Figure 1.3. Structural results for IspH (LytB): (A,B) crystal structure results for Aquifex aeolicus 
IspH; (C) initial docking pose for HMBPP to oxidized IspH Fe4S4 cluster obtained by using the 
“open-form” structure; (D) Comparison of HMBPP bound to IspH from X-ray (green) and 
docking (red).  
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Chapter 2 
Bisphosphonate Inhibition of a Plasmodium Farnesyl 
Diphosphate Synthase and a General Method for 
Predicting Cell-Based Activity from Enzyme Data 
 
 
2.1 Notes and Acknowledgements 
We thank Raymond Hui of the Structural Genomics Consortium (Toronto, Canada) for providing 
the P. vivax protein expression system. This work was supported by the United States Public 
Health Service (NIH grant GM65307). 
 
2.2 Introduction 
Malaria causes ~106 deaths annually, so there is considerable interest in developing novel drugs 
to treat this disease.  One pathway of interest is that involved in the isoprenylation of signaling 
proteins, where  protein-farnesyl transferase inhibitors have shown promise(1), since they act by 
preventing the post-translational modification of proteins such as Ras.  A second potential target 
involves inhibition of the enzymes (such as farnesyl diphosphate synthase, FPPS) that produce 
the isoprene diphosphates used in protein prenylation, and in recent work we showed that 
bisphosphonates, drugs that target FPPS and are widely used in treating bone resorption 
diseases(2), had both in vitro and in vivo activity against Plasmodium parasites(3, 4).  There 
were, however, some puzzling aspects to the results(4), in particular, the most active species 
against P. falciparum had little activity against a variety of expressed FPPS enzymes, while 
other, known potent FPPS inhibitors, had low activity against the parasite. 
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 There are three likely explanations for these observations.  First, it might be that FPPS is 
not the actual (or only) target.  Second, there might be surprising differences in the sensitivity of 
Plasmodium FPPS and human (or other) FPPS enzymes, since Plasmodium FPPS can also 
produce geranylgeranyl diphosphate (GGPP), due to a smaller barrier to chain elongation at the 
end of the binding site. Third, it might just be difficult to obtain good correlations between 
enzyme and cell inhibition data, due to neglect of “transport” issues.  This latter point is an 
exceptionally important one(5) and is of very broad general interest for drug development, since 
while enzyme inhibition assays can generally be carried out very rapidly (and accurately), cell 
based assays are more expensive and take much longer.  Indeed, in some cases, cell data may be 
essentially uncorrelated with enzyme inhibition.  A good recent example of this is that of the 
inhibition of undecaprenyl diphosphate synthase from Streptococcus pneumoniae reported by 
Peukert et al.(6), in which an R2 = 0.03 is found from the reported cell/enzyme pIC50 (= -log10 
IC50) results, obviously complicating lead optimization using enzyme based assays. 
 In this work, we report the inhibition of a Plasmodium FPPS (from P. vivax) by a library 
of 26 bisphosphonates whose activity against P. falciparum cell growth in vitro was reported 
previously(4).  The P. falciparum and P. vivax enzymes have very similar sequences (73% 
identity, 89% similarity) and catalytic site residues, but we find that there is essentially no 
correlation between the cell and enzyme pIC50 values (R2 = 0.06). We find, however, that 
regression of cell, enzyme, and two other descriptors leads to a remarkable improvement in the 
correlation between experimental and predicted cell pIC50 (to R2 = 0.74), suggesting that small 
descriptor sets might be used to predict cell activity results in many other systems, nine of which 
(including other anti-parasitic, anti-bacterial, anti-viral, anti-diabetic and anti-cancer drug leads) 
are investigated in this work. Overall, our results show that cell activity in 10 very varied 
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systems can be well predicted by using enzyme inhibition data, when combined with the 
combinatorial descriptor search approach.  
 
2.3 Results and Discussion 
We show in Figure 2.1 the structures of the 26 bisphosphonates (1-26) investigated 
previously(4).  These compounds have IC50 values in P. falciparum growth inhibition varying 
from 1.43 to 222 µM(4) with the most active species also having in vivo activity in a P. berghei 
ANKA suppressive test (up to an 80% reduction in parasitemia).  The IC50/pIC50 values in FPPS 
inhibition are presented in Table 2.1, together with the previously published cell growth 
inhibition results(4).  When the cell pIC50 and enzyme pIC50 values are compared, we see that 
there is essentially no correlation between the two data sets (R2 = 0.06), Figure 2.2a, resulting in 
a leave-2–out set of predictions having an R2=0.01.  For example, the most active species in 
FPPS inhibition is 15 (IC50 = 400 nM), but this compound has poor activity in vitro (33.6 µM, 
Table 2.1).  It might therefore be thought that FPPS is not the actual (or only) target for these 
bisphosphonates, or that there are small but significant differences in structure between the P. 
falciparum and P. vivax enzymes.  However, on further inspection of Figure 2.2a, there appear to 
be several possible “clusters” of compounds (A, B, C in Figure 2.2a), with the more active 
species in cells having more hydrophobic features.  For example, in cluster A, known 
bisphosphonates such as risedronate (20), ibandronate (16), zoledronate (23) and minodronate 
(17) all have very poor  (>70µM) cell activity (Table 2.1), even though they have good activity 
in the enzyme assay. Since these compounds are among the most hydrophilic ones investigated 
(with an average SlogP = -5.00, for 9 compounds in this cluster), it is possible that their poor cell 
based activity is due to poor transport. This idea receives support from the observation that a 
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second class of bisphosphonates (such as 13, 15; cluster B, with average SlogP = -4.60, for 5 
compounds) that have improved hydrophobicity also exhibit improved cell activity, and 
compounds which have the highest cell-based activity (1-6, Figure 2.1, Cluster C) also contain 
the most hydrophobic side chains (average SlogP = -3.60, for 10 compounds). But how can we 
put these qualitative observations on a more quantitative footing? Can we predict cell activity 
from the enzyme inhibition results? And if this turns out to be possible in the Plasmodium 
system: can the method be generalized to other systems, something that would be of very broad, 
general interest. 
The results shown in Table 2.1 and Figure 2.2a clearly indicate that there is essentially no 
correlation between the cell pIC50 and enzyme pIC50 values. Plus, the range in cell activity 
(~100x) is much larger than the range in enzyme inhibition (~5x range in IC50). Why is this?  
While, as noted above, there are several possibilities (other targets, poor P. vivax/P. falciparum 
similarity), the observation that many of the bisphosphonates investigated have similar enzyme 
inhibition activity at the same time that their cell-based activity covers a ~100x range, together 
with the observation that cell based activity appears to increase as hydrophobicity increases, 
suggests the possibility that cell permeability may be particularly important in governing overall 
cell activity.  To test this hypothesis, we chose to represent the cell based activity (pIC50 (cell)) 
mathematically as: 
 pIC50(cell) = a•pIC50(enzyme) + b SlogP + c (1) 
where SlogP is a computed oil/water partition coefficient. We chose Slog P (rather than say 
clogP, etc.) without any particular basis, a point we return to shortly.  Data were analyzed by 
using linear regression, from which we find a = 1.26, b = 0.62 and c = -0.34.  Now, when the 
pIC50 (cell, experiment) results are correlated with the predicted pIC50 (cell) results, we find a 
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good correlation between experiment and prediction, with an R2 = 0.66.  Given this promising 
result, we then sought to find other descriptors and descriptor combinations that might give 
improved predictivity, rather than restricting ourselves to SlogP. In some initial calculations we 
used enzyme pIC50 values together with 3 descriptors, or 4 random descriptors chosen from 
MOE(7), that gave the best experimental versus predicted R2 values. However, this approach was 
found to lead to over-fitting, since some predictions using randomized cell activity data had R2 
values of ca. 0.5.  We thus eventually chose the following equation: 
 pIC5 (cell) = a• pIC50 (enzyme) + b • B + c • C + d (2) 
in which two additional descriptors (B,C) were chosen from a combinatorial search, performed 
on a large set of descriptors (Table 2.4) in MOE(7). We chose to fix pIC50 (enzyme) as one 
descriptor, since the objective is to predict cell activity from enzyme activity, where standard 
QSAR and structure-based methods can be employed to optimize enzyme inhibition. There are 
230 descriptors available in MOE, and a full search and cross-validation of all (26,335) two-
descriptor combinations for a dataset containing 26 compounds is lengthy (~30 hours). However, 
we found that it was not necessary to use all the 230 descriptors, for two reasons: First, because 
some descriptors are linear combinations of other descriptors in the database. And second, 
because some descriptors are Boolean (with predominantly either zeros or ones) and do not 
contribute significantly in the linear regression. In the set of 26 P. vivax FPPS inhibitors, after 
eliminating redundant and Boolean descriptors, we obtained 150 descriptors, of which all 
combinations of two (B1, C1; B2, C2;……; B150, C150) were investigated, the coefficients 
(a…d) being determined via linear regression. The 10 descriptor combinations (pIC50; Bi; Cj) 
giving the highest R2 values (for the training set experimental versus predicted pIC50 correlation) 
are shown in Table 2.   
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         As can be seen in Table 2.2, the best experimental/predicted pIC50 correlation has an R2 = 
0.77 (Figure 2.2b), a major increase over the cell/enzyme correlation (R2 = 0.06) alone.  For the 
top 10 predictions, 9/10 contain a SlogP or logP(o/w) term, indicating the importance of 
hydrophobicity in cell based activity. And in 6/10 cases, this SlogP or logP(o/w) term has the 
largest relative contribution to the correlation (Table 2.2).  In the four cases where this term does 
not dominate, enzyme activity dominates, but as can be seen in Table 2.2, both enzyme pIC50 and 
logP-like terms are important in all cases, and the R2 range is very small, 0.74 to 0.77. So, both 
enzyme and “logP” contribute to cell activity, with the cell activity results apparently being well 
predicted based on the enzyme inhibition and two-descriptor model. Of course, considerable care 
needs to be taken in order to not over-fit data when using this approach. We tested this in several 
ways: First, we used a leave-two-out (L2O) method in which we systematically left out all 
possible pairs of data points (26C2=26x25/2 = 325 calculations), re-evaluating the a-d coefficients 
for all possible B, C descriptors (total time ~12 hours). The results of this L2O test set of 
predictions are shown graphically in Figure 2.2c, where we find an R2 = 0.74 for the 
experimental/predicted pIC50  test set correlation, close to the R2 = 0.77 for the training set 
(Figure 2.2b). Second, we scrambled the cell pIC50 values and repeated the L2O test set 
prediction, 10 times. On average, the R2 value was 0.16 for this scrambled test set, strongly 
supporting the idea that the approach, when applied to real cell growth inhibition data, is highly 
predictive. Using larger numbers of descriptors increased the R2 value for both the unscrambled 
and scrambled L2O data sets, and is not recommended, at least for relatively small data sets. 
 These results encouraged us to see to what extent this approach might enable us to 
improve cell activity predictions, based on enzyme activity and the combinatorial descriptor 
search, for a variety of other systems. We first chose to investigate two other systems we 
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reported on previously: Dictyostelium discoideum(8) (a eukaryote, used as a screen for bone 
resorption drugs that target FPPS), and Leishmania donovani(3, 9), a causative agent of visceral 
leishmaniasis.  Both systems (or very close relatives) have been shown by knockouts or 
overexpression to require FPPS, and that FPPS is the target for bisphosphonate drugs or 
inhibitors. 
 For Dictyostelium discoideum growth inhibition(8) the cell/enzyme R2 value is 0.49 
(Figure 2.3a) or R2 = 0.46 for a L2O enzyme only test set, and this increases to R2 = 0.70 for the 
training set, using two additional descriptors (Figure 2.3b; Table 2.5), with pIC50 (enzyme) being 
the most important contributor to the correlation.  This is not unexpected since, unlike the 
Plasmodium results, we do see a correlation between cell and enzyme data, Figure 3a.  The 
leave-two-out test set results (Table 2.3, Figure 2.3c) are likewise good (R2 = 0.70) and as with 
the Plasmodium results, the scrambled data set has essentially no predictivity (R2 = 0.07).  
Slightly improved results are obtained for Leishmania donovani cell growth inhibition.  Here, the 
raw cell/enzyme correlation is R2 = 0.55 (Table 2.3, Figure 2.3d), translating to a L2O enzyme-
based test set R2 = 0.47.  The experimental /predicted cell pIC50 correlation increases to R2 = 0.87 
for the training set using two additional descriptors (Figure 2.3e and Table 2.6) and 0.80 for the 
L2O test set results (Figure 2.3f), while using scrambled cell data yields R2 = 0.11 (Table 2.3).  
We should also note here that in both D. discoideum and L. donovani, FPPS inhibition results for 
the specific organisms were not available, so we used a composite data set of Trypanosoma 
brucei(10), T. cruzi(11), L. major(12) and human(13) FPPS results to model the D. discoideum 
and L. donovani data, just as we used P. vivax data to interpret the P. falciparum results. 
Naturally, it is reasonable to believe that using e.g. L. donovani FPPS to model L. donovani 
growth inhibition will be preferred to using e.g. L. major FPPS inhibition data. However, the 
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predictions are still good, with for P. falciparum, D. discoideum and L. donovani, the average R2  
value increasing from 0.37 (cell/enzyme L2O test set predictions) to 0.72, using pIC50 (enzyme) 
plus two descriptors, while the average R2 for the scrambled cell activity data sets is R2 = 0.11. 
But, given that all of the inhibitors studied here are bisphosphonates and the targets protozoa or a 
unicellular eukaryote, it is fair to ask: Is this method robust? Does it apply to other types of cell 
and inhibitor? Is it, in short, a general method for probing cell activity based on enzyme 
inhibition? 
Anti-bacterial and Anti-Viral Systems. 
To test the generality of this approach, we investigated two bacterial and two viral systems. In 
each case, the enzyme targeted in the enzyme assay was the same as that targeted in the cell 
based assay. In one recent study, workers at Novartis(6) reported the discovery of a series of 
novel inhibitors (tetramic, tetronic acids and dihydropyridin-2-ones) of the enzyme undecaprenyl 
diphosphate synthase (UPPS) that also had good cellular activity(6).  These inhibitors are of 
interest since UPPS is a potentially important target for anti-infective development, because 
undecaprenyl diphosphate is used in Lipid A biosynthesis, and UPPS inhibition is expected to 
block bacterial cell wall biosynthesis. Plus, the structures of some UPPS enzymes are now 
known(14, 15).  Streptococcus pneumoniae enzyme and (approximate) cell growth inhibition 
results (inhibition at 1 µM, 2 µM, 4 µM etc. inhibitor concentrations) were reported, but as with 
our Plasmodium results, there is little correlation between the cell growth and enzyme inhibition 
data sets (R2 = 0.03; Figure 2.3g), even though in this case the enzyme target (S. pneumoniae 
UPPS) is thought to be exactly the same as that present in the bacterium, Streptococcus 
pneumoniae(6).  The small range in cell activity (128x) combined with the limited precision of 
the cell data (the IC50 values were rounded off by factors of 2) makes this a challenging case. 
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Even so, using the reported enzyme pIC50 results together with two descriptors yields a 
considerable improvement, with R2 increasing from 0.10 for the L2O test set using enzyme data 
only, to R2 = 0.69 (Figure 2.3i) for the L2O test set predictions using two extra descriptors, with 
R2 for the L2O test set using scrambled data being 0.14, Table 2.3. As can be seen in Table 2.7, 
descriptors such as SlogP and logS (also found in the Plasmodium data sets) are again found here 
and, when combined with enzyme inhibition data, enable greatly improved predictions of the cell 
activity results. Another set of anti-bacterials are glutamic acid analogs that inhibit S. 
pneumoniae glutamate racemase (MurI)(16). In this case, there is a moderate correlation between 
cell growth and MurI inhibition (R2 = 0.61), and this increases to 0.72 (training) or 0.68 (leave-
two-out) test set predictions using the combinatorial descriptor search, Table 2.3 and Figure 2.4 
and Table 2.8, with the R2 for scrambled cell activity test set data being 0.13. 
 In addition to these results with anti-bacterial systems, we find good predictivity in an 
anti-viral assay using hepatitis C virus protease inhibitors(17). Here, there is again a very poor 
correlation between enzyme and cell pIC50 values (obtained in a cell-based replicon assay) with 
R2 = 0.03 (Figure 2.4d). This increases to R2 = 0.78 (training) and R2 = 0.77 (leave-two-out) test 
set results (Figures 2.4e and 2.4f) with incorporation of two additional descriptors. In this case, 
the best results were obtained by using PAMPA (parallel artificial membrane permeability assay) 
as one of the descriptors (determined experimentally by Li et. al.(17)). In these calculations, we 
added reported PAMPA, Caco-2, log P-neutral, log D-pH 7.4, clog P, and mlog P values to the 
230 potential descriptor fields in MOE, with PAMPA being selected in the descriptor search as 
the most important descriptor, followed by the enzyme pKi (Table 2.9). So, the predictivity of the 
method can be improved when experimental data on permeability is available. 
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 We also investigated a second series of anti-virals, novel phthalimide-analog inhibitors of 
HIV-1 integrase(18). The results of enzyme pIC50, HIV-1 replication in a cell-based assay 
(pEC50), as well as cell-based toxicity (pCC50) have been reported(18). There is only a very poor 
correlation between the enzyme pIC50 and cell-based replication activity (pEC50), with R2 = 0.12 
(Figure 2.4g; R2 = 0.01 for the L2O enzyme based test set). Using the combinatorial descriptor 
search, we find that pCC50 is the most important descriptor, enabling an experimental versus 
predicted pIC50 R2=0.69 (Figure 2.4h). That is, pCC50 makes the major contribution to the 
apparent cell (HIV) replication results (Table 2.10), an observation of interest for further 
optimization of this class of compounds. And on average, for the four anti-bacterial/antiviral 
systems, we see that R2 increases from 0.22 to 0.70 (L2O test sets) on addition of two 
descriptors, about the same as that found for the  protozoal/primitive eukaryote systems with 
scrambled cell data, R2 = 0.13, about the same as the R2 = 0.11 found with the protozoa/simple 
eukaryotes. 
Mammalian Cell Lines: Anti-Diabetic and Anti-cancer Drugs. 
Finally, we wanted to test the method described above on three mammalian cell lines, in diabetes 
and cancer assays, as opposed to the primarily anti-infective drugs/targets described in the 
preceding sections. We investigated three systems: acyl urea inhibitors of human liver glycogen 
phosphorylase (hlGP)(19) having activity in rat hepatocytes; 1,4-dihydroindeno[1,2-c]pyrazoles 
targeting a KDR kinase in NIH3T3 cells(20), and an indazole-pyridine series of protein kinase 
B/Akt inhibitors, active in pancreatic cancer cells(21). 
         In the case of the acyl urea inhibitors of human liver glycogen phosphorylase, the 
enzyme/cell correlation was already evident (R2= 0.55), and this improved to R2=0.74 for the 
L2O test set of 35 compounds, Table 2.3 and Figures 2.5a-c and Table 2.11. The scrambled data 
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was, as expected, not predictive, with an R2=0.19. Results for the KDR kinase (Table 2.3, 
Figures 2.5d-f and Table 2.12) were slightly worse (L2O test set R2=0.58), while results with the 
Akt kinase (Table 2.3, Figures 2.5g-i) were good, with an R2=0.68 for the test set (Table 2.13). 
 
2.4 Conclusions 
The results described above are of interest for several reasons.  First, we screened a library of 
bisphosphonates against a P. vivax FPPS enzyme.  The results were surprising since we found 
that inhibition of the P. vivax enzyme was essentially uncorrelated with growth inhibition by 
these same bisphosphonates of the malaria parasite, P. falciparum.  However, when pIC50 results 
together with two additional descriptors were regressed against cell growth inhibition pIC50 
results, we found good predictivity of the cell results, with an R2 = 0.77 (0.74 for a leave-two-out 
test set). This observation then led to a general method for predicting the cell-based activity of a 
compound from its activity in an enzyme assay, in which we use a combinatorial descriptor 
search to choose two descriptors (B,C) that, in combination with the enzyme pIC50 results, 
enabled relatively good cell activity predictions.  For the ten diverse systems investigated here, 
which cover anti-parasitic, anti-bacterial, anti-viral, anti-diabetes and anti-cancer drug 
candidates, the average R2 value increases from 0.28 for the leave-two-out test set predictions 
using solely enzyme inhibition data, to 0.70 for the leave two-out test sets with two additional 
descriptors, to be compared with 0.13 for predictions based on randomized cell activity data.  
This approach should be particularly useful in optimizing cell activity when target structures are 
known, since structure-based (x-ray, QSAR) methods can be used to optimize enzyme inhibition, 
with the combinatorial descriptor search then being used to make good predictions of cell based 
activity.  Plus, when experimental data on permeability is available, this can be included in the 
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descriptor field as another potential descriptor, to be used in cell activity predictions.  A larger 
number of descriptors than the (on average) 124 we employed can also of course be used, at the 
expense of computational time, which can become large (~300 hours for a 230 descriptor based 
series of calculations, including validation tests). The approach described above should thus 
enable the use of both crystallographic and enzyme QSAR data for enzyme inhibition 
optimization, with cell growth inhibition (or viral replication) activity being described using the 
combinatorial descriptor approach. The method should also be applicable in some cases to 
modeling toxicity and in vivo results as well, when sufficient data is available. 
 
2.5 Materials and Methods 
P. vivax FPPS expression and inhibition. 
A clone encoding P. vivax FPPS (PlasmoDB gene ID: Pv092040) with an N-terminally His6-
tagged fusion protein and a TEV protease site was expressed in E. coli BL21-codon Plus (DE3) 
RIL (Stratagene) at 20 °C in baffled flasks. Cells were lysed in the presence of lysozyme 
(Sigma), Benzonase® Nuclease (Novagen), and a protease inhibitor cocktail (Sigma), and 
protein purified chromatographically by using a Ni-NTA resin. The P. vivax FPPS assays were 
carried out by using 96-well plates with 150 µL reaction mixture in each well. The condensation 
of geranyl diphosphate (GPP) with isopentenyl diphosphate (IPP) was monitored at room 
temperature by using a continuous spectrophotometric assay for phosphate releasing enzymes in 
a reaction mixture containing 25 mM Hepes and 2.5 mM MgCl2 at pH 7.4. The inhibitors were 
preincubated with the enzyme for 30 min at room temperature. The IC50 values were obtained 
from fitting the dose-response curve using Prism 4.0(22). 
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Computational Aspects. 
We performed a complete combinatorial descriptor search in MATLAB(23) (running on a Dual 
2 GHz PowerPC G5 or a Dual-Core Intel Xeon Mac Pro) , using linear regression of enzyme 
pIC50 plus all possible two-descriptor combinations (150C2=11175 combinations for a database 
containing 150 descriptors, for example) against the cell activities,  pIC50(cell). For the leave-
two-out (L2O) cross-validation, the same exhaustive search was performed, using a training set 
obtained by leaving out two compounds from the initial data set. This process was repeated for 
all pair-wise combinations of the compounds (e.g. for 26 compounds, 1,2; 1,3;…1,26; 2,3; 2,4; 
….; 24,25; 24,26; 25,26). So, if there are 26 compounds (as in P. vivax), then each compound is 
left out (and predicted) 25 times. In this way, for P. vivax FPPS we obtained 25 predicted values 
for each compound in the dataset, and these were then averaged to give the overall leave-two-out 
predicted value, for each compound. To test whether the correlations obtained might occur by 
chance, we randomly scrambled the cell activities, then performed the leave-two-out validation 
on the scrambled data. The process was repeated 10 times and the mean R2 values are reported. 
For the 10 systems investigated, each scrambling analysis requires ~10-90 hours, depending 
upon the number of descriptors (80-150) and the number of compounds (21-102) in the data set. 
Linearly dependent descriptors were eliminated based on the occurrence of rank deficiency in the 
descriptor correlation matrix (in MATLAB23). 
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2.6 Tables and Figures 
Table 2.1. Experimental IC50 and pIC50 values for P.falciparum growth inhibition and P. 
vivax FPPS inhibition. 
 
Compounda IC50 (Enzyme, µM) pIC50 (Enzyme)b IC50 (Cell, µM) pIC50 (Cell)c 
1 0.63 6.20 1.43 5.84 
2 4.09 5.39 2.12 5.67 
3 0.61 6.21 2.9 5.54 
4 0.71 6.15 3.32 5.48 
5 0.68 6.17 3.82 5.42 
6 0.63 6.20 4.34 5.36 
7 0.63 6.20 6.43 5.19 
8 0.91 6.04 10.6 4.97 
9 0.69 6.16 11.1 4.95 
10 0.49 6.31 11.5 4.94 
11 0.88 6.06 22.1 4.66 
12 2.32 5.63 22.6 4.65 
13 0.45 6.35 22.8 4.64 
14 0.82 6.09 28.2 4.55 
15 0.4 6.40 33.6 4.47 
16 0.92 6.04 73.8 4.13 
17 0.64 6.19 90.2 4.04 
18 5.18 5.29 112 3.95 
19 0.71 6.15 115 3.94 
20 0.59 6.23 129 3.89 
21 0.78 6.11 131 3.88 
22 1.24 5.91 159 3.80 
23 0.79 6.10 167 3.78 
24 0.87 6.06 184 3.74 
25 98.62 4.01 200 3.70 
26 0.9 6.05 222 3.65 
a See Figure 2.1 for chemical structures 
b The enzyme assays were performed on FPPS from Plasmodium vivax 
c The cell assay data is for Plasmodium falciparum(4) 
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Table 2.2. Top ten “enzyme plus 2-descriptor” combinations with coefficients and 
relative contributions for P. falciparum growth inhibition predictions. 
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Table 2.2. Top ten “e zyme plus 2-descriptor” combinations with coefficients and relative contributions for P. falciparum 
growth inhibition predictions. 
 
1 from the equation: pIC50 (cell) = a•pIC50 (enzyme) + b•B + c•C + d 
2 Descriptors selected are described in   Table 2.4
 Rank R2 Coefficient a
1 
(enzyme) 
Relative 
Contribution 
(enzyme) 
Coefficient b1 Descriptor B2 
Relative 
Contribution 
(B) 
Coefficient c1 Descriptor C2 
Relative 
Contribution 
(C) 
Constant, d1 
1 0.77 1.0407 0.72 0.52375 logP(o/w) 1.00 -0.0028993 E_sol 0.47 -3.2113 
2 0.76 1.3081 0.84 -0.5824 logS 1.00 4.6753 E_oop 0.42 -3.7232 
3 0.76 1.0806 0.69 0.56454 logP(o/w) 1.00 4.9535 GCUT_SMR_0 0.45 1.4987 
4 0.75 1.3317 1.00 0.42892 SlogP 0.75 0.011375 PEOE_VSA_NEG 0.50 -3.7753 
5 0.75 0.98902 0.70 0.51324 logP(o/w) 1.00 -292.05 BCUT_PEOE_1 0.44 -203.38 
6 0.75 1.2344 0.85 0.62848 SlogP 1.00 1.0862 E_strain 0.30 -0.23834 
7 0.75 1.342 1.00 0.5162 SlogP 0.89 0.17337 chi1_C 0.40 -1.8939 
8 0.75 1.2085 1.00 0.49972 SlogP 0.96 1.8143 GCUT_SLOGP_1 0.42 0.49546 
9 0.75 1.044 0.74 0.51263 logP(o/w) 1.00 0.86654 BCUT_SLOGP_0 0.44 1.5301 
10 0.74 1.0733 1.00 0.44935 SlogP 0.97 0.0098483 PEOE_VSA-1 0.49 -0.61185 
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Table 2.3. Results for ten different systems showing the correlations between enzyme 
and cell activities, and the correlations between experimental and predicted cell 
activities. 
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Table 2.3. Results for ten different systems showing the correlations between enzyme 
and cell activities, and the correlations between experimental and predicted cell 
activities. 
 
 
 
 
 
a Correlation obtained from a leave-two-out analysis 
b Correlations based on cell activity predictions using a combinatorial descriptor search 
c Average correlation obtained from a leave-two-out analysis of 10 sets of scrambled 
data 
 
Target Cell 
R2, 
Enzyme 
vs. Cell 
R2, 
Enzyme 
Test 
Seta 
R2, 
Training 
Setb 
R2, 
Test 
Seta 
R2, 
Scrambledc 
Descriptors 
tested 
Number of 
compounds 
FPPS Plasmodium 
vivax 0.06 0.01 0.77 0.74 0.16 150 26 
FPPS Dictyostelium 
discoideum 0.49 0.46 0.70 0.70 0.07 123 102 
FPPS Leishmania 
donovani 0.55 0.47 0.87 0.8 0.11 138 21 
UPPS Streptococcus 
pneumoniae 0.03 0.10 0.71 0.69 0.14 109 27 
MurI Streptococcus 
pneumoniae 0.61 0.57 0.72 0.68 0.13 123 42 
HCV NS3 
Protease Hu-7 0.03 0.02 0.78 0.77 0.12 142 34 
HIV-1 
integrase MT4 0.12 0.04 0.69 0.64 0.13 126 30 
HLG 
Phosphorylase 
Rat 
hepatocytes 0.55 0.48 0.71 0.74 0.19 132 35 
KDR kinase NIH 3T3 0.36 0.30 0.60 0.58 0.09 117 42 
Akt Kinase 
MiaPaCa-2 
(pancreatic 
cancer) 
0.41 0.35 0.68 0.68 0.12 80 48 
Average  0.32 0.28 0.72 0.70 0.13 124 42 
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Table 2.4. List of descriptors used in the Combinatorial Descriptor Searcha 
Code Descripton Number of 
Occurencesb 
log(PAMPA) Log of parallel artificial membrane permeability 10 
log(Caco-2) 
Log of permeability coefficient for transport into 
Caco-2 cells 1 
log P-neutral 
Log of the concentrations of un-ionized compound 
between water and octanol  
log D-pH 7.4 
Log of the ratio of the sum of concentrations of 
solute’s various forms between water and octanol  
clogP Log P calculated by Sybyl  7.3(24)  
mlogP Measured log P calculated by Sybyl 7.3(24)  
diameter Largest value in the distance matrix  
petitjean Value of (diameter - radius) / diameter.  
petitjeanSC 
 
Petitjean graph Shape Coefficient(25): (diameter -
 radius) / radius.  
VDistEq 
 
 
 
If m is the sum of the distance matrix entries then 
VdistEq is defined to be the sum of log2 m -
 pi log2 pi / m where pi is the number of distance 
matrix entries equal to i.  
VDistMa 
 
 
If m is the sum of the distance matrix entries then 
VDistMa is defined to be the sum of log2 m -
 Dij log2 Dij / m over all i and j.  
weinerPath 
 
Wiener path number: half the sum of all the distance 
matrix entries(26, 27)  
weinerPol 
 
Wiener polarity number: half the sum of all the 
distance matrix entries with a value of 3(26)  
BCUT_PEOE_0 
BCUT_PEOE_1 
BCUT_PEOE_2 
BCUT_PEOE_3 
 
 
 
 
The BCUT descriptors(28) are calculated from the 
eigenvalues of a modified adjacency matrix. Each ij 
entry of the adjacency matrix takes the value 
1/sqrt(bij) where bij is the formal bond order between 
bonded atoms i and j. The diagonal takes the value of 
the PEOE partial charges. The resulting eigenvalues 
are sorted and the smallest, 1/3-ile, 2/3-ile and 
largest eigenvalues are reported. 
1 
 
 
 
 
BCUT_SLOGP_0 
BCUT_SLOGP_1 
BCUT_SLOGP_2 
BCUT_SLOGP_3 
The BCUT descriptors using atomic contribution to 
logP (using the Wildman and Crippen SlogP 
method) instead of partial charge(29). 
 
1 
 
 
BCUT_SMR_0 
BCUT_SMR_1 
BCUT_SMR_2 
BCUT_SMR_3 
The BCUT descriptors using atomic contribution to 
molar refractivity (using the Wildman and Crippen 
SMR method) instead of partial charge(29). 
  
GCUT_PEOE_0 
GCUT_PEOE_1 
GCUT_PEOE_2 
GCUT_PEOE_3 
 
 
 
 
The GCUT descriptors are calculated from the 
eigenvalues of a modified graph distance adjacency 
matrix. Each ij entry of the adjacency matrix takes 
the value 1/sqr(dij) where dij is the (modified) graph 
distance between atoms i and j. The diagonal takes 
the value of the PEOE partial charges. The resulting 
eigenvalues are sorted and the smallest, 1/3-ile, 2/3-
ile and largest eigenvalues are reported.  
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Table 2.4. continued  
Code Descripton Number of 
Occurencesb 
GCUT_SLOGP_0 
GCUT_SLOGP_1 
GCUT_SLOGP_2 
GCUT_SLOGP_3 
The GCUT descriptors using atomic contribution to 
logP (using the Wildman and Crippen SlogP 
method) instead of partial charge(29). 
 
3 
 
 
GCUT_SMR_0 
GCUT_SMR_1 
GCUT_SMR_2 
GCUT_SMR_3 
The GCUT descriptors using atomic contribution to 
molar refractivity (using the Wildman and Crippen 
SMR method) instead of partial charge(29). 
 1 
a_count 
Number of atoms (including implicit hydrogens). 
This is calculated as the sum of (1 + hi) over all non-
trivial atoms i.  
a_IC 
 
Atom information content (total). This is calculated 
to be a_ICM times n.  
a_ICM 
 
 
 
 
 
 
Atom information content (mean). This is the 
entropy of the element distribution in the molecule 
(including implicit hydrogens but not lone pair 
pseudo-atoms). Let ni be the number of occurrences 
of atomic number i in the molecule. Let pi = ni / n 
where n is the sum of the ni. The value of a_ICM is 
the negative of the sum over all i of pi log pi.  
b_1rotN 
 
 
Number of rotatable single bonds. Conjugated single 
bonds are not included (e.g., ester and peptide 
bonds).  
b_1rotR 
 
Fraction of rotatable single bonds: b_1rotN divided 
by b_heavy. 
1 
 
b_count 
 
 
Number of bonds (including implicit hydrogens). 
This is calculated as the sum of (di/2 + hi) over all 
non-trivial atoms i.  
b_rotN 
 
 
Number of rotatable bonds. A bond is rotatable if it 
has order 1, is not in a ring, and has at least two 
heavy neighbors.  
b_rotR 
 
Fraction of rotatable bonds: b_rotN divided by 
b_heavy. 1 
b_single 
Number of single bonds (including implicit 
hydrogens). Aromatic bonds are not considered to be 
single bonds.  
chi0v 
 
 
Atomic valence connectivity index (order 0)(30, 31). 
This is calculated as the sum of 1/sqrt(vi) over all 
heavy atoms i with vi > 0.  
chi0v_C 
 
 
Carbon valence connectivity index (order 0). This is 
calculated as the sum of 1/sqrt(vi) over all carbon 
atoms i with vi > 0.  
chi1v 
 
 
Atomic valence connectivity index (order 1)(30, 31). 
This is calculated as the sum of 1/sqrt(vivj) over all 
bonds between heavy atoms i and j where i < j.  
chi1v_C 
 
 
Carbon valence connectivity index (order 1). This is 
calculated as the sum of 1/sqrt(vivj) over all bonds 
between carbon atoms i and j where i < j.  
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Table 2.4. continued  
Code Descripton Number of 
Occurencesb 
Weight 
 
Molecular weight (including implicit hydrogens) 
with atomic weights taken from CRC Handbook of 
Chemistry and Physics, CRC Press (1994).  
b_heavy Number of bonds between heavy atoms.  
a_nC Number of carbon atoms: #{Zi | Zi = 6}.  
chi0 
 
 
Atomic connectivity index (order 0)(30, 31). This is 
calculated as the sum of 1/sqrt(di) over all heavy 
atoms i with di > 0.  
chi0_C 
 
 
Carbon connectivity index (order 0). This is 
calculated as the sum of 1/sqrt(di) over all carbon 
atoms i with di > 0.  
chi1 
 
 
Atomic connectivity index (order 1)(30, 31). This is 
calculated as the sum of 1/sqrt(didj) over all bonds 
between heavy atoms i and j where i < j.  
chi1_C 
 
 
Carbon connectivity index (order 1). This is 
calculated as the sum of 1/sqrt(didj) over all bonds 
between carbon atoms i and j where i < j. 
1 
 
 
VAdjEq 
 
 
 
 
Vertex adjacency information (equality): -(1-f)log2(1-
f) - f log2 f where f = (n2 - m) / n2, n is the number of 
heavy atoms and m is the number of heavy-heavy 
bonds. If f is not in the open interval (0,1), then 0 is 
returned.  
VAdjMa 
 
 
Vertex adjacency information (magnitude): 
1 + log2 m where m is the number of heavy-heavy 
bonds. If m is zero, then zero is returned.  
zagreb Zagreb index: the sum of di2 over all heavy atoms i.  
balabanJ Balaban's connectivity topological index(32).  
PC+ 
Q_PC+ 
PEOE_PC+ 
Total positive partial charge: the sum of the positive 
qi. Q_PC+ is identical to PC+ which has been 
retained for compatibility. 
2 
 
 
PC- 
Q_PC- 
PEOE_PC- 
Total negative partial charge: the sum of the negative 
qi. Q_PC- is identical to PC- which has been retained 
for compatibility.  
RPC+ 
Q_RPC+ 
PEOE_RPC+ 
 
Relative positive partial charge: the largest positive qi 
divided by the sum of the positive qi. Q_RPC+ is 
identical to RPC+ which has been retained for 
compatibility. 
1 
 
 
RPC- 
Q_RPC- 
PEOE_RPC- 
 
Relative negative partial charge: the smallest 
negative qi divided by the sum of the negative qi. 
Q_RPC- is identical to RPC- which has been retained 
for compatibility. 
5 
 
 
PEOE_VSA+0 Sum of vi where qi is in the range [0.00,0.05). 2 
PEOE_VSA+1 Sum of vi where qi is in the range [0.05,0.10).  
PEOE_VSA-0 Sum of vi where qi is in the range [-0.05,0.00).  
PEOE_VSA-1 Sum of vi where qi is in the range [-0.10,-0.05). 1 
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Table 2.4. continued  
Code Descripton Number of 
Occurencesb 
Q_VSA_FHYD 
PEOE_VSA_FHYD 
 
 
 
Fractional hydrophobic van der Waals surface area. 
This is the sum of the vi such that |qi| is less than or 
equal to 0.2 divided by the total surface area. The vi 
are calculated using a connection table 
approximation. 
3 
 
 
Q_VSA_FNEG 
PEOE_VSA_FNEG 
 
 
Fractional negative van der Waals surface area. This 
is the sum of the vi such that qi is negative divided by 
the total surface area. The vi are calculated using a 
connection table approximation. 
3 
 
 
Q_VSA_FPNEG 
PEOE_VSA_FPNEG 
 
 
Fractional negative polar van der Waals surface area. 
This is the sum of the vi such that qi is less than -0.2 
divided by the total surface area. The vi are 
calculated using a connection table approximation. 
1 
 
 
 
Q_VSA_FPOL 
PEOE_VSA_FPOL 
 
 
Fractional polar van der Waals surface area. This is 
the sum of the vi such that |qi| is greater than 0.2 
divided by the total surface area. The vi are 
calculated using a connection table approximation. 
4 
 
 
Q_VSA_FPOS 
PEOE_VSA_FPOS 
 
 
Fractional positive van der Waals surface area. This 
is the sum of the vi such that qi is non-negative 
divided by the total surface area. The vi are 
calculated using a connection table approximation. 
3 
 
 
Q_VSA_FPPOS 
PEOE_VSA_FPPOS 
 
 
Fractional positive polar van der Waals surface area. 
This is the sum of the vi such that qi is greater than 0.2 
divided by the total surface area. The vi are 
calculated using a connection table approximation.  
Q_VSA_HYD 
PEOE_VSA_HYD 
 
 
Total hydrophobic van der Waals surface area. This 
is the sum of the vi such that |qi| is less than or equal 
to 0.2. The vi are calculated using a connection table 
approximation. 
2 
 
 
Q_VSA_NEG 
PEOE_VSA_NEG 
 
Total negative van der Waals surface area. This is the 
sum of the vi such that qi is negative. The vi are 
calculated using a connection table approximation. 
1 
 
Q_VSA_PNEG 
PEOE_VSA_PNEG 
 
 
Total negative polar van der Waals surface area. This 
is the sum of the vi such that qi is less than -0.2. The vi 
are calculated using a connection table 
approximation.  
Q_VSA_POL 
PEOE_VSA_POL 
 
 
Total polar van der Waals surface area. This is the 
sum of the vi such that |qi| is greater than 0.2. The vi 
are calculated using a connection table 
approximation. 
1 
 
 
Q_VSA_POS 
PEOE_VSA_POS 
 
Total positive van der Waals surface area. This is the 
sum of the vi such that qi is non-negative. The vi are 
calculated using a connection table approximation.  
Q_VSA_PPOS 
 
 
 
Total positive polar van der Waals surface area. This 
is the sum of the vi such that qi is greater than 0.2. 
The vi are calculated using a connection table 
approximation. 
1 
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Table 2.4. continued  
Code Descripton Number of 
Occurencesb 
lip_acc The number of O and N atoms.  
opr_nrot The number of rotatable bonds(33).  
E 
 
 
 
Value of the potential energy. The state of all term 
enable flags will be honored (in addition to the term 
weights). This means that the current potential setup 
accurately reflects what will be calculated. 
1 
 
 
E_ang 
 
 
Angle bend potential energy. In the Potential Setup 
panel, the term enable flag is ignored, but the term 
weight is applied.  
E_ele 
 
 
Electrostatic component of the potential energy. In 
the Potential Setup panel, the term enable flag is 
ignored, but the term weight is applied. 
2 
 
 
E_nb 
 
 
 
Value of the potential energy with all bonded terms 
disabled. The state of the non-bonded term enable 
flags will be honored (in addition to the term 
weights). 
3 
 
 
E_oop 
 
 
Out-of-plane potential energy. In the Potential Setup 
panel, the term enable flag is ignored, but the term 
weight is applied. 
5 
 
E_sol 
 
 
Solvation energy. In the Potential Setup panel, the 
term enable flag is ignored, but the term weight is 
applied. 
1 
 
E_stb 
 
 
Bond stretch-bend cross-term potential energy. In the 
Potential Setup panel, the term enable flag is 
ignored, but the term weight is applied.  
E_str 
 
 
Bond stretch potential energy. In the Potential Setup 
panel, the term enable flag is ignored, but the term 
weight is applied. 
1 
 
E_strain 
 
 
 
 
 
 
 
 
Local strain energy: the current energy minus the 
value of the energy at a near local minimum. The 
current energy is calculated as for the E descriptor. 
The local minimum energy is the value of the E 
descriptor after first performing an energy 
minimization. Current chirality is preserved and 
charges are left undisturbed during minimization. 
The structure in the database is not modified (results 
of the minimization are discarded). 
1 
 
 
 
 
E_tor 
 
 
Torsion (proper and improper) potential energy. In 
the Potential Setup panel, the term enable flag is 
ignored, but the term weight is applied. 
3 
 
E_vdw 
 
 
van der Waals component of the potential energy. In 
the Potential Setup panel, the term enable flag is 
ignored, but the term weight is applied.  
Kier1 First kappa shape index: (n-1)2 / m2 (31).  
Kier2 Second kappa shape index: (n-1)2 / m2 (31). 1 
Kier3 
 
Third kappa shape index: (n-1) (n-3)2 / p32 for odd n, 
and (n-3) (n-2)2 / p32 for even n (31). 
1 
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Table 2.4. continued  
Code Descripton Number of 
Occurencesb 
KierA1 
 
First alpha modified shape index: s (s-1)2 / m2 where 
s = n + a (31). 
2 
 
KierA2 
 
Second alpha modified shape index: s (s-1)2 / m2 
where s = n + a (31). 
1 
 
KierA3 
 
 
Third alpha modified shape index: (n-1) (n-3)2 / p32 
for odd n, and (n-3) (n-2)2 / p32 for even n where 
s = n + a (31). 
1 
 
KierFlex 
 
Kier molecular flexibility index: (KierA1) 
(KierA2) / n (31).  
logs 
 
 
Log of the aqueous solubility This property is 
calculated from an atom contribution linear atom 
type model(34) with r2 = 0.90, ~1,200 molecules. 
7 
 
apol 
 
 
Sum of the atomic polarizabilities (including implicit 
hydrogens) with polarizabilities taken from CRC 
Handbook of Chemistry and Physics, CRC Press (1994). 
1 
 
bpol 
 
 
 
Sum of the absolute value of the difference between 
atomic polarizabilities of all bonded atoms in the 
molecule (including implicit hydrogens) with 
polarizabilities taken from CRC Handbook of 
Chemistry and Physics, CRC Press (1994).  
mr 
 
 
 
Molecular refractivity (including implicit 
hydrogens). This property is calculated from an 11 
descriptor linear model with r2 = 0.997, RMSE = 0.168 
on 1,947 small molecules. 
  
dipole 
 
Dipole moment calculated from the partial charges of 
the molecule.  
dipoleX 
 
The x component of the dipole moment (external 
coordinates). 
1 
 
dipoleY 
 
The y component of the dipole moment (external 
coordinates). 
2 
 
dipoleZ 
 
The z component of the dipole moment (external 
coordinates).  
pmi Principal moment of inertia. 5 
pmiX 
 
x component of the principal moment of inertia 
(external coordinates). 
5 
 
pmiY 
 
y component of the principal moment of inertia 
(external coordinates). 
3 
 
pmiZ 
 
z component of the principal moment of inertia 
(external coordinates). 
3 
 
rgyr Radius of gyration.  
vsa_acc 
 
 
 
Approximation to the sum of VDW surface areas of 
pure hydrogen bond acceptors (not counting acidic 
atoms and atoms that are both hydrogen bond 
donors and acceptors such as -OH).  
vsa_hyd 
 
Approximation to the sum of VDW surface areas of 
hydrophobic atoms. 
1 
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Table 2.4. continued  
Code Descripton Number of 
Occurencesb 
vsa_pol 
 
 
Approximation to the sum of VDW surface areas of 
polar atoms (atoms that are both hydrogen bond 
donors and acceptors), such as -OH.  
SlogP 
 
 
 
 
 
 
Log of the octanol/water partition coefficient 
(including implicit hydrogens). This property is an 
atomic contribution model(29) that calculates logP 
from the given structure; i.e., the correct protonation 
state (washed structures). Results may vary from the 
logP(o/w) descriptor. The training set for SlogP was 
~7000 structures. 
11 
 
 
 
 
SlogP_VSA0 Sum of vi such that Li <= -0.4.  
SlogP_VSA2 Sum of vi such that Li is in (-0.2,0].  
SlogP_VSA7 Sum of vi such that Li is in (0.25,0.30].  
SlogP_VSA8 Sum of vi such that Li is in (0.30,0.40].  
SlogP_VSA9 Sum of vi such that Li > 0.40.  
SMR 
 
 
 
 
 
Molecular refractivity (including implicit 
hydrogens). This property is an atomic contribution 
model(29) that assumes the correct protonation state 
(washed structures). The model was trained on 
~7000 structures and results may vary from the mr 
descriptor.  
SMR_VSA2 Sum of vi such that Ri is in (0.26,0.35].  
SMR_VSA3 Sum of vi such that Ri is in (0.35,0.39].  
SMR_VSA5 Sum of vi such that Ri is in (0.44,0.485].  
SMR_VSA7 Sum of vi such that Ri > 0.56.  
ASA 
 
 
 
Water accessible surface area calculated using a 
radius of 1.4 A for the water molecule. A polyhedral 
representation is used for each atom in calculating 
the surface area. 
 
1 
 
 
 
ASA+ 
 
Water accessible surface area of all atoms with 
positive partial charge (strictly greater than 0).  
ASA- 
 
Water accessible surface area of all atoms with 
negative partial charge (strictly less than 0).  
ASA_H 
 
Water accessible surface area of all hydrophobic 
(|qi|<0.2) atoms. 
4 
 
ASA_P 
 
Water accessible surface area of all polar (|qi|>=0.2) 
atoms. 
1 
 
CASA+ 
 
Positive charge weighted surface area, ASA+ times 
max { qi > 0 }(35).  
CASA- 
 
Negative charge weighted surface area, ASA- times 
max { qi < 0 }(35).  
DASA 
 
Absolute value of the difference between ASA+ and 
ASA-. 
1 
 
DCASA 
 
Absolute value of the difference between CASA+ 
and CASA-(35). 
2 
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Table 2.4. continued  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code Descripton Number of 
Occurencesb 
FASA+ Fractional ASA+ calculated as ASA+ / ASA.  
FASA- Fractional ASA- calculated as ASA- / ASA.  
FASA_H Fractional ASA_H calculated as ASA_H / ASA. 4 
FASA_P Fractional ASA_P calculated as ASA_P / ASA. 4 
FCASA+ Fractional CASA+ calculated as CASA+ / ASA.  
FCASA- Fractional CASA- calculated as CASA- / ASA. 2 
VSA 
 
 
van der Waals surface area. A polyhedral 
representation is used for each atom in calculating 
the surface area. 
2 
 
TPSA 
 
 
 
Polar surface area calculated using group 
contributions to approximate the polar surface area 
from connection table information only. The 
parameterization is that of Ertl et al. (36).  
density 
 
Molecular mass density: Weight divided by 
vdw_vol.  
vdw_area 
 
Area of van der Waals surface calculated using a 
connection table approximation.  
vdw_vol 
 
van der Waals volume calculated using a connection 
table approximation. 
1 
 
dens 
 
Mass density: molecular weight divided by van der 
Waals volume as calculated in the vol descriptor.  
glob 
 
 
 
 
Globularity, or inverse condition number (smallest 
eigenvalue divided by the largest eigenvalue) of the 
covariance matrix of atomic coordinates. A value of 1 
indicates a perfect sphere while a value of 0 indicates 
a two- or one-dimensional object.  
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Table 2.4. continued  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Descriptors searched and their descriptions are generally taken from MOE(7) 
b Times that the descriptor occurred in the top ranked descriptor combinations 
std_dim1 
 
 
 
 
Standard dimension 1: the square root of the largest 
eigenvalue of the covariance matrix of the atomic 
coordinates. A standard dimension is equivalent to 
the standard deviation along a principal component 
axis.  
std_dim2 
 
 
 
 
Standard dimension 2: the square root of the second 
largest eigenvalue of the covariance matrix of the 
atomic coordinates. A standard dimension is 
equivalent to the standard deviation along a 
principal component axis. 
1 
 
 
 
std_dim3 
 
 
 
 
Standard dimension 3: the square root of the third 
largest eigenvalue of the covariance matrix of the 
atomic coordinates. A standard dimension is 
equivalent to the standard deviation along a 
principal component axis.  
vol 
 
van der Waals volume calculated using a grid 
approximation (spacing 0.75 A).  
logP(o/w) 
 
 
 
 
Log of the octanol/water partition coefficient 
(including implicit hydrogens). This property is 
calculated from a linear atom type model 
[LOGP 1998] with r2 = 0.931, RMSE=0.393 on 1,827 
molecules. 
4 
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Table 2.5. Top ten “enzyme (FPPS) plus 2-descriptor” combinations with their 
coefficients and relative contributions for the D. discoideum cell pIC50 predictions. 
Dictyostelium discoideum 
(FPPS) 
pIC (cell) = 
R2 
Relative 
Importance of 
pIC50(enzyme) 
Relative 
Importance of 
Descriptor B 
Relative 
Importance of 
Descriptor C 
         -20.76307 
        +0.48341 * pIC50Enzyme 
       -14.18055 * GCUT_PEOE_0 
        +3.20333 * BCUT_PEOE_3 
 
0.69692 1.000000 0.484251 0.729151 
        -12.32173 
        +0.57298 * pIC50Enzyme 
        +4.56066 * BCUT_SMR_3 
        +0.01669 * E_vdw 
 
0.68450 1.000000 0.416094 0.388190 
        -6.15020 
        +0.50365 * pIC50Enzyme 
        +3.02716 * BCUT_PEOE_3 
        +0.000724775 * CASA+ 
 
0.67415 1.000000 0.661355 0.393880 
        -6.94591 
        +0.49467 * pIC50Enzyme 
        +3.32192 * BCUT_PEOE_3 
        +0.00390 * ASA+ 
 
0.67085 1.000000 0.738924 0.417312 
       -3.89017 
        +0.52832 * pIC50Enzyme 
        +2.05150 * BCUT_PEOE_3 
        +0.01401 * E_vdw 
 
0.66951 1.000000 0.427270 0.353525 
         2.94011 
        +0.46041 * pIC50Enzyme 
        -0.00635 * ASA_P 
        +0.63821 * PEOE_PC+ 
 
0.66825 1.000000 0.392190 0.638878 
        -8.79712 
        +0.50884 * pIC50Enzyme 
        +2.97502 * BCUT_PEOE_3 
        -0.62648 * PEOE_PC- 
 
0.66574 1.000000 0.643330 0.362862 
       -17.05598 
        +0.56036 * pIC50Enzyme 
        +6.27128 * BCUT_SMR_3 
        +0.000757926 * CASA+ 
 
0.66511 1.000000 0.585055 0.370214 
        -8.75301 
        +0.48545 * pIC50Enzyme 
        +3.48930 * BCUT_SMR_3 
        +0.45159 * PEOE_PC+ 
 
0.66286 1.000000 0.375754 0.428755 
        -6.09568 
        +0.49120 * pIC50Enzyme 
        +3.03006 * BCUT_PEOE_3 
        +0.35326 * FCASA+ 
 
0.66042 1.000000 0.678777 0.361338 
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Table 2.6. Top ten “enzyme (FPPS) plus 2-descriptor” combinations with their 
coefficients and relative contributions for the L. donovani cell pIC50 predictions. 
Leishmania donovani (FPPS) 
pIC (cell)  = R
2 a Relative Importance of pIC50(enzyme) a 
Relative Importance 
of Descriptor B a 
Relative Importance 
of Descriptor C a 
        12.82134 
        +0.74773 * pIC50Enzyme 
        -1.23653 * FCASA- 
       -14.34579 * Q_VSA_FPOS 
 
0.86952 0.269777 0.915872 1.000000 
        -1.52445 
        +0.74773 * pIC50Enzyme 
        -1.23653 * FCASA- 
       +14.34579 * Q_VSA_FNEG 
 
0.86952 0.269777 0.915872 1.000000 
         2.63995 
        +0.56184 * pIC50Enzyme 
        +0.10038 * SlogP 
        -2.72841 * b_rotR 
 
0.80829 1.000000 0.615015 0.987653 
         2.63995 
        +0.10038 * SlogP 
        -2.72841 * b_1rotR 
        +0.56184 * pIC50Enzyme 
 
0.80829 0.615015 0.987653 1.000000 
         2.43168 
        +0.67597 * pIC50Enzyme 
        +0.01062 * PEOE_VSA+0 
        -4.40941 * Q_VSA_FPOS 
 
0.80745 1.000000 0.806196 0.793464 
        -1.97773 
        +0.67597 * pIC50Enzyme 
        +0.01062 * PEOE_VSA+0 
        +4.40940 * Q_VSA_FNEG 
 
0.80745 0.793464 0.806196 1.000000 
         2.78569 
        +0.67570 * pIC50Enzyme 
        -3.01289 * Q_VSA_FPOS 
        +0.14382 * SlogP 
 
0.80578 1.000000 0.861479 0.732693 
        -0.22720 
        +0.67570 * pIC50Enzyme 
        +0.14382 * SlogP 
        +3.01289 * Q_VSA_FNEG 
 
0.80578 1.000000 0.732693 0.861479 
         5.23713 
        +0.35909 * pIC50Enzyme 
        +0.00796 * Q_VSA_HYD 
        -0.19768 * KierA1 
 
0.80375 0.319957 0.726844 1.000000 
         4.83355 
        +0.30356 * pIC50Enzyme 
        -0.22903 * KierA1 
        +0.00805 * VSA 
 
0.80300 0.233458 1.000000 0.738323 
a Identical values are obtained when descriptors are linearly dependent
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Table 2.7. Top ten “enzyme (UPPS) plus 2-descriptor” combinations with their 
coefficients and relative contributions for the S. pneumoniae cell pIC50 predictions. 
 
Streptococcus pneumoniae (UPPS) 
pIC (cell)  = R
2 
Relative 
Importance of 
pIC50Enzyme 
Relative Importance 
of Descriptor B 
Relative 
Importance of 
Descriptor C 
         2.36039 
        +0.09521 * pIC50Enzyme 
        +5.57167 * E_oop 
        +0.30641 * logS 
 
0.70859 0.206740 0.770366 1.000000 
         2.73916 
        -0.02058 * pIC50Enzyme 
        -0.25615 * dipoleY 
        -0.50252 * SlogP 
 
0.65294 0.036773 0.664638 1.000000 
         4.02259 
        -0.10469 * pIC50Enzyme 
        +0.44931 * logS 
        -0.00111 * pmiZ 
 
0.63628 0.155024 1.000000 0.380149 
         1.93265 
        +0.02581 * pIC50Enzyme 
        +5.82244 * E_oop 
        -0.38762 * SlogP 
 
0.63029 0.059775 0.858685 1.000000 
         2.91917 
        +0.05651 * pIC50Enzyme 
        -0.16171 * dipoleY 
        +0.33943 * logS 
 
0.61395 0.110774 0.460388 1.000000 
         3.29294 
        +0.11608 * pIC50Enzyme 
        +8.55584 * E_oop 
        -0.01199 * vsa_hyd 
 
0.60705 0.213066 1.000000 0.682444 
         3.00970 
        -0.02670 * pIC50Enzyme 
        +0.30685 * logS 
        -0.000145748 * pmiY 
 
0.59586 0.057891 1.000000 0.472137 
         2.72405 
        +0.01829 * pIC50Enzyme 
        +0.01022 * E_nb 
        +0.37898 * logS 
 
0.59540 0.032109 0.334330 1.000000 
         0.97384 
        +0.21900 * pIC50Enzyme 
        -0.000223701 * pmiY 
        +6.34230 * E_oop 
 
0.59461 0.542273 0.827566 1.000000 
         2.46641 
        +0.03924 * pIC50Enzyme 
        +0.12363 * E_str 
        +0.40087 * logS 
 
0.59423 0.065125 0.332503 1.000000 
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Table 2.8. Top ten “enzyme (MurI) plus 2-descriptor” combinations with their 
coefficients and relative contributions for the S. pneumoniae cell pIC50 predictions. 
 
a Identical values are obtained when descriptors are linearly dependent 
Streptococcus pneumoniae 
(MurI) 
pIC (cell)  = 
R2  a Relative Importance of  pIC50(enzyme) a 
Relative Importance 
of Descriptor B a 
Relative Importance 
of Descriptor C a 
        10.52552 
        +0.67868 * pIC50Enzyme 
        -8.00526 * FASA_H 
        -9.58941 * Q_VSA_FPOL 
 
0.72033 0.760086 0.930312 1.000000 
         2.52026 
        +0.67868 * pIC50Enzyme 
        -9.58941 * Q_VSA_FPOL 
        +8.00526 * FASA_P 
 
0.72033 0.760086 1.000000 0.930312 
         0.93611 
        +0.67868 * pIC50Enzyme 
        -8.00526 * FASA_H 
        +9.58941 * Q_VSA_FHYD 
 
0.72033 0.760086 0.930312 1.000000 
        -7.06915 
        +0.67868 * pIC50Enzyme 
        +9.58941 * Q_VSA_FHYD 
        +8.00526 * FASA_P 
 
0.72033 0.760086 1.000000 0.930312 
        1.11064 
        +0.73485 * pIC50Enzyme 
        +0.00116 * pmiZ 
        -0.00189 * DCASA 
 
0.70598 1.000000 0.352718 0.412965 
         0.96166 
        +0.74218 * pIC50Enzyme 
        -0.01333 * ASA_H 
        +0.02650 * Q_VSA_HYD 
 
0.70104 0.683156 1.000000 0.978195 
         1.07105 
        +0.73955 * pIC50Enzyme 
        +0.00121 * pmiZ 
        -0.00932 * DASA 
 
0.69820 1.000000 0.367214 0.401603 
         5.68232 
        +0.68410 * pIC50Enzyme 
        -5.36646 * Q_VSA_FPOL 
        -0.00565709 * ASA_H 
 
0.69080 1.000000 0.730430 0.673985 
         0.31586 
        +0.68410 * pIC50Enzyme 
        -0.00565708 * ASA_H 
        +5.36646 * Q_VSA_FHYD 
 
0.69080 1.000000 0.673985 0.730430 
        -0.26123 
        +0.77505 * pIC50Enzyme 
        -0.00154943 * DCASA 
       +10.54584 * PEOE_RPC+ 
0.68937 1.000000 0.261402 0.321590 
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Table 2.9. Top ten “enzyme (NS3 protease) plus 2-descriptor” combinations with their 
coefficients and relative contributions for the HCV replicon cell pIC50 predictions. 
Hepatitis C Virus (NS3 
protease) 
pIC (cell)  = 
R2 Relative Importance of  pIC50(enzyme) 
Relative Importance 
of Descriptor B 
Relative 
Importance of 
Descriptor C 
        -1.29239 
       +0.91301 * pIC_Enzyme 
       +0.58847 * log(PAMPA) 
        -0.00017357 * pmiY 
0.77744 0.730339 1.000000 0.305259 
        -2.44335 
        +0.92235 * pIC50Enzyme 
        +0.55294 * log(PAMPA) 
        +0.25772 * log(Caco-2) 
 
0.74101 0.785205 1.000000 0.261151 
         0.11561 
        +0.84966 * pIC50Enzyme 
        +0.55981 * log(PAMPA) 
        -0.56438 * std_dim2 
 
0.73967 0.714448 1.000000 0.231869 
        -2.11082 
        +0.91600 * pIC50Enzyme 
        +0.58198 * log(PAMPA) 
        -0.16375 * dipoleX 
 
0.73819 0.740897 1.000000 0.222535 
        -1.07166 
        +0.92801 * pIC50Enzyme 
        +0.62367 * log(PAMPA) 
        -0.24639 * PEOE_PC+ 
 
0.73569 0.700433 1.000000 0.198231 
        -1.43622 
        +0.92293 * pIC50Enzyme 
        +0.65322 * log(PAMPA) 
        -0.06097 * KierA2 
 
0.73564 0.665088 1.000000 0.197280 
        -1.52542 
        +0.92611 * pIC50Enzyme 
        +0.64820 * log(PAMPA) 
        -0.04420 * Kier2 
 
0.73518 0.672545 1.000000 0.195686 
        -1.58484 
        +0.91365 * pIC50Enzyme 
        +0.65058 * log(PAMPA) 
        -0.05945 * Kier3 
 
0.73454 0.661071 1.000000 0.193573 
        -1.85996 
        +0.96397 * pIC50Enzyme 
        +0.61988 * log(PAMPA) 
        -0.00374 * Q_VSA_PPOS 
 
0.73415 0.732031 1.000000 0.203505 
        -1.61354 
        +0.95796 * pIC50Enzyme 
        +0.61521 * log(PAMPA) 
        -0.00310 * Q_VSA_POL 
 
0.73394 0.732983 1.000000 0.203058 
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Table 2.10. Top ten “enzyme (HIV-1 integrase) plus 2-descriptor” combinations with 
their coefficients and relative contributions for the HIV-1 integrase replicon cell pIC50 
predictions. 
 
MT4 cells  (HIV-1 integrase) 
pIC (cell)  = R
2 
Relative 
Importance of 
pIC50(enzyme) 
Relative Importance 
of Descriptor B 
Relative 
Importance of 
Descriptor C 
          -4.83173 
        +0.98896 * pIC50_enzyme 
        +1.36334 * pCC50 
        -0.00697 * Weight 
0.68808 0.892564 1.000000 0.526629 
          -3.90054 
        +0.79998 * pIC50_enzyme 
        +1.24225 * pCC50 
        -0.00990 * vsa_hyd 
0.68552 0.792381 1.000000 0.520038 
          -5.92926 
        +0.89119 * pIC50_enzyme 
        +1.37520 * pCC50 
        -0.000147 * pmi 
0.68063 0.797385 1.000000 0.489095 
          -5.67093 
        +0.84883 * pIC50_enzyme 
        +1.35713 * pCC50 
        -0.000166 * pmiX 
0.67775 0.769595 1.000000 0.482305 
           -2.59105 
        +0.71970 * pIC50_enzyme 
        +1.22060 * pCC50 
        -0.30594 * chi1v 
0.67651 0.725509 1.000000 0.509833 
          -5.53671 
        +0.85017 * pIC50_enzyme 
        +1.34149 * pCC50 
        -0.19817 * dipole 
0.67241 0.779798 1.000000 0.477547 
          -5.45844 
        +0.84242 * pIC50_enzyme 
        +1.33341 * pCC50 
        -0.19829 * dipoleX 
0.67078 0.777374 1.000000 0.475734 
          -2.07656 
        +0.67785 * pIC50_enzyme 
        +1.16006 * pCC50 
        -0.00792 * vol 
0.66766 0.718981 1.000000 0.519278 
          -2.88642 
        +0.78860 * pIC50_enzyme 
        +1.21043 * pCC50 
        -0.18150 * chi0v 
0.66619 0.801639 1.000000 0.497274 
          -6.15351 
        +0.91486 * pIC50_enzyme 
        +1.35583 * pCC50 
        +0.20861 * logS 
0.66278 0.830251 1.000000 0.471726 
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Table 2.11. Top ten “enzyme (hlGP) plus 2-descriptor” combinations with their 
coefficients and relative contributions for the rat hepatocytes pIC50 predictions. 
Rat Hepatocytes (hlGP) 
pIC (cell)  = R
2 Relative Importance of  pIC50(enzyme) 
Relative Importance 
of Descriptor B 
Relative Importance 
of Descriptor C 
        -2.48325 
        +0.74485 * pIC50Enzyme 
        +0.02112 * PEOE_VSA_PNEG 
        +0.00797 * Q_VSA_HYD 
 
0.71312 1.000000 0.671022 0.456010 
        -2.61987 
        +0.81722 * pIC50Enzyme 
        +0.01567 * PEOE_VSA_PNEG 
        +0.38040 * E_str 
 
0.70675 1.000000 0.453849 0.360041 
        -2.47800 
        +0.77133 * pIC50Enzyme 
        +0.02157 * PEOE_VSA_PNEG 
        +0.00356 * ASA_H 
 
0.70330 1.000000 0.661853 0.414954 
        -3.30393 
        +0.77214 * pIC50Enzyme 
        +0.02442 * PEOE_VSA_PNEG 
        +3.06864 * FASA_H 
 
0.70198 1.000000 0.748269 0.455019 
        -0.23529 
        +0.77214 * pIC50Enzyme 
        +0.02442 * PEOE_VSA_PNEG 
        -3.06864 * FASA_P 
 
0.70198 1.000000 0.748269 0.455019 
        -7.57118 
        +0.89039 * pIC50Enzyme 
        +0.01755 * PEOE_VSA_PNEG 
        -2.55393 * BCUT_PEOE_0 
 
0.70019 1.000000 0.466411 0.329457 
        -8.83556 
        +0.83245 * pIC50Enzyme 
        +0.01546 * PEOE_VSA_PNEG 
        +2.90552 * GCUT_SMR_3 
 
0.69768 1.000000 0.439538 0.327327 
        -7.31859 
        +2.61295 * GCUT_SLOGP_3 
        +0.79188 * pIC50Enzyme 
        +0.01647 * PEOE_VSA_PNEG 
 
0.69753 1.000000 0.345396 0.492133 
        -7.31859 
        +0.79188 * pIC50Enzyme 
        +0.01647 * PEOE_VSA_PNEG 
        +2.61295 * GCUT_SLOGP_3 
 
0.69753 1.000000 0.492133 0.345396 
        -2.00842 
        +0.73115 * pIC50Enzyme 
        +0.01897 * PEOE_VSA_PNEG 
        +0.00634 * vsa_hyd 
 
0.69664 1.000000 0.614097 0.397957 
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Table 2.12. Top ten “enzyme (KDR kinase) plus 2-descriptor” combinations with their 
coefficients and relative contributions for the NIH3T3 cell pIC50 predictions. 
NIH 3T3 (KDR, type III receptor 
tyrosine kinase) 
pIC (cell)  = 
R2 Relative Importance of  pIC50(enzyme) 
Relative Importance 
of Descriptor B 
Relative Importance 
of Descriptor C 
         0.82478 
        +0.85331 * pIC50Enzyme 
        +6.56543 * PEOE_VSA_FPOL 
        +0.05504 * E_tor 
 
0.60006 1.000000 0.494191 0.718790 
         0.66511 
        +0.86124 * pIC50Enzyme 
        +0.05066 * E_tor 
       +12.60955 * PEOE_VSA_FPNEG 
 
0.59907 1.000000 0.655445 0.485462 
         9.32007 
        +0.79676 * pIC50Enzyme 
       -18.85532 * PEOE_RPC- 
        -0.06827 * apol 
 
0.59487 0.766096 0.760710 1.000000 
         10.76167 
        +0.82694 * pIC50Enzyme 
       -19.03382 * PEOE_RPC- 
        -0.00815127 * ASA 
 
0.59352 0.795265 0.768062 1.000000 
        10.23883 
        +0.80199 * pIC50Enzyme 
       -20.80145 * PEOE_RPC- 
        -0.00895460 * vdw_vol 
 
0.59328 0.730389 0.794900 1.000000 
        10.31493 
        +0.79311 * pIC50Enzyme 
       -20.41614 * PEOE_RPC- 
       -0.01264080 * vol 
 
0.59276 0.729847 0.788320 1.000000 
        10.31493 
        +0.79311 * pIC50Enzyme 
       -20.41614 * PEOE_RPC- 
       -0.01264080 * vol 
 
0.58789 0.708545 0.798883 1.000000 
         -0.21236 
        +0.91159 * pIC50Enzyme 
        +0.03452 * E 
        -0.05235 * E_nb 
 
0.58380 0.500955 0.743845 1.000000 
         1.32645 
        +0.89890 * pIC50Enzyme 
        -0.01124 * E_nb 
        +0.04199 * E_tor 
 
0.58330 1.000000 0.434552 0.520573 
          2.55668 
        +0.72281 * pIC50Enzyme 
        -0.75267 * KierA3 
        +1.19503 * PEOE_PC+ 
 
0.58114 0.783185 1.000000 0.775189 
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Table 2.13. Top ten “enzyme (Akt kinase) plus 2-descriptor” combinations with their 
coefficients and relative contributions for the MiaPaCa-2 cell pIC50 predictions. 
MiaPaca-2 human pancreatic 
cancer cells (Akt Kinase) 
pIC (cell)  = 
R2 Relative Importance of  pIC50Enzyme 
Relative Importance 
of Descriptor B 
Relative Importance 
of Descriptor C 
         4.33712 
        +0.45265 * pIC50Enzyme 
        -0.0000929650 * pmiX 
        -4.23429 * GCUT_SLOGP_2 
 
0.68326 1.000000 0.556839 0.424186 
         2.55169 
        +0.44882 * pIC_Enzyme 
        -0.000099391 * pmi 
        +0.00253 * ASA_H 
0.68020 1.000000 0.711354 0.499224 
         4.44515 
        +0.39949 * pIC50Enzyme 
        -0.0000873893 * pmiX 
        -0.02504 * E_ele 
 
0.67971 1.000000 0.593093 0.458662 
         4.23090 
        +0.42619 * pIC50Enzyme 
        -0.0000879041 * pmiX 
        -1.87949 * FASA_P 
 
0.67557 1.000000 0.559220 0.423219 
         2.35141 
        +0.42619 * pIC50Enzyme 
        -0.0000879041 * pmiX 
        +1.87949 * FASA_H 
 
0.67557 1.000000 0.559220 0.423219 
         4.65687 
        +0.41086 * pIC50Enzyme 
        -0.0000778479 * pmi 
        -4.34328 * GCUT_SLOGP_2 
 
0.67513 1.000000 0.608637 0.479355 
          4.54500 
        +0.38640 * pIC50Enzyme 
        -1.96877 * FASA_P 
        -0.0000739953 * pmi 
0.67115 1.000000 0.488967 0.615143 
         2.57623 
        +0.38640 * pIC50Enzyme 
        -0.0000739953 * pmi 
        +1.96877 * FASA_H 
 
0.67115 1.000000 0.615143 0.488967 
         4.34247 
        +0.40352 * pIC_Enzyme 
        -0.0025494 * ASA_P 
        -0.0000831233 * pmiX 
0.67007 1.000000 0.435308 0.558505 
         4.71925 
        +0.35970 * pIC50Enzyme 
        -0.0000719880 * pmi 
        -0.02523 * E_ele 
 
0.66794 1.000000 0.642875 0.513363 
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Figure 2.1. Structures of the 26 compounds investigated in cell (Plasmodium falciparum) 
and enzyme (Plasmodium vivax FPPS) assays. 
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Figure 2.2. Correlation plots for cell ( Plasmodium falciparum) and enzyme (Plasmodium 
vivax FPPS) assays and predicted cell activities from the training and test set data, 
obtained by using the combinatorial descriptor search method. (a) Plot showing 
correlation between cell pIC50 (= - log10{IC50}) and enzyme pIC50 values. (b) Best 
correlation between predicted cell pIC50 (enzyme plus two molecular descriptors) and 
experimental pIC50 values: training set results. (c) Test set pIC50 predictions (leave-two-
out analysis) plotted against the experimental values. The R2 value increases from ~0 to 
0.74, when adding the two molecular descriptors to the enzyme data. The colored 
circles (A-C) indicate bisphosphonates with side chains having different relative 
hydrophobicities and potencies in the cell assay (low, intermediate or high, 
respectively), as discussed in the Text. 
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Figure 2.3. Correlation plots for the cell and enzyme assays, and predicted cell activities 
from the training and test set data in: Dictyostelium discoideum (a-c), Leishmania donovani 
(d-f) and Streptococcus pneumoniae (g-i). (a) Plot showing the correlation between cell (D. 
discoideum) pIC50 and enzyme (FPPS) pIC50 values. (b) Correlation between predicted 
cell pIC50 values (from the best combination of enzyme plus two molecular descriptors) 
for the training set, with the experimental pIC50. (c) Correlation between test set pIC50 
predictions obtained from a leave-two-out analysis. (d) Plot showing the correlation 
between cell (L. donovani) pIC50 and enzyme (FPPS) pIC50 values. (e) Correlation 
between predicted cell pIC50 values (from the best combination of enzyme plus two 
molecular descriptors) for the training set, with the experimental pIC50. (f) Correlation 
between test set pIC50 predictions obtained from a leave-two-out analysis. (g) Plot 
showing the correlation between cell (S. pneumoniae) pIC50 and enzyme (UPPS) pIC50 
values. (h) Correlation between predicted cell pIC50 values (from the best combination 
of enzyme plus two molecular descriptors) for the training set, with the experimental 
pIC50. (i) Correlation between test set pIC50 predictions obtained from a leave-two-out 
analysis. 
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Figure 2.4. Correlation plots for the cell and enzyme assays, and predicted cell activities 
from the training and test set data in Streptococcus pneumoniae (MurI) (a-c), Hu-7 (HCV 
NS3 protease replication) (d-f) and MT4 (HIV-1 integrase) (g-i). (a) Plot showing the 
correlation between cell (S. pneumoniae) pIC50 and enzyme (MurI) pIC50 values. (b) 
Correlation between predicted cell pIC50 values (from the best combination of enzyme 
plus two molecular descriptors) for the training set, with the experimental pIC50. (c) 
Correlation between test set pIC50 predictions obtained from a leave-two-out analysis. 
(d) Plot showing the correlation between cell (HCV/Hu-7) pIC50 and enzyme (HCV 
NS3 protease) pIC50 values. (e) Correlation between predicted cell pIC50 values (from 
the best combination of enzyme plus two molecular descriptors) for the training set, 
with the experimental pIC50. (f) Correlation between test set pIC50 predictions obtained 
from a leave-two-out analysis. (g) Plot showing the correlation between cell (HIV/MT4) 
pIC50 and enzyme (HIV-1 integrase) pIC50 values. (h) Correlation between predicted cell 
pIC50 values (from the best combination of enzyme plus two molecular descriptors) for 
the training set, with the experimental pIC50. (i) Correlation between test set pIC50 
predictions obtained from a leave-two-out analysis. 
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Figure 2.5. Correlation plots for the cell and enzyme assays, and predicted cell activities 
from the training and test set data in rat hepatocytes (hlGP) (a-c), NIH3T3 (KDR kinase) 
(d-f) and MiaPaCa-2 (Akt kinase) (g-i). (a) Plot showing the correlation between cell 
(Rat hepatocytes) pIC50 and enzyme (hlGP) pIC50 values. (b) Correlation between 
predicted cell pIC50 values (from the best combination of enzyme plus two molecular 
descriptors) for the training set, with the experimental pIC50. (c) Correlation between 
test set pIC50 predictions obtained from a leave-two-out analysis. (d) Plot showing the 
correlation between cell (NIH 3T3) pIC50 and enzyme (KDR kinase) pIC50 values. (e) 
Correlation between predicted cell pIC50 values (from the best combination of enzyme 
plus two molecular descriptors) for the training set, with the experimental pIC50. (f) 
Correlation between test set pIC50 predictions obtained from a leave-two-out analysis. 
(g) Plot showing the correlation between cell (MiaPaCa-2) pIC50 and enzyme (Akt 
kinase) pIC50 values. (h) Correlation between predicted cell pIC50 values (from the best 
combination of enzyme plus two molecular descriptors) for the training set, with the 
experimental pIC50. (i) Correlation between test set pIC50 predictions obtained from a 
leave-two-out analysis. 
 
 
 
 
52 
 
2.7 References 
1. Buckner FS, Eastman RT, Yokoyama K, Gelb MH, & Van Voorhis WC (2005) Protein 
Farnesyl Transferase Inhibitors for the Treatment of Malaria and African trypanosomiasis. 
Curr Opin Investig Drugs 6(8):791-797. 
2. Dunford JE, et al. (2008) Structure-activity relationships among the nitrogen containing 
bisphosphonates in clinical use and other analogues: time-dependent inhibition of human 
farnesyl pyrophosphate synthase. J Med Chem 51(7):2187-2195. 
3. Martin MB, et al. (2001) Bisphosphonates inhibit the growth of Trypanosoma brucei, 
Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium 
falciparum: a potential route to chemotherapy. J Med Chem 44(6):909-916. 
4. Ghosh S, et al. (2004) Effects of Bisphosphonates on the Growth of Entamoeba 
histolytica and Plasmodium Species In vitro and In vivo. (Translated from English) J. 
Med. Chem. 47(1):175-187 (in English). 
5. Dobson PD & Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: 
an exception or the rule? Nat Rev Drug Discov 7(3):205-220. 
6. Peukert S, et al. (2008) Design and structure-activity relationships of potent and selective 
inhibitors of undecaprenyl pyrophosphate synthase (UPPS): tetramic, tetronic acids and 
dihydropyridin-2-ones. Bioorg Med Chem Lett 18(6):1840-1844. 
7. Anonymous (2006) Molecular Operating Environment (MOE) (Chemical Computing 
Group, Inc., Montreal, Quebec). 
 
 
 
53 
8. Szabo CM, Martin MB, & Oldfield E (2002) An Investigation of Bone Resorption and 
Dictyostelium discoideum Growth Inhibition by Bisphosphonate Drugs. J Med Chem 
45(14):2894-2903. 
9. Yardley V, et al. (2002) In vivo activities of farnesyl pyrophosphate synthase inhibitors 
against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother 
46(3):929-931. 
10. Montalvetti A, et al. (2003) Farnesyl pyrophosphate synthase is an essential enzyme in 
Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J Biol 
Chem 278(19):17075-17083. 
11. Montalvetti A, et al. (2001) Bisphosphonates are Potent Inhibitors of Trypanosoma cruzi 
Farnesyl Pyrophosphate Synthase. J Biol Chem 276(36):33930-33937. 
12. Sanders JM, et al. (2003) 3-D QSAR Investigations of the Inhibition of Leishmania 
major Farnesyl Pyrophosphate Synthase by Bisphosphonates. J Med Chem 46(24):5171-
5183. 
13. Dunford JE, et al. (2001) Structure-Activity Relationships for Inhibition of Farnesyl 
Diphosphate Synthase In vitro and Inhibition of Bone Resorption In vivo by Nitrogen-
Containing Bisphosphonates. J Pharmacol Exp Ther 296(2):235-242. 
14. Fujihashi M, et al. (2001) Crystal Structure of cis-Prenyl Chain Elongating Enzyme, 
Undecaprenyl Diphosphate Synthase. Proc Natl Acad Sci U S A 98(8):4337-4342. 
15. Guo RT, et al. (2007) Bisphosphonates target multiple sites in both cis- and trans-
prenyltransferases. Proc Natl Acad Sci U S A 104(24):10022-10027. 
 
 
 
54 
16. de Dios A, et al. (2002) 4-Substituted D-glutamic acid analogues: the first potent 
inhibitors of glutamate racemase (MurI) enzyme with antibacterial activity. J Med Chem 
45(20):4559-4570. 
17. Li C, et al. (2008) Correlation between PAMPA permeability and cellular activities of 
hepatitis C virus protease inhibitors. Biochem Pharmacol 75(5):1186-1197. 
18. Verschueren WG, et al. (2005) Design and optimization of tricyclic phtalimide analogues 
as novel inhibitors of HIV-1 integrase. J Med Chem 48(6):1930-1940. 
19. Klabunde T, et al. (2005) Acyl ureas as human liver glycogen phosphorylase inhibitors 
for the treatment of type 2 diabetes. J Med Chem 48(20):6178-6193. 
20. Dinges J, et al. (2007) 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as 
novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the 
hERG ion channel. J Med Chem 50(9):2011-2029. 
21. Zhu GD, et al. (2007) Syntheses of potent, selective, and orally bioavailable indazole-
pyridine series of protein kinase b/akt inhibitors with reduced hypotension. J Med Chem 
50(13):2990-3003. 
22. Anonymous (2005) GraphPad Prism Version 4.0c (GraphPad Software, Inc., La Jolla, 
CA). 
23. Anonymous (2007) MATLAB Version 7.4 (The Mathworks, Inc., Natick, MA). 
24. Anonymous (Sybyl 7.3 (Tripos, Inc., St. Louis, MO). 
25. Petitjean M (1992) Applications of the Radius Diameter Diagram to the Classification of 
Topological and Geometrical Shapes of Chemical-Compounds. (Translated from English) 
Journal of Chemical Information and Computer Sciences 32(4):331-337 (in English). 
 
 
 
55 
26. Balaban AT (1979) Five New Topological Indices for the Branching of Tree-Like Graphs. 
Theoretica Chimica Acta. 53:355-375. 
27. Weiner H (1947) Structural Determination of Paraffin Boiling Points. J Am Chem Soc 
69:17-20. 
28. Pearlman RS & Smith KM (1998) Novel Software Tools for Chemical Diversity. Persp 
Drug Disc Desc 9/10/11:339-353. 
29. Wildman SA & Crippen GM (1999) Prediction of physicochemical parameters by atomic 
contributions. (Translated from English) Journal of Chemical Information and Computer 
Sciences 39(5):868-873 (in English). 
30. Hall LH & Kier LB (1977) The Nature of Structure-Activity Relationships and Their 
Relation to Molecular Connectivity. Eur J Med Chem 12:307. 
31. Hall LH & Kier LB (1991) The Molecular Connectivity Chi Indices and Kappa Shape 
Indices in Structure-Property Modeling. Reviews of Computational Chemistry 2. 
32. Balaban AT (1982) Highly Discriminating Distance-Based Topological Index. Chem 
Phys Lett 89(5):399-404. 
33. Oprea TI (2000) Property Distribution of Drug-Related Chemical Databases. J Comp Aid 
Mol Des 14:251-264. 
34. Hou TJ, Xia K, Zhang W, & Xu XJ (2004) ADME Evaluation in Drug Discovery. 4. 
Prediction of Aqueous Solubility Based on Atom Contribution Approach. J Chem Inf 
Comput Sci 44:266-275. 
35. Stanton D & Jurs P (1990) Anal Chem 62:2323. 
 
 
 
56 
36. Ertl P, Rohde B, & Selzer P (2000) Fast Calculation of Molecular Polar Surface Area as a 
Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug 
Transport Properties. J. Med. Chem. 43:3714-3717. 
 
 
 
 
 
57 
Chapter 3 
Lipophilic Analogs of Zoledronate and Risedronate 
Inhibit Plasmodium Geranylgeranyl Diphosphate 
Synthase and Have Potent Activity Against Malaria 
Parasites 
 
 
3.1 Notes and Acknowledgements 
This work was supported by the United States Public Health Science (NIH grant GM 65307). 
High throughput screening (HTS) assay, in vitro cell assay and in vivo experiment were carried 
out by Dr. Fernando Dossin at Institut Pasteur Korea. 
 
3.2 Introduction 
Malaria, caused by Plasmodium spp., causes ~1 million deaths each year (1) and there are ever 
present problems due to drug resistance (2). There is, therefore, a need for new drugs, and drug 
leads. In earlier work, we and others found that the bisphosphonate class of drugs (3) used to 
treat bone-related diseases-osteoporosis, Paget’s disease and hypercalcemia due to malignancy, 
also inhibited the growth of a range of parasitic protozoa including Trypanosoma cruzi(4, 5), T. 
brucei (4, 6), Leishmania spp. (4, 7, 8),  Toxoplasma gondii (4, 9), Cryptosporidium parvum (10, 
11), Entamoeba histolytica (4, 12, 13) and Plasmodium spp. (4, 13-15). In the case of 
Plasmodium spp., the most potent inhibitors were not, however, the nitrogen-containing 
bisphosphonates such as risedronate or zoledronate used to treat bone diseases, but more 
lipophilic n-alkyl bisphosphonates (13), although their target in P. falciparum was not 
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determined. More recently, a P. vivax geranylgeranyl diphosphate synthase (PvGGPPS) has been 
cloned, expressed, purified and crystallized and its three-dimensional structure determined (16). 
The enzyme is potently inhibited by bisphosphonates (16) so it seemed possible that it might be a 
target for the inhibitors discovered earlier. To investigate this possibility, we recently determined 
the IC50 values for 25 bisphosphonates against PvGGPPS and compared the results for enzyme 
inhibition with P. falciparum growth inhibition pIC50 (= -log10IC50) values (17). The correlation 
was very poor: R2 = 0.06.  For example, zoledronate had an IC50 of ~790 nM in the enzyme 
assay, but an IC50 = 120 µM in cells, and similar results were found with several other systems 
with the average R2 value being 0.30 (17) for 10 diverse assays (3 from our group; 7 from other 
groups). This strongly suggested that zoledronate had poor permeability in the P. falciparum/red 
cell assay, due to its highly polar nature (log P = -2.9). However, when incorporating 
mathematical descriptors (such as logP) to begin to account for permeability, we found that good 
(R2=0.7) correlations between cell and enzyme activity could be obtained (17). These results 
indicated, at least for these types of compounds, that simply screening for good enzyme 
inhibitors might not be particularly informative since many such inhibitors would be unable to 
get into cells, and that cell assays would be much more desirable. 
A second set of problems with the bisphosphonate class of molecules is that they bind 
very tightly to bone mineral (18, 19), resulting in their rapid removal from the bloodstream.  This 
is of course a desirable feature of a bone drug, but not of an anti-infective (or anti-cancer) drug 
lead and in recent work, we have been developing a class of compounds called “lipophilic 
bisphosphonates” (20, 21) in which the 1-OH group on the bisphosphonate backbone, part of the 
tri-dentate “bone-hook”, is removed and in which a variety of hydrophobic side-chains are 
attached to the molecules in order to increase clogP values, typically from ~ -2 or -3 to ~ 2 or 3.  
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These lipophilic bisphosphonates have far more potent activity both in vitro and in vivo than do 
conventional bisphosphonates in tumor cell growth inhibition and γδ T cell activation assays (20, 
21), as well as against malaria parasites (14).  In this work, we thus elected to screen our in-
house library of 564 prenyl synthase inhibitors, developed over the past decade as anti-cancer 
drug leads and as anti-bacterials (20-24), for their activity in P. falciparum growth inhibition 
inside red cells. We discovered two potent leads, lipophilic analogs of the commercial drugs 
risedronate and zoledronate and determined their single crystal x-ray crystallographic structures 
bound to P. vivax GGPPS, in addition to testing them in vivo, finding potent activity, opening up 
the possibility that other commercial bisphosphonates, inactive themselves against Plasmodium 
spp. as well as other organisms) may be converted to species that are highly active both in vitro 
and in vitro, via simple chemical modification. 
 
3.3 Results and Discussion 
Inhibitor Library and High Throughput Screening (HTS).   
We screened 564 compounds for their ability to inhibit Plasmodium falciparum cell growth 
inside erythrocyctes. The library consisted of a diverse selection of bisphosphonates, 
phosphonosulfonates and cationic species known to inhibit head-to-tail and/or head-to-head 
prenyl transferases that have been developed in our laboratory over the past decade, primarily as 
anti-cancer and anti-bacterial agents.  
In Plasmodium spp., the initial steps in isoprenoid biosynthesis are carried out by the so-
called methylerythritol phosphate (MEP) pathway, which produces isopentenyl diphosphate (IPP) 
and dimethylallyl diphosphate (DMAPP) from pyruvate and glyceraldehyde-3-phosphate, Figure 
3.1 (25).  DMAPP then condenses sequentially with three molecules of IPP to form geranyl 
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diphosphate (GPP), farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), which 
is then used to prenylate proteins (26).  In addition, in P. falciparum, GGPP is converted via 
prephytoene diphosphate to phytoene and thence to carotenoids (27), plus, the longer chain 
diphosphates are converted to quinones such as Men-4 (28) as well as dolichols (29).  In 
Plasmodium spp., GGPPS appears to be bi-functional, making both FPP as well as GGPP, but 
based on its sequence and x-ray crystallographic structure with bound inhibitors (16), the enzyme 
is clearly more similar to other FPPS than GGPPS enzymes – as evidenced for example by the 
presence of a third Asp in the second conserved DDXXD-domain (16), inhibition by zoledronate 
and risedronate (unlike human and S. cerevisae GGPPS), and the presence of the 3Mg2+ seen in 
these structures, compared to the 2Mg2+ typically found in S. cerevisae GGPPS (30). However, 
the enzyme is a more effective producer of GGPP than of FPP (16).  Our library contained 474 
bisphosphonates that might inhibit the Plasmodium GGPPS, in addition to 5 
phosphonosulfonates and related systems that inhibit head-to-head prenyl synhtases (22-24) such 
as the Staphylococcus aureus protein CrtM (dehydrosqualene; (22)). Such compounds inhibit 
both dehydrosqualene as well as squalene synthase (31) and could also inhibit Plasmodium 
phytoene synthase. We also screened 34 cationic species (such as Ro 48-8071 and quinuclidines), 
some of which are known to inhibit Plasmodium cell growth (28, 32).  In addition, we screened 
51 pyrophosphate mimics that are potential inhibitor in isoprenoid pathway. 
We first screened all compounds at 10 µM to find possible hits, using artemisinin as a 
positive control (IC50 = 20 nM).  There were 78 hits (defined as giving ≥ 70% inhibition at 10 
µM), Figure 3.2A, and the Z´ factor for the control wells was 0.72, Figure 3.2B.  The Zʹ′ factor is 
defined (33) as: 
Z´ = 1 – 3(σc+ + σc-) / | µc+ - µc-| 
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where σc+/σc- are the standard deviations of the positive (artemisinin)/negative (phosphate 
buffered saline) controls and µc+/µc- are the corresponding mean values (33) with Zʹ′ = 0.72 
indicating an excellent assay.  Full assay details are given in Methods.  We then determined 
dose-response curves for these hits (structures shown in Figure 3.7): dose-response curves are 
shown in Figure 3.8. The chemical structures of the 10 most active compounds are shown in 
Figure 3.9. To determine which of these compounds might be worth further investigation, we 
next determined the IC50 values for each of these 10 compounds in inhibiting the growth of three 
human cell lines.  Typical dose-response curves are shown in Figure 3.2C and all IC50 values are 
given in Table 3.2. We then used a therapeutic index plot, Figure 3.2D, in which we plotted the 
therapeutic index (T.I.), defined as: 
T.I. (therapeutic index) = IC50 (human cell assay)/IC50 (P. falciparum assay) 
versus the P. falciparum IC50 values to find those compounds with the best activity versus P. 
falciparum that also had the low toxicity to human cells.  Most compounds were very toxic but 
two: BPH-703 and BPH-811: had relatively low activity in these assays (IC50 values of 133 and 
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28 µM, respectively) and good activity in the P. falciparum growth inhibition assay (IC50 = 690 
nM and 1 µM, for BPH-703 and BPH-811, respectively).  Both compounds also have favorable 
logP values (logP ~2; Table 3.2) in addition to good cell activity, as illustrated in Figure 3.2E.  
Remarkably, of the 564 compounds assayed, the two most promising leads were both found to 
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both be simple derivatives of risedronate and zoledronate in which the 1-OH group is replaced 
by an H, and the aryl group contains a C10 or C12, hydrophobic substituent that improves logP 
and is expected to reduce bone binding, as shown previously with BPH-715 (19). 
Target Identification.   
The results presented above are of considerable interest since we find that two of the most potent 
inhibitors with low toxicity are both “lipophilic” analogs of the well-known bisphosphonate 
drugs zoledronate (Zometa®/Reclast®) and risedronate (Actonel®/Atelvia®) which target FPPS 
(3). This strongly suggested the possibility that both of these lipophilic bisphosphonates (LBPs) 
target one or more prenyl synthases. In the case of BPH-703, as illustrated in Figure 3.2F, it can 
be seen that this molecule can be thought of as being derived from a “fusion” of the key 
structural features found in zoledronate (the bisphosphonate and imidazolium/carbocation-
isostere) with the hydrophilic diphosphate and lipophilic features found in FPP, or GGPP.   In 
previous work, we found that the lipophilic pyridinium bisphosphonate BPH-715 was a potent 
inhibitor of both liver stage as well as blood state malaria parasites (14), but BPH-703 is far less 
active than is BPH-715 against three human cell lines (~133 µM vs. ~168 nM, for BPH-715), 
Table 3.2.  In the case of BPH-811, it can again be seen (Figure 3.2F) that this compound is 
basically a more lipophilic analog of risedronate in which there is a decyloxy side-chain addition, 
and the 1-OH is replaced by H.  The logP values for risedronate and zoledronate are -2.9 and -
3.5, while those for the LBPs are much more positive (Table 3.2):  BPH-703 = 2.5; BPH-811 = 
1.5, which can be expected to result in enhanced cell activity (17).  
To determine whether Plasmodium GGPPS is in fact a major target for the lipophilic 
bisphosphonates, we expressed GGPPS from P. vivax (whose x-ray structure is known and 
which has 73% identity and 89% similarity to the P. falciparum protein) and determined dose-
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response curves for both inhibitors from which we find IC50 values of 1.2 µM (BPH-703) and 2.5 
µM (BPH-811), corresponding to Ki values of 270 and 566 nM, consistent with a GGPPS target 
in P. falciparum.  To further test this idea, we next carried out cell growth inhibition “rescue” 
experiments, as reported previously for T. brucei (34) and human tumor cell lines (20), in which 
we added either farnesol, geranylgeraniol or solanesol (C45) to the growth medium. The results 
(Figure 3.10) clearly indicated that only GGOH (at 20µM) rescued cell growth, supporting a 
GGPPS target for both BPH-703 and BPH-811. These results are of interest since the extremely 
potent Plasmodium GGPPS inhibitors risedronate and zoledronate (16) have little activity in P. 
falciparum growth assays (4), and were not found to be hits in our initial screen, even though 
they have GGPPS IC50 values of ~500 nM (Table 3.2 and Ref.(16)) against P. vivax GGPPS. We 
thus next sought to determine how BPH-703 and BPH-811 bound to Plasmodium vivax GGPPS, 
whose x-ray crystallographic structure we recently reported (16) . 
Crystallographic structures of PvGGPPS-inhibitor complexes.   
As we and others reported previously (30, 35, 36), there are four main ligand (substrate or 
inhibitor) binding sites in human and S. cerevisae GGPPS, illustrated in Fig. 2.3 (from Fig. 3 in 
ref (36).  Two are polar binding sites where the diphosphates in the substrates (IPP, and FPP) 
bind, and two are hydrophobic sites, where the C15 (FPP) substrate or C20 (GGPP) products can 
bind.  Bisphosphonate inhibitors can bind with their phosphonate groups in either polar binding 
site, and there are three district polar/non-polar motifs for bisphosphonates bound to S. cerevisae 
GGPPS (30, 36), as shown in Figure 3.3A, while in PvGGPPS, small bisphosphonates bind to 
the FPP site while the GGPP product spans the IPP-FPP site (Figure 3.3A). We thus next 
obtained the single crystal x-ray crystallographic structures of BPH-703 and BPH-811 bound to 
PvGGPPS, using co-crystallization. Full crystallographic and structure refinement details are 
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given in Table 3.1; crystallization details were as described previously (16).  With PvGGPPS 
(PDB ID code 3LDW), zoledronate binds to the FPP site (in yellow), Figure 3.3A, B, and unlike 
the situation found with human and S. cerevisae GGPPS, is a potent inhibitor (IC50 ~510 nM, 
versus ~100 µM in human GGPPS (Table 3.2), due to the fact that the zoledronate 
bisphosphonate group binds to 3 Mg2+ in the PvGGPPS protein, just as in human FPPS (37, 38).  
With the zoledronate analog BPH-703, we find that the bisphosphonate headgroup also binds to 
3 Mg2+ in the active site, just as the parent molecule zoledronate does, Figure 3.3A, B.  In 
addition, the imidazolium group is situated in essentially the same position as found with 
zoledronate bound to PvGGPPS (PDB ID code 3LDW): a 0.79 Å rmsd based on a protein 
structure alignment; 0.37 Å for the imidazole, Mg2+ and bisphosphonate P, O atoms, based on a 
ligand/Mg2+ alignment.  The polar headgroup in the lipophilic bisphosphonate thus binds in a 
very similar manner as does its zoledronate parent.  However, the alkyl chain present in the 
lipophilic species BPH-703 occupies the FPP substrate hydrophobic site –not either or the GGPP 
product (or inhibitor) sites seen in other structures (30, 35, 36).  The GGPP product site found in 
the yeast and human enzymes is blocked by R50 and the site that houses the “tail” of the FPP-
analog inhibitor, S-thiolo-FPP, is blocked by F88. In addition, the BPH-703 side-chain can be 
seen to occupy a 13Å long hydrophobic pocket lined by numberous polar residues that spans 
both molecules in the dimer, Figure 3.11. 
In the case of the lipophilic risedronate-analog, BPH-811, we again find that the 
bisphosphonate headgroup binds to a [Mg2+]3 cluster, with its long alkyl chain located in the FPP 
substrate side-chain site, Figure 3.4A.  Protein contacts are shown in Figure 3.4B.  The local 
(risedronate/Mg2+) structure is very similar to that seen with risedronate bound to T. cruzi FPPS a 
(0.82 Å rmsd, protein alignment; 0.50 Å rmsd, ligand (Mg2+ local alignment, as described above), 
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as shown in Figure 3.4A.  Moreover, the BPH-811 structure is very similar to that seen with 
BPH-703, is shown in Figure 3.4C. Overall, both PvGGPPS structures containing lipophilic 
bisphosphonates are thus characterized binding to a [Mg2+]3 cluster; close register of the 
risedronate, zoledronate cationic features in the liphophilic bisphosphonates with their more 
hydrophilic parent compounds; hydrophobic/alkyl groups that occupy the FPP side-chain pocket; 
and close register between the hydrophobic side-chains in both PvGGPPS inhibitors (an 1.19 Å 
rmsd for 10 carbons). 
Interestingly, when both lipophilic bisphosphonates bind to PvGGPPS these do so by 
opening up a “hydrophobic tunnel” that spans the dimer structure. In the case of zoledronate 
(Figure 3.11A), this tunnel is closed but in the presence of either BPH-703 (Figure 3.11B) or 
BPG-811 (Figure 3.11C) it is readily apparent that there is a continuous tunnel that encompasses 
both GGPPS molecules, the surface shown being visualized using the ligand-free structures 
using the Pymol program (Delano Scientific, Palo Alto, CA), the ligands being superposed. In 
contrast, the polar part of GGPP binds to the IPP diphosphate-binding site while the side-chain is 
bent and occupies the FPP side-chain site, Figure 3.11D and the channel linking the two 
monomers is absent, as expected. 
Isothermal Titration Calorimetry:  Enzyme inhibition and Bone Binding.   
Next, we investigated the thermodynamics of binding of BPH-703, BPH-811, as well as 
zoledronate and risedronate, to PvGGPPS by using isothermal titration calorimetry (ITC).  The 
headgroups in the lipophilic bisphosphonates bind to PvGGPPS in a s similar manner to that seen 
with risedronate and zoledronate, but how does alkyl substitution affect the thermodynamics of 
binding?  
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In earlier work, we investigated the thermodynamics of binding of six bisphosphonates to 
FPPS from T. brucei (39), and related results have been reported for bisphosphonates binding to 
human FPPS (37, 38).  With bisphosphonates having cationic side-chains (e.g. pamidronate, 
ibandronate and pyridinium-1-yl bisphosphonates), binding was overwhelmingly entropy driven 
(39), due to the hydrophobic effect.  However, with neutral side-chain containing species e.g. 
risedronate and deaza-risedronate, binding was enthalpy driven.  With PvGGPPS, binding is 
neither overwhelmingly entropy nor enthalpy driven.  For BPH-703, the zoledronate analog, we 
find (Table S3) ∆G = -8.7 kcal mole-1 with ∆H = -5 kcal mole-1 and ∆S = 12 cal deg-1 mole-1, 
Figure 3.5A, to be compared with ∆G = -9.5 kcal mole-1, ∆H = -4.8 kcal mole-1 and ∆S = 16 cal 
deg-1 mole-1 for zoledronate, Figure 3.5B.  So in this case, alkyl substitution (and loss of the 1-
OH group) results in only a small overall change in ∆G of ~0.8 kcal mole-1.  This is an 
encouraging result since it indicates that making a major structural change in the inhibitor – 
adding a C12 side-chain, has only a relatively minor effect on GGPP binding, consistent with the 
enzyme inhibition results (Table 3.2,where of course Mg2+ and IPP-binding are also involved).  
This is in sharp contrast to the observation that BPH-703 is a potent inhibitor of P. falciparum 
growth in vitro, while the zoledronate parent has only very low activity where we find an IC50 = 
167 µM (13).  The same trend is seen with BPH-811 and its parent, risedronate, Figs. SA,B.  
With BPH-811, we find ∆G = -9.3 kcal mole-1, ∆H = -2.9 kcal mole-1 and ∆S = 21 cal deg-1 
mole-1 (Table 3.3) while for the risedronate parent, ∆G = -9.3 kcal mole-1, ∆H = -2.5 kcal mole-1 
and ∆S = 25 cal deg-1 mole-1.  In this case, the effect of adding the C10 decyloxy side-chain and 
remaining the 1-OH group does not affect ∆G.  So:  in both cases, conversion of the parent 
bisphosphonate to the more lipophilic analog, expected to have enhanced cell/tissue permeability 
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(17) and poor bone-binding capacity (18), has little or no effect on ligand binding and only a 
small effect on enzyme inhibition – even though there are major effects in cell-based assays. 
It is also of interest to see how these results with GGPPS compare with those we reported 
previously, on FPPS (39).  As can be seen in Figure 3.5C, the four ∆H, ∆S values fall on the line 
discussed previously for 6 bisphopshonates (at 2 pH values) binding to FPPS from T. brucei (39).  
The apparent “enthalpy-entropy compensation” is due simply to the fact that the overall range in 
∆G is small while that for ∆H (and ∆S) is large so that ∆H = T∆S +b with a slope ∂(∆H)i/∂(∆S)i 
= T, and as expected the slope found in Figure 3.5C is 298K, the temperature at which the ITC 
experiments were performed.  What is surprising about these results is that the zoledronate/BPH-
703 ∆S/∆H results are very close, as are the risedronate/BPH-811 results, Figure 3.5C.  
Moreover, the two sets of results are themselves quite close, with neither the extreme entropy or 
enthalpy-driven behavior seen with FPPS (39).  In FPPS, binding of all bisphosphonates 
containing a cationic side-chain in entropy driven (top right, Figure 3.5C).  In GGPPS, however, 
we see behavior that is “in-between” these extremes.  While this could of course be due to an 
inappropriate comparison between the different structures, the fact that the FPPS/GGPPS 
structures with e.g. zoledronate  bound are essentially superimposable (16) suggests either that 
the charge center does not contribute to binding in GGPPS, or that the presence of the large 
neutral side-chain simply reduces the effects of the cation center.  The former view is supported 
by the observation in S. cerevisae GGPPS that the cation center is not essential for GGPPS 
inhibition (36) unlike the situation with FPPS (3). 
In vivo Testing Results.   
To see to what extend the lipophilic bisphosphonates have in vivo activity, we used a P.chabaudi 
suppressive test. We first injected mice with 106 parasites followed by 10 mg/kg of each 
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bisphosphonate, i.p., for 4 days. With BPH-703, there was a 100% reduction in parasitemia, 
Figure 3.6A, and a 100 % survival at day 14, Figure 3.6B, although there was weight loss that 
disappeared after treatment. In the case of BPH-811, there was an ~80% decrease in parasitemia 
and an 80% survival at day 14.  We then carried out a second series of experiments using a 
reduced (3mg/kg, i.p.) dosing protocol. As with the 10 mg/kg dose, the best results were obtained 
with BPH-703 (Figure 3.6C,D) where there was a 100% survival (Figure 3.6D) and only ~ 8% 
parasitemia (Figure 3.6C), 14 days after dosing.  As can be seen in Table 3.2, BPH-703 has good 
in vitro IC50 and logP values and little effects on human cell lines as well as good in vivo activity 
and thus represents a potentially attractive lead for further development. 
 
3.4 Conclusions 
Overall, the results presented here are of interest since they show that GGPPS is a promising 
target for anti-malarials, and that the lipophilic analogs of the bone resorption drugs zoledronate 
and risedronate have activity boh in vitro as well as in vivo. BPH-703 is a lipophilic analog of 
zoledronate in which the 1-OH group is removed (to prevent bone binding) and the ring is 
alkylated, to enhance lipophilicity. BPH-811 is an analog of risedronate in which, again, the 1-
OH group is removed and a lipophilic tail added, to increase cell permeability, decrease bone-
binding, and enhance tissue distribution.  Both compounds have potent activity in vitro and in 
vivo while the parent drugs, zoledronate and risedronate, have only modest activity against P. 
falciparum in intra-erythrocytic assays, and risedronate, while reducing parasitemia, has no 
effect on survival (15). Also of interest is the observation that the lipophilic bisphosphonate 
inhibitors in the Plasmodium GGPPS structures adopt very similar binding poses to those of their 
parent compounds bound to both GGPPS as well as FPPS, and have similar enzyme activity and 
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∆G values, for GGPPS binding.  It thus seems likely that these and related lipophilic 
bisphosphonates will have improved activity over that already reported with more hydrophilic 
bisphosphonates (4-15) against other parasitic protozoa, such as T. brucei, T. cruzi, Leishmania 
spp., T. gondii, C. parvum and E. histolytica. 
 
3.5 Materials and Methods 
P. falciparum culture. 
 P. falciparum strain 3D7 was maintained in vitro in human O+ erythrocytes at 3% hematocrit in 
RPMI 1640 media supplemented with L-glutamine, 25 mM HEPES and sodium bicarbonate. 
Albumax I (0.5%) and HT Supplement (0.1 mM hypoxanthine and 16 µM thymidine) were 
added to complete the media.  
P. falciparum drug screening and rescue experiments.   
A total of 564 compounds were screened at 10 µM, in duplicates. For screening, the P. 
falciparum culture was adjusted to 2% hematocrit, 0.5% parasitemia, dispensed by a WellMate 
(Thermo) to 384 wells plate (Greiner) containing the compounds (final volume 50 µL) and 
incubated for 72 hours. Chloroquine, artemisinin and DMSO were used within the assay plates to 
serve as controls.  
 After three days, the parasite lactate dehydrogenase (pLDH) assay was used to assess 
drug efficacy. Briefly, at the end of 72 h the plates were frozen overnight at -20°C. After 
thawing, the plates were shaken for 45 seconds at 1700 rpm in a Mix Mate (Eppendorf) and 5 µL 
of the lysate transferred into the corresponding well of another plate containing 30 µL of Malstat 
Reagent (40) and incubated for 2 h. The absorbance (650 nm) was read using a Spectramax M5 
(Molecular Devices, USA). For hit confirmation, those compounds selected as hits were cherry-
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picked, serially diluted (range 9.7 nM to 40 µM) and tested in triplicates under the same 
conditions as used in the initial screening. To confirm the activity of the compounds using 
another readout, we adapted a SybrGreen assay (41) to a 384 well plate format and tested a 
randomly chosen sample of the hits (15%), as follows.  After incubation with the compounds, 25 
µL of lysis buffer (30mM Tris pH 7.5, 7.5 mM EDTA, 0.012% saponin, 0.12% Triton X-100 
plus 0.3 µL SybrGreen per mL) were added to each well. The plates were shaken for 45 seconds 
at 1700 rpm in a Mix Mate, incubated for 1 hour at room temperature, and fluorescence read (Ex 
485nm/ Em 530nm) using a Spectramax M5. 
For cell growth inhibition rescue experiments, selected compounds were tested over a 
range of concentrations (39 nM to 20 µM). Parasites were incubated with either the compound 
alone, the compound and 20 µM farnesol or the compound and 20 µM geranylgeraniol in 384 
well plates and under the same conditions as the hits confirmation experiments. 
Cell Growth Inhibition Assays, Human FPPS Inhibition and Human GGPPS Inhibition. 
The tumor cell, human FPPS and human GGPPS inhibition assays were carried out as described 
in our previous work (42). 
Synthetic Aspects.   
All reagents used were purchased from Aldrich and Alfa Aesar. The purities of all bisphosphonic 
acids were routinely monitored by using 1H NMR and 31P NMR spectroscopy on Varian (Palo 
Alto, CA) Unity spectrometers and by microchemical analysis.  BPH-688, BPH-710 and BPH-
715 were available from previous work (43). 
2-(5-decyloxypyridin-3-yl)ethylidene-1,1-bisphosphonic acid (BPH-811).  
(EtO)2(O)P P(O)(OEt)2
NaH/THF
N
ClO9 N
O
9
P(O)(OEt)2
P(O)(OEt)2
TMSBr
N
O
9
P(O)(OH)2
P(O)(OH)2
BPH-811  
 
 
 
71 
To a suspension of NaH (480 mg, 60% in mineral oil, 12 mmol) in anhydrous THF (20 
mL) at 0 °C was added tetraethyl methylenebisphosphonate (2.88 g, 10 mmol) and the mixture 
was allowed to stir at room temperature for 30 min. 3-Decyloxy-5-chloromethyl-pyridine (2.83 
g, 10 mmol,  in 5 mL THF) and NaI (1.8g, 12 mmol) were added, and the reaction mixture was 
refluxed under nitrogen for 2 h. The mixture was then queched with saturated aq. NH4Cl at room 
temperature. Extraction with ethyl acetate, and flash chromatography (ethanol: ethyl acetate, 
5:95) afforded the tetraethyl ester as a colorless oil (2.6 g, 50% yield). Dealkylation using 8 
equivalent of TMSBr gave BPH-811 as a white powder (1.7 g, 80%). Anal. (C17H31NO7P2•H2O). 
1H NMR (D2O, 400 MHz): δ 7.9 (1H, s), 7.8 (1H, s), 7.2 (1H, s), 4.0 (3H, t, J = 6.4Hz), 2.9 (2H, 
td, J = 15Hz, 6.8Hz), 1.9 (1H, tt, J = 21 Hz, 6.8Hz), 1.5-1.6 (2H, m), 1.0-1.15 (12H, m), 0.63 
(3H, t, J = 6.0 Hz). 31P NMR (D2O, 162 MHz): δ 19.6. 
All pyridinium-1-yl bisphosphonates (BPH-816, BPH-776, BPH-805, BPH-725, BPH-817, 
BPH-820, BPH-638) were prepared as described previously (44). 
2-(3-decylaminopyridium)-1-yl-ethylidene-1,1-bisphosphonic acid (BPH-816). 
 Anal. (C17H32NO6P2•0.75H2O). 1H NMR (D2O, 400 MHz): δ 7.91  (1H, s), 7.84 (1H, d, J = 
5.2Hz), 7.30-7.41 (2H, m), 4.5 (2H, t, J = 15Hz, 6.8Hz), 3.14 (2H, t, J = 6.8Hz), 2.2 (1H, tt, J = 
21 Hz, 6.8Hz), 1.5-1.6 (2H, m), 1.0-1.4 (14H, m),  0.67 (3H, t, J = 6.0 Hz). 31P NMR (D2O, 162 
MHz): δ 14.6. 
2-(3-undecyloxypyridinium-1-yl)ethylidene-1,1-bisphosphonic acid (BPH-776). 
 Anal. (C18H31NO6P2•1.5H2O). 1H NMR (D2O, 400 MHz): δ 8.49  (1H, s), 8.35(1H, d, J = 6Hz), 
7.76 (1H, d, J = 9Hz), 7.6 (1H, d, J = 9Hz), 4.3 (2H, t, J = 15Hz, 6.8Hz), 4.0 (2H, t, J = 6.0Hz), 
2.2 (1H, tt, J = 21 Hz, 6.8Hz), 1.62-1.74 (2H, m), 1.0-1.3 (16H, m), 0.67(3H, t, J = 6.0 Hz). 31P 
NMR (D2O, 162 MHz): δ 14.6. 
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2-(3-Bromo-5-decyloxy-pyridium)-1-yl-ethylidene-1,1-bisphosphonic acid (BPH-805). 
 Anal. (C17H29BrNNaO7P2). 1H NMR (D2O, 400 MHz): δ 8.65  (1H, s), 8.54 (1H, s), 8.03 (1H, 
s), 4.6 (2H, t, J = 15Hz, 6.8Hz), 4.1 (2H, t, J = 6.4Hz), 2.2 (1H, tt, J = 21 Hz, 6.8Hz), 1.5-1.6 
(2H, m), 0.9-1.4 (14H, m), 0.64(3H, t, J = 6.0 Hz). 31P NMR (D2O, 162 MHz): δ 14.3. 
2-(3-Decylsulfanyl-pyridinium-1-yl)-1,1-bisphosphonic acid (BPH-817). 
 Anal. (C17H31NO6P2S•0.1H2O) 1H NMR (D2O, 400 MHz): δ 8.65  (1H, s), 8.50 (1H, d, J = 
4.5Hz), 8.03 (1H, d, J = 8.5Hz), 7.67 (1H, t, J = 8.5Hz), 4.7 (2H, tt J = 15Hz, 6.8Hz), 2.97 (2H, t, 
J = 7Hz), 2.2 (1H, tt, J = 21 Hz, 6.8Hz), 1.46-1.53 (2H, m), 1.0-1.4 (14H, m), 0.66(3H, t, J = 6.0 
Hz). 31P NMR (D2O, 162 MHz): δ 14.5. 
2-(3-Dodecylsulfanyl-pyridinium-1-yl)-1,1-bisphosphonic acid (BPH-820). 
 Anal. (C19H35NO6P2S) 1H NMR (D2O, 400 MHz): δ 8.64  (1H, s), 8.51 (1H, d, J = 4.5Hz), 8.0 
(1H, d, J = 8.5Hz), 7. 7 (1H, t, J = 8.5Hz), 4.7 (2H, m), 2.94 (2H, t, J = 7Hz), 2.2 (1H, tt, J = 21 
Hz, 6.8Hz), 1.46-1.53 (2H, m), 1.0-1.4 (18H, m), 0.64(3H, t, J = 6.0 Hz). 31P NMR (D2O, 162 
MHz): δ 14.4. 
2-(3-decylpyridinium-1-yl)ethylidene-1,1-bisphosphonic acid (BPH-638). 
 Anal. (C17H31NO6P2•0.5H2O). 1H NMR (D2O, 400 MHz): δ 8.67  (1H, s), 8.64 (1H, d, J = 
4.8Hz), 8.0 (1H, d, J = 8.0Hz), 7. 7 (1H, t, J = 8.0Hz), 4.7 (2H, tt, J = 15Hz, 6.8Hz), 2.67 (2H, t, 
J = 7.5Hz), 2.2 (1H, tt, J = 21 Hz, 6.8Hz), 1.46-1.53 (2H, m), 1.0-1.4 (14H, m), 0.68(3H, t, J = 
6.0 Hz). 31P NMR (D2O, 162 MHz): δ 14.8. 
2-[3-(3,7-dimethyloctyloxy)pyridinium-1-yl]ethylidien-1,1-bisphosphonic acid  
 (BPH-776). 
 Anal. (C17H29NO6P2•1.75H2O). 1H NMR (D2O, 400 MHz): δ 8.8 (1H, s), 8.42(1H, d, J = 6Hz), 
7.82 (1H, d, J = 9Hz), 7.6 (1H, d, J = 9Hz), 4.8 (2H, m), 4.2 (2H, t, J = 6.0Hz), 2.2 (1H, tt, J = 21 
 
 
 
73 
Hz, 6.8Hz), 1.0-1.8 (10H, m), 1.0-1.3 (16H, m), 0.84 (2H, d, J = 6.5Hz), 0.79(3H, t, J = 6.5 Hz). 
31P NMR (D2O, 162 MHz): δ 14.6. 
Protein expression and purification.   
A clone encoding P. vivax GGPPS (PlasmoDB gene ID: Pv092040) with an N-terminally His6-
tagged fusion protein and a TEV protease site was expressed in Escherichia coli BL21-codon 
Plus (DE3) RIL (Stratagene) at 15 °C in baffled flasks. Cells were lysed by sonication in the 
presence of Benzonase Nuclease (Novagen), and a protease inhibitor cocktail (Sigma), and the 
protein then purified chromatographically by using a Ni-NTA resin. EDTA was added 
immediately to 1mM to the elution fraction and 5mM of DTT added after 15 minutes.  The 
eluted protein was then concentrated and loaded onto a Sephadex 26/60 gel filtration column and 
fractions containing PvGGPPS collected for further experiments.  
in vitro enzyme assay.   
The P. vivax GGPPS assays were carried out as describe in previous work (45). 
Molecular Docking.   
Docking calculations by performed by using PvGGPPS (PDB ID code 3RMB) minus the BPH-
703 ligand as a template. The target protein was prepared using the protein preparation wizard in 
Maestro 8.0 (46). For monomer docking, only chain A was selected. For preparation of the 
ligand LigPrep (47) was used to geometry optimize the ligand at a target pH of 7.0. A grid was 
generated to cover the binding site, as well as the dimer interface in the case of dimer docking 
Glide (48) was used for docking calculation under, standard precision (SP) mode. The top 5 
poses from the docking calculation was compared to the crystallographically-determined ligand 
pose by measuring the Cα RMSD with the superposition tool in Maestro. 
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Protein Crystallization.   
Wild type PvGGPPS was eluted from column using 500 mM NaCl, 10 mM HEPES, pH 7.5 and 
concentrated to 15 mg/mL. Co-crystallization of PvGGPPS with the bisphosphonate inhibitors 
was carried out by first incubating PvGGPPS with 1mM bisphosphonate (BPH-703 or BPH-811) 
and 1mM MgCl2 for 30 minutes, on ice. After incubation, 1.5 uL of crystallization buffer (19% 
PEG 3350, 1mM MgCl2, 0.1M Tris-HCl pH7.4 and 0.1 M LiSO4 ) was added to 1.5 uL of 
incubated protein by using the hanging-drop method, at 15˚C. Crystals appeared the next day.  
Data collection was carried out at [ADD] and indexed, integrated and scaled by using the 
HKL2000 program package (49).  Structures were determined by using the molecular 
replacement method using the Phaser program (50).  The PvGGPPS structure 2Q58, minus the 
ligand was used as a template. Further model building and refinement employed Coot (51), 
Refmac (52, 53), CNS (54), and the ProDRG server (55). Figures were obtained by using PyMol 
(56). 
Isothermal Titration Calorimetry.   
Isothermal titration calorimetry measurements were carried out at 298K using a MicroCal VP-
ITC (MicroCal, Northampton, MA). 10 µL of 0.4 mM bisphosphonates were titrated from a 250-
µL syringe (rotating at 270 rpm) into the sample cell containing 1.42 mL of a 0.03 mM 
PvGGPPS solution. The buffer solution was 50 mM Hepes (pH 7.4) and 1 mM MgCl2. For 
running parameters, the duration of injection was set to 19.2 s, and the delay between injections 
was set as 300 s. The initial delay prior to the first injection was 60 s. To derive the heat 
associated with each injection, the area under each heat burst curve (microcalories per second 
versus seconds) was determined by integration (using Origin version 5.0 software; MicroCal, 
Northampton, MA). Fitting to a one-site binding model gave good accord with experiment.  
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In vivo experiments.   
Mice were infected by intraperitoneal (i.p.) injection of Plasmodium chabaudi AJ strain (1x106 
parasites/mouse – day 0). Mice were separated into groups of 5 and compound treatments were 
given for 4 consecutive days (day 0-3) at 3, 10 (i.p.) or 100 mg/kg (gavage). Parasitaemia was 
monitored by using GIEMSA stained slides prepared with a sample of blood collected from the 
tail vein. Blood samples were collected daily for 10 consecutive days (days 3-12). Parasitaemia 
was determined by counting of at least 1000 cells in each sample (3). Mortality was followed for 
30 days. All procedures were in accord with Korean regulations and were approved by Institut 
Pasteur-Korea Ethics Committee. 
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3.6 Tables and Figures 
Table 3.1. Data collection, phasing, and refinement statistics. 
Data collection PvGGPPs-Mg-703 PvGGPPs-Mg-811 
Space group P212121 P212121 
Resolution (Å)a 45.59-2.61 50.0-2.80 
 (2.67-2.61) (2.85-2.80) 
Unit cell dimensions 
a (Å) 107.68 99.74 
b (Å) 107.95 106.58 
c (Å) 140.70 139.03 
No. of reflections 
Unique 50687 37133 
Completeness (%) 99.15 98.60 
Rmerge (%) 8.3 (30.5) 14.1 (65.9) 
I/σ(I) 28.9 (7.29) 14.0 (1.05) 
Refinement 
No. of reflections 44719(3340) 34572(2237) 
Rwork (%) 20.67(25.2) 20.69(25.0) 
Rfree (%) 24.75(31.2) 29.92(36.3) 
Geometry deviations 
Bond lengths (Å) 0.018 0.013 
Bond angles (°) 1.7 1.5 
No. of all protein  
atoms 12025 12074 
Mean B-values (Å2) 34.5 42.6 
No. of all cofactor 
atoms   
Mean B-values (Å2) 15.4 36.85 
No. of water 
molecules 266 254 
Mean B-values (Å2) 29.2 50.6 
Ramachandran plot 
(%)   
Most favored 96.5 92.3 
Additionally allowed 2.77 5.61 
Generously allowed 0.78 1.42 
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Table 3.2. Enzyme and cell growth inhibition results. 
compounds LogP 
P. falciparum 
in vitro 
PvFPPS 
IC50 
PvGGPPS 
IC50 
Cancer Cell 
Average 
HsGGPPS 
IC50 
HsFPPS 
IC50 
BPH-2 (risedronate) -2.5 129 0.59 0.5 191 350 0.24 
BPH-91 (zoledronate) -2.9 167 0.79 0.51 15.8 100 0.11 
BPH-638 2.4 0.59 3.8 0.78 0.16 0.4 1.57 
BPH-688 1.4 0.73 0.57 1 2.3 1.23 0.26 
BPH-703 2.5 0.69 1.8 1.2 133 3.3 1.7 
BPH-710 1.4 0.79 0.62 1.1 0.73 2.1 0.009 
BPH-715 2.1 0.8 1.9 NA 0.17 0.25 0.032 
BPH-728 1.9 0.72 0.3 0.74 7.5 15 1.2 
BPH-776 2.6 0.73 1.9 1.3 0.04 2.2 1.16 
BPH-805 2.9 0.75 0.87 1.4 3.1 0.51 120 
BPH-811 1.5 0.55 5.2 2.5 28 4.5 1.31 
BPH-816 1.8 0.47 0.73 0.66 0.32 1.3 0.83 
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Table 3.3. ITC results. 
 
 
 
 
 
 
compounds ΔG ΔH ΔS 
BPH-2 (risedronate) -9.32 -2.47 23.0 
BPH-91 (zoledronate) -9.54 -4.83 15.8 
BPH-703 -8.69 -5.02 12.3 
BPH-811 -9.30 -2.92 21.4 
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Figure 3.1. Isoprenoid biosynthesis Plasmodium spp. and potential targets. Bisphosphonates 
inhibits FPPS/GGPPS as well as the long chain prenyl synthases involved in quinone 
biosynthesis, protein prenylation and dolichol formation; phosphonosulfonates and realated 
species inhibit head-to-tail prenyl transferases such as squalene and dehydrisqualene synthase 
and may target phytoene synthase; cationic nitrogen-containing species such as Ro48-8071 
inhibit diverse prenyl transferases. 
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Figure 3.2. Selection of lead compounds for furhter investigation. (A) Representative screening 
results. Black: negative control (PBS; N=399 wells); blue: positive control (artemisinin. 192nM; 
N=181); gree, test compounds (N=564 compounds, 10μM). (B) Positive and negative controls 
along, Z´ = 0.72. (C) Dose-response curves for humen cell growth inhibition in NCIH-460, 
MCF-7 and SF-268 cell lines. Red: BPH-703; blue: BPH-776. (D)Therapeutic index plot for hits: 
BPH-703 and BPH-811 had good activity and low toxicity. (E) Scatter plot of P. falciparum 
pIC50 (=-log10IC50, M) versus logP values indicating good pIC50, logP values for compounds 
selected from (D). (F) Schematic illustration illustrating combination of structureal features of 
bisphosphonates and FPP substrate to yield lipophilic bisphosphonates. 
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Figure 3.3. Crystallographic structure of the lipophilic zoledronate analog BPH-703 bound to 
PvGGPPS. (A)-(D) crystallographic structures of IPP, FPP, GGPP and several bisphosphonates 
bound to human, yeast or P. vivax GGPPS, after Fig.4. in (36). (A) the GGPP binding site in 
human and yeast (pH5.5) GGPPS. (B) the P. vivax zoledronate, T. cruzi risedronate  and yeast 
FPP site. On both A, B, the ligand polar groups bind to the Mg2+/Asp site, top left. (C) the IPP-
GGPP site occupied by a bisphosphonate inhibitors. (D) the GGPP product site occupied in yeast 
GGPPS (pH=7.5) or PvGGPPS. (E) Superposition of BPH-703 bound to PvGGPPS with bound 
zoledronate. This is the FPP-binding site seen in (B) with the yeast enzyme, but the distal end of 
the inhibitor occupying a hydrophoic tunnel that spans the two monomers in the GGPPS dimer. 
(F) Protein-ligand interactions for BPH-703. (structures are rendered using PyMOL from Delano 
Scientific, Palo Alto, CA). 
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Figure 3.4. Crystallographic struture of the lipophilic analog of risedronate and BPH-811. (A) 
BPH-811 superposed on the risedronate-TcFPPS structure (B) protein-ligand interaction for 
BPH-811. (C) Overlay of BPH-811 structure with BPH-811 structure. Both occupy the 
hydrophobic tunnel between the dimer molecules. 
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Figure 3.5. Isothermal titration calorimetry results. (A) zoledronate binding to PvGGPPS. (B) 
BPH-703 binding to PvGGPPS. (C) ΔH/ΔS plot for zoledronate, BPH-703, risedronate and 
BPH-811 binding to PvGGPPS (in red) superposed on risedronate, zoledronate and other 
bisphosphonates binding to T. brucei FPPS. (the latter based on result in (39)). There is no 
evidence for the dominance of entropy driven binding seen with cationic species binding to FPS, 
consistant with the obsevation that the presence of a cationic species is not important for GGPPS 
inhibitions. 
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Figure 3.6. Effect of BPH-703 and BPH-811 on mouse survival and parasitemina. (A) Survival 
at 10mg/kg. (B) Parasitemia at 10mg/kg. (C) Survival at 3mg/kg. (D) Parasitemia at 3mg/kg. 
Black circle: PBS control; red triangle, BPH-703; blue triangle, BPH-811; green triangle, 
chloroquinine positive control. 
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Figure 3.7. Plasmodium screening hits. 
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Figure 3.7. continued. 
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Figure 3.7. continued. 
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Figure 3.7. continued. 
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Figure 3.7. continued. 
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Figure 3.7. continued. 
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Figure 3.7. continued. 
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Figure 3.8. Dose response curve for hits. 
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Figure 3.8. continued. 
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Figure 3.8. continued. 
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Figure 3.8. continued. 
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Figure 3.8. continued. 
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Figure 3.9. Structures of top 10 bisphosphonate hits. 
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Figure 3.10. Rescue experiments on BPH-703 and BPH-811 by solanesol, FOH and GGOH. 
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Figure 3.11.  Surface representation of (A)zoledronate, (B) BPH-703, (C) BPH-811 and (D) 
GGPP. 
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Figure 3.12. ITC results of (A) risedronate and (B) BPH-811. 
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Chapter 4 
Lipophilic Bisphosphonates Are Potent Inhibitors of 
Plasmodium Liver-Stage Growth 
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4.2 Introduction 
The malaria parasite Plasmodium is transmitted via the bite of an infected female Anopheles 
mosquito that injects sporozoites into the skin. The parasites enter the bloodstream and invade 
hepatocytes, where the sporozoites transform into liver stages, usually called exo-erythrocytic 
forms (EEFs). These then undergo multiple rounds of nuclear division and produce thousands of 
merozoites that enter the blood circulation and infect erythrocytes, leading to malaria symptoms. 
EEFs are thus targets for prophylactic drugs and vaccines. At present, however, there are a very 
limited number of drugs that target Plasmodium liver stages. Primaquine is one, but its use is 
limited by its associated toxicity and increased risk of hemolysis when administered to persons 
with glucose-6-phosphate dehydrogenase (G6PD) deficiency (2). This latter problem also affects 
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two related compounds under development: bulaquine and tafenoquine (19, 20). Although there 
has been considerable progress in the treatment of bloodstream infections using artemisinin-
based combination therapies, recent reports have indicated the possible development of 
resistance to artemisinin among Asian isolates (6). This situation is potentially serious 
considering how widespread is the resistance to the other anti-malarials, chloroquine, or the 
pyrimethamine-sulfadoxine combination (14). Under these circumstances, there is, therefore, a 
need to identify new lead compounds active against malaria. In particular, there is currently great 
interest (10) in developing drugs that inhibit the liver stage forms that precede blood infections, 
thereby preventing symptomatology, and blocking transmission (21).  
During the early stages of EEF development, the Plasmodium plasma membrane is 
covered with the circumsporozoite protein (CSP). In infected hepatocytes, parasites are 
contained inside a parasitophorous membrane, but CSP is still exported into the hepatocyte 
cytoplasm and nucleus (17), generating profound changes in the transcriptional program of the 
host cell. In previous work we noticed that the gene that was most highly upregulated on CSP 
expression in infected HeLa cells (17) or HepG2 cells (M. Zhang, and V. Nussenzweig, 
unpublished data) was Rap1A. Since Rap proteins are geranylgeranylated at their C-terminus, 
and since there are such large changes in Rap1A gene expression on CSP expression in HeLa 
cells, it seemed possible that blocking protein geranylgeranylation would have a significant 
effect on liver stage parasite proliferation.  
To inhibit prenylation we investigated the effects of several different bisphosphonates, a 
class of drugs known to inhibit protein prenylation. Bisphosphonates are potent, low nM 
inhibitors of the enzyme farnesyl diphosphate synthase (FPPS), which catalyzes the condensation 
of the isoprenoids dimethylallyl diphosphate (DMAPP) and isopentenyl diphosphate (IPP), 
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produced in the mevalonate pathway (Figure 4.1) to form geranyl diphosphate (GPP).  This then 
condenses with a second IPP molecule to form farnesyl diphosphate (FPP) and thence, 
geranylgeranyl diphosphate (GGPP) (Figure 4.1). As a result of this FPPS inhibition, 
bisphosphonates block protein prenylation, as well as sterol, ubiquinone, dolichol, and heme a 
biosynthesis (15). Bisphosphonates also stimulate human γδ T cells (containing the Vγ2Vδ2 T 
cell receptor) (8), and may therefore have anti-parasitic activity. Bisphosphonate inhibition of 
FPPS also results in the accumulation of the substrate IPP, which becomes conjugated to AMP to 
form a toxic ATP analogue, O-isopentenyl-ATP, ApppI, Figure 4.1, which can inhibit the 
mitochondrial adenine nucleotide translocase and induce apoptosis (11).  
We reasoned that novel, lipophilic bisphosphonates (23) might have enhanced effects on 
the survival of malaria parasites over the more polar bisphosphonates reported previously (7, 9) 
and we focus here on a comparison of the activity of three lipophilic bisphosphonates (currently 
being developed as anti-cancer drug leads) with the activity of the second and third generation 
bisphosphonates pamidronate and risedronate, in both liver stage (EEF) and blood stage 
Plasmodium infection models.  
 
4.3 Results and Discussion 
Growth inhibition of P. berghei EEFs in vitro.  
We first tested the effects of two bisphosphonate drugs, pamidronate (Aredia) and risedronate 
(Actonel) (Figure 4.2), together with the effects of pravastatin, an isoprenoid biosynthesis 
inhibitor that targets 3-hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase (Figure 4.1, 
4.2), on P. berghei EEF growth in HepG2 cells. Pamidronate and pravastatin were inactive at the 
concentrations tested (IC50 >200 µM), Table 4.1. The risedronate IC50 was ~16 µM (Figure 4.3B 
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and Table 4.1) while the lipophilic bisphosphonates (BPH-715; BPH-942 and BPH-943; Table 
4.1 and Figure 4.3A) had IC50 values in the range ~8-10 µM. We also tested the toxicity of the 
active bisphosphonates on HepG2 cells and their TC50s were in the range of 1-13 mM (Table 
4.1).  All of the active bisphosphonates had therapeutic index values >100, comparable to that of 
primaquine (5).  In addition, we tested the geranylgeranyl transferase I inhibitor GGTI-298 
(Figure 4.2) finding an IC50 ~30 µM (Table 4.1), but this compound was later found to have no 
activity in vivo (Table 4.2). 
Bisphosphonates inhibit the growth of P. berghei EEFs at an early stage.  
We next treated sporozoite-infected hepatocytes with one of the lipophilic bisphosphonates 
(BPH-715), chosen since it has already been tested for safety in mice (23) and examined the 
cultures 50 hours later, using light microscopy, Figure 4.4A, B. When BPH-715 was present at 
30 µM, there was a >9x reduction in the EEF area (Figure 4.4C). There was no difference in the 
total numbers of EEFs in the control and treated groups. BPH-715 thus inhibits EEF growth at an 
early trophozoite stage. 
Bisphosphonates also inhibit P. berghei EEF growth in vivo.  
To evaluate to what extent the lipophilic bisphosphonates had activity in vivo, we injected them 
i.p. once daily into mice, starting two days before and ending two days after, infection with 
sporozoites (a total of 5 days). When challenged with 3,000 infectious sporozoites, the 
bisphosphonates showed a wide range of effects, ranging from no activity to complete protection 
(Table 4.2, Tables 4.3 and 4.4). The most active compound (BPH-715) protected mice 
completely at a dose of 1.5 mg/kg body weight (Table 4.2 and Table 4.4). The next most active 
compound, BPH-943, showed a five-day delay in the pre-patent period at a dose of 2 mg/kg body 
weight, which also represents a very large reduction in parasite burden. Risedronate was less 
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active than was BPH-715, although it did show a 4-day reduction in pre-patent period at 20 
mg/kg (Table 4.2). The lipophilic bisphosphonates were, therefore, far more potent than the 
commercial bisphosphonate, risedronate. We also tested GGTI-298 (Figure 4.2), a commercially 
available inhibitor of geranylgeranyl transferase  (GGTI) in vivo (up to a dose of 5 mg/kg), but 
GGTI-298 did not show any activity against the liver stage parasites in vivo, although it did show 
very modest (~30 µM) activity in vitro. Another GGTI inhibitor (DU40, Figure 4.2) also failed to 
show any in vivo activity against the EEFs. So, only the lipophilic bisphosphonates have good  in 
vivo activity. 
Bisphosphonates inhibit P. falciparum blood stage parasites in vitro.  
We next tested risedronate and the three lipophilic bisphosphonates for activity against P. 
falciparum, in vitro. We found that with the chloroquine sensitive strain 3D7, the lipophilic 
bisphosphonates (BPH-715, BPH-942 and BPH-943) had IC50 values in the sub-micromolar 
range (Table 4.5), while risedronate had an IC50 of ~1.2 µM (Table 4.5). BPH-942 and BPH-943 
showed 3-4-fold less activity against the chloroquine-resistant strain (W2mef) as compared to the 
chloroquine sensitive strain (3D7), but BPH-715 had good activity, against both strains (Table 
4.5).  
Bisphosphonates inhibit P. berghei blood stage parasites in vivo.  
Two bisphosphonates (risedronate and the lipophilic bisphosphonate, BPH-715) were then tested 
in vivo for activity against a blood stage parasite challenge. Risedronate was given at 20 mg/kg 
for 5 days with the mice being challenged with 5 x 106 blood stage parasites on day 0. Under 
these conditions, there was a one day delay in the pre-patent period (Table 4.6).  BPH-715, on 
the other hand, was more effective.  A similar treatment regime with BPH-715 at 1.5 mg/kg gave 
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a 4 day delay in the pre-patent period, indicating a larger reduction in blood stage parasite 
growth. 
Activity of bisphosphonates against Plasmodium GGPPS and against human FPPS and 
GGPPS.  
In order to better understand the activities of the different bisphosphonates in vitro and in vivo, 
we determined their IC50 values against three different drug targets:  a Plasmodium vivax GGPPS 
(using GPP, FPP as substrates); human FPPS (HsFPPS) and human GGPPS (HsGGPPS) using 
the methods described previously (13, 16, 22, 23) .  Results are shown in Table 4.7.  As can be 
seen in Table 4.7, all compounds inhibit the PvGGPPS as well as HsFPPS.  However, only the 
lipophilic bisphosphonates inhibit HsGGPPS, with risedronate being inactive (IC50 
 
>~  300 µM, 
Table 4.7).  These results are consistent with direct activity against the Plasmodium enzyme, 
which can be expected to contribute to their activity in the cell-based assays.  What is puzzling, 
however, is that the pattern of activity with the lipophilic bisphosphonates (BPH-715, BPH-942 
and BPH-943) against either the PvGGPP, or HsFPPS and HsGGPPS, does not track the activity 
seen in vivo.  In vitro, in both the EEF and blood stage assays, all three compounds have broadly 
similar activity (~8-10 µM, in vitro, EEF, Table 4.1; ~0.5-2.2 µM, in vitro, blood stage assay) 
and this is consistent with their similar range of activity in the enzyme inhibition assays, Table 
4.7.  However, in the in vivo EEF experiments (Table 4.2), BPH-715 is clearly far more effective 
than is BPH-943 (at essentially the same dosing:  1.5 mg/kg vs. 2.0 mg/kg).  A likely explanation 
for this is that BPH-715 has much better uptake into the liver since it is more lipophilic than is 
BPH-943.  Table 4.7 shows the SlogP (the logarithm of the oil/water partition coefficient) values 
computed in MOE (1) for all four bisphosphonates. From these results we see that BPH-715 is 
clearly more lipophilic than is BPH-943, with an SlogP value of -1.2, to be compared with -3.4 
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for BPH-943.  The -5.5 SlogP for risedronate represents an extremely hydrophilic species, which 
together with its lack of activity against HsGGPPS (Table 4.7) likely explains its lower activity 
than the lipophilic bisphosphonates, in vivo. 
 
4.4 Conclusions 
The results we have described above show that lipophilic bisphosphonates have potent activity 
against liver stage P. berghei in vivo, with the most active compound completely protecting mice 
against sporozoite challenge (at a dose of 1.5 mg/kg body weight for 5 days) over the 28 day 
observation period, with no adverse effects.  The enhanced activity of this compound over that 
seen with the other bisphosphonates tested arises, we propose, from enhanced uptake into the 
liver.  The bisphosphonate risedronate has poorer efficacy than does BPH-715 in vivo, but still 
provides a modest delay (4 days) in the pre-patent period. Interestingly, while BPH-715 is more 
potent in inhibiting liver stage rather blood stages in vivo, it generates a much smaller effect on 
blood stage parasites in vivo, even though it is quite potent in vitro. One possible explanation is 
that BPH-715 uptake into the liver may simply be much more effective because of the much 
higher lipophilicity of this species (SlogP value 2-4 units greater than with any of the other 
bisphosphonates tested). At present, we cannot quantify the relative importance of host versus 
pathogen targeting in the liver stages, where PbGGPPS, HsFPPS and/or HsGGPPS could all be 
inhibited, to varying degrees.  Indeed, in recent work (13) we reported that, in TEN simpler 
systems, the correlation between enzyme inhibition (pIC50 = -log10 IC50) and cell activity pIC50 
values for a broad range of assays, was only R2 = 0.30 (13).  This pointed to a key role of 
transport or cell permeability and when this was taken into account, the correlation improved to 
R2 = 0.70 (13).  However, applying the mathematical model used in that approach to liver stage 
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Plasmodium spp. (in vitro or in vivo) is a challenge since there are, in principle, at least 3 targets 
(PbGGPPS, HsFPPS and HsGGPPS) and at least THREE “permeability” barriers (the host cell, 
the Plasmodium plasma membrane, and the parasitophorous vacuole membrane).  In blood stage 
Plasmodium, this may be more tractable since the HsFPPS/HsGGPPS are not targets, but quite 
large data sets (>20 compounds) are needed for this sort of analysis (13). In addition, we cannot 
rule out other possible targets, such as octaprenyl diphosphate synthase, and indeed, in other 
work we have shown that bisphosphonates can inhibit multiple prenyl synthase targets- 
something that may contribute to their potent activity.   
In any case, the results we have obtained here are clearly of considerable interest since 
we find complete protection against P. berghei liver stage infection in mice using the lipophilic 
bisphosphonate, BPH-715.  Interestingly, this compound has also been found to be the most 
potent inhibitor of tumor cell growth, both in vitro and in vivo (23), due, we proposed, to its 
potent activity against both human FPPS and GGPPS, and its lipophilic nature (as compared with 
other bisphosphonates).  This suggests the possibility that BPH-715 does, in fact, block protein 
geranylgeranylation and notably, in three human cell lines, we found that cell growth inhibition 
could be “rescued” by addition of geranylgeraniol – although of course this rescue-effect would 
not have probative value in Plasmodium liver stage experiments since the effects on both 
PbGGPPS and HsGGPPS inhibition would both be “rescued” (by providing the exogenous 
isoprenoid source). 
In the blood stage P. falciparum experiments, the effects of BPH-715 and the more 
hydrophilic species, risedronate, are quite similar to each other, with the IC50 ratio 
(risedronate/BPH-715) being only about a factor of 2-3.  Since there is no isoprenoid 
biosynthesis in the red blood cell, HsFPPS/HsGGPPS inhibition is not involved, so solely the 
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Plasmodium GGPPS is being targeted.  Notably, this factor of ~2.5 is the same as that seen with 
the Plasmodium EEFs (Table 4.1) in which risedronate has an IC50 of 16 µM for EEF inhibition, 
while that for BPH-715 is IC50 = 10 µM (Table 4.1), suggesting the possibility that the 
Plasmodium GGPPS is a primary target in both blood and liver stage forms, in vitro.  The 
improved activity of the more lipophilic bisphosphonates is in agreement with results we 
reported previously (on much less active compounds): that the most lipophilic bisphosphonates 
have the best activity, against Plasmodium blood stages parasites (7). 
In summary then: lipophilic bisphosphonates are potential leads against the liver stages of 
malaria parasites, including the hypnozoites of P. vivax, and could have a role in malaria 
chemoprophylaxis.  
 
4.5 Materials and Methods 
Animals.  
The methods for mice use and care were approved by the New York University School of 
Medicine Institutional Animal Care and Use Committee and are in accordance with PHS policy 
on Care and Use of Laboratory Animals under the guidance of the Office of Laboratory Animal 
Welfare (OLAW) within the NIH. 
Reagents.  
The compounds used were: pravastatin and pamidronate from Sigma; GGTI-298 from 
Calbiochem; risedronate, synthesized as described in (9); and BPH-715, BPH-942, and BPH-
943, lipophilic bisphosphonates synthesized as described (4) .  
In vitro growth inhibition assay for liver stage parasites.  
Drug solutions were prepared in 1x sterile PBS. The diluted solutions were added to 24-well 
 
 
 
117 
culture plates containing human HepG2 cells seeded a day prior to the experiment, and 0.5 ml 
complete DMEM medium containing 10% FBS, together with an antibiotic-antimycotic. 
Infection was initiated by adding 10,000 P. berghei sporozoites (NK65 line). Infected cultures 
were then allowed to grow at 37°C in a 5 % CO2 atmosphere, for 48 hours. Culture medium was 
changed 24 hours after infection, and fresh compounds were added at the same concentration, to 
maintain inhibitor pressure throughout the growth period. At the end of the 48 hour incubation 
period, total RNA was extracted using TrizolTM reagent. Reverse transcription from 4 µg RNA 
was performed to obtain cDNA. In a real-time PCR mix of 50 µL, cDNA equivalent of 0.5 µg 
RNA was used. The real-time PCR mix also contained P. berghei 18S rRNA specific primers 
and SYBR green dye (3). Real time PCR was performed in a BioRad Icycler and the copy 
numbers were calculated, using the known amount of plasmid standard having the amplification 
target sequence (3). Parasite growth inhibition was calculated by dividing the 18S rRNA copy 
number of the experimental group by that of the untreated control group. Non-linear regression 
analysis was performed using Sigma-plot (version-10), to determine IC50 values. 
In vivo growth inhibition assay for liver stage parasites (EEFs).  
Compounds were injected into mice i.p. for a variable number of days, depending on the 
experiment. Treatments started on day -2, -1 or 0, where day 0 corresponds to sporozoite 
infection by the intravenous route. Treatments were continued on day +1 and +2 post infection. 
EEF development was evaluated by the success of the ensuing blood stage infection. Blood 
smears were prepared on day three, post-infection. Percent parasitemia was monitored until it 
reached 3-5%, and animals were then sacrificed. Complete protection is defined as the absence 
of parasites in blood smears up to two weeks post challenge with sporozoites.  
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Blood stage parasite growth inhibition assay in infected mice.  
Mice (five per group) were injected i.p. with 5x106 blood stage P. berghei parasites/mouse, to 
initiate infection. Treatments started on day 0 and were continued on days +1 and +2, post 
infection. Blood smears were prepared on day 2 and onwards, post parasite-challenge. 
Parasitemia was monitored microscopically until it reached 3-5%, then the animals were 
sacrificed. 
In vitro growth inhibition assay for P. falciparum blood stage parasites.  
Bisphosphonates were evaluated for their inhibitory activity against blood stages of P. 
falciparum strains 3D7 (chloroquine sensitive) and W2mef (chloroquine resistant). Each 
compound was tested in triplicate in 96-well culture plates in a volume of 100 µL. Drug 
concentrations of 1, 10, 100, 1,000, and 10,000 nM were tested. Chloroquine at concentrations of 
10 and 100 nM was used as a positive control. P. falciparum were cultured in O-positive washed 
erythrocytes in RPMI 1640 medium using the candle-jar technique (18). Parasites were added to 
reach an appropriate parasitemia (0.2-0.3%). Flasks were kept in a dessicator, and a low oxygen 
environment was produced by flushing with mix gas (90% N2, 5% CO2 and 5% O2). Cells were 
incubated at 37°C and percent parasitemia determined microscopically. 
Toxicity assays in hepatocytes.  
HepG-2 (human liver hepatoma) cells were seeded at 70% confluency (with 0.5 mL medium) in 
24-well tissue culture plates a day prior to treatment with inhibitors. Various concentrations of 
inhibitors were added to the HepG2 cells, which were then incubated at 37°C under 5 % CO2 for 
22 hours. After incubation, cell titer one-reagentTM (Promega) was added to the wells, followed 
by 2 additional hours of incubation (12). The plates were briefly spun and the clear media 
transferred to 96-well plates. The OD495 was then determined by using a microplate reader 
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(Molecular Devices), and the 50% cell growth inhibition (IC50) value determined by nonlinear 
regression (percent viable cells at various concentrations of the individual BPs).  
Immunofluorescence staining and size measurements.  
HepG 2 cells were seeded (50% confluent) into 24 well tissue culture plates containing glass 
cover slips, a day prior to bisphosphonate treatment. BPH-715 was added one hour prior to the 
addition of P. berghei sporozoites. Cells were then incubated at 37 °C and 5% CO2 for 48 hours. 
Cover slips were removed after 48 hours incubation and cells were fixed with 4% formaldehyde, 
followed by permeabilization with saponin [0.2 % in phosphate buffered saline (PBS)]. 
Permeabilized cells were blocked with 3% bovine serum albumin (BSA) in PBS for 2 hours, 
followed by 1-hour incubation with primary antibody 2E6 (monoclonal, against parasite HSP70). 
After the primary antibody incubation, three washes with PBST (PBS with 0.05% Tween-20) 
were given in order to diminish nonspecific binding. Cells were further incubated with secondary 
antibody (rabbit anti-mouse IgG coupled to Alexa 594), for 1 hour, followed by three more 
washes with PBST. A final wash was given with PBS and cover slips were mounted using anti-
fade (Bio-Rad) followed by sealing with nail polish. Images of liver stage parasites were 
captured in a CCD camera attached to a fluorescence microscope (Nikon E-800). The Image Pro-
Plus program (Media Cybernetics, USA) was used to measure the size of the liver-stage 
parasites. 
Enzyme inhibition assays.   
We used exactly the same methods as described previously (13, 16, 23) for PvGGPPS, HsFPPS 
and HsGGPPS expression, purification, and inhibition. 
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4.6 Tables and Figures 
Table 4.1.  In vitro activity of compounds against Plasmodium EEFs. 
 
Compound IC50 for EEFs   
(µM) 
TC50 for HepG2 
cells (mM) 
Therapeutic 
Index  (TI ) 
Pamidronate >200 NDa NAb 
Risedronate 16 13 813 
Pravastatin >200 ND NA 
BPH-715 10 2 200 
BPH-942 8.8 1 114 
BPH-943 8 1 125 
GGTI-298 ~30 NDa NAb 
   a ND: Not determined 
b NA: Not applicable. 
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Table 4.2. In vivo activity of bisphosphonates against Plasmodium EEFs. 
 
Compounds Mouse Dose 
(mg/kg) for 5 
days (-2,-1,0, 
+1+2) 
Pre-patent day a Delay in pre-patent 
period (PPP) in days 
Untreated None 4 0 
Risedronate  20 8 4 
BPH-715 1.5 > 28b > 28b 
BPH-942 0.8 7 3 
BPH-943 2 9 5 
GGTI-298 5 4 0 
     a Day 0 corresponds to challenge with 3000 P. berghei sporozites.  
b > 28 = No blood stage parasites through the 28-day observation period. 
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Table 4.3. In vivo drug testing (Risedronate): P. berghei sporozoite challenge. 
 
Treatment 
(dose & days) 
Challenge 
(no. of 
sporozoites) 
Difference 
In PPP 
Mouse 
& age 
Detection method  
& comments 
5mpk 
x 2 d 
(0,+1) 
10,000 
 
0.5 day Balb/c 
12wk 
Smear 
5 fold less 
parasite 
17.5mpk 
x 2d 
(0,+1) 
10,000 
 
1 day Balb/c 
12wk 
Smear 
10 fold less 
parasite 
20mpk  
x4d 
(0,+1+2+3) 
3,000 
 
4 days C57BL/6 
8 WK 
Smear 
20mpk  
x5d 
-1,0,+1,+2,+3 
3,000 
 
6 days C57BL/6 
8 WK 
Smear 
(Delayed Toxicity) 
20mpk  
x4d 
-2-1,0,+1, 
3,000 
 
2.5 days C57BL/6 
12 WK 
Smear 
20mpk  
x3d 
-1,0,+1, 
3,000 
 
0.5 day C57BL/6 
12 WK 
Smear 
10mpk  
x4d 
-2-1,0,+1, 
3,000 
 
No  
difference 
C57BL/6 
12 WK 
Smear 
10mpk  
x3d 
-1,0,+1, 
3,000 
 
No  
difference 
C57BL/6 
12 WK 
Smear 
20mpk  
x5d 
-2,-1,0,+1,+2, 
10,000 
 
3 days C57BL/6 
14 WK 
Smear 
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Table 4.4. In vivo drug testing P. berghei sporozoite challenge. 
 
 
Drug used Treatment 
Dose & days 
Challenge Difference 
in Pre-patent 
period 
Mouse 
& age 
Detection 
method 
BPH-715 0.5mpk 
x4d 
-2-1,0,+1, 
3,000 
 
3 day C57BL/6 
12 WK 
Smear 
GGTI-298 5mpk  
x5d 
-2,-1,0,+1,+2, 
10,000 
 
No 
difference 
C57BL/6 
14 WK 
Smear 
BPH-715 1.5mpk  
x5d 
-2,-1,0,+1,+2, 
10,000 
 
> 28 days 
No Blood 
Stages 
C57BL/6 
14 WK 
Smear 
BPH-715 5mpk  
x5d 
-2,-1,0,+1,+2, 
10,000 
 
> 28 days 
No Blood 
Stages 
C57BL/6 
14 WK 
Smear 
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Table 4.5. IC50 values for the selected bisphosphonates against blood stage Plasmodium 
falciparum chloroquine-sensitive and-resistant strains in vitro. 
 
 
 
 
 
 
Inhibitor 3D7, IC50 (nM)  
[Average ± SD] 
W2mef, IC50 (nM) 
[Average ± SD] 
Risedronate 1200 ± 90 1400 ± 100 
BPH-715 670 ± 40 590 ± 15 
BPH-942 650 ± 90 2000 ± 75 
BPH-943 450 ± 110 2200 ± 150 
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Table 4.6: In vivo activity of bisphosphonates against Plasmodium berghei blood stage parasites. 
 
 
 
 
 
 
 
 
Mice were challenged on day 0 with 5x106 parasites.  Inhibitor treatment was given once a day on days -2, 
-1,0,+1,+2. 
Compound Dose (per 
mouse) 
 Pre-patent day 
(% parasitemia) 
Delay in pre-patent 
period 
None  Untreated 1  (0.06% + 0.01) 0 
 Risedronate 20 mg/kg        
for 5 days 
2 (0.09%+ 0.02) 1 day 
BPH-715 1.5 mg/kg       
for 5 days  
5  (0.01%+ 0.003) 4 days 
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Table 4.7. Enzyme inhibition for Plasmodium vivax  GGPPS, human FPPS and human GGPPS, 
together with SlogP values. 
 
 
a Measured as described in Ref. 13.   
b Measured as described in Ref. 16.   
c Measured as described in Ref. 22.  
d Calculated using the MOE program (Ref. 1). 
Compound 
IC50/ Ki for 
PvGGPPS  
(mM) [GPP]a 
IC50/ Ki for 
PvGGPPSa 
(mM) [FPP] 
IC50/ Ki for 
HsFPPS  (mM)b 
IC50/ Ki for 
HsGGPPS c 
(mM) 
SlogPd 
Risedronate 1.1 / 0.024 1.7 / 0.048 0.11 / 0.013 300 / 8.3 -5.5 
BPH-715 0.56 / 0.013 1.5 / 0.043 0.032 / 0.0037 0.25 / 0.0069 -1.2 
BPH-942 0.63 / 0.015 1.5 / 0.043 0.0041 / 0.0047 0.44 / 0.012 -4.1 
BPH-943 0.70 / 0.016 1.5 / 0.043 0.016 / 0.0018 0.12 / 0.0033 -3.4 
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Figure 4.1. Schematic illustration of isoprenoid biosynthesis pathways (in humans and 
Plasmodium spp) and sites of action of several inhibitors. Malaria parasites make IPP and 
DMAPP via the non-mevalonate pathway. Inhibition of isoprenoid biosynthesis affects protein 
prenylation; IPP build up activates γδ T cells; IPP is converted to toxic ATP analogs on FPPS 
inhibition. ANT, adenine nucleotide translocase; DXP, 1-deoxy-D-xylulose 5-phosphate; MEP, 
2-C-methyl-D-erythritol 4-phosphate, HMG, 3-hydroxy-3-methyl-glutaryl-CoA; TNF-α, tumor 
necrosis factor alpha; IFNγ, interferon gamma. 
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Figure 4.2. Structures of the inhibitors tested. 
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Figure 4.3. Typical dose-response curves for in vitro activity of two bisphosphonates versus  
Plasmodium berghei EEF cell growth inhibition. 
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Figure 4.4. Results showing growth of untreated (A) and (B) treated (30 µM BPH-715) EEFs 50     
hours post infection with sporozoites. EEFs were visualized by IFA using anti-HSP70 (parasite 
protein) monoclonal  as the primary antibody and anti-mouse IgG Alexa 594 as the secondary 
antibody. BPH-715 treated EEFs show severe growth defects. (C), Area measurements of 
treated, and untreated, EEFs 50 hours post-infection with sporozoites.  
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Chapter 5 
Inhibition of the Fe4S4 Cluster-containing Protein 
IspH (LytB): EPR, Metallacycles and Mechanisms 
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5.2 Introduction 
The Rohmer, methyl-D-erythritol phosphate or non-mevalonate pathway is responsible for 
isoprenoid biosynthesis in most pathogenic bacteria, as well as in malaria parasites.(1, 2) Since 
isoprenoids are essential for survival in these organisms and since the non-mevalonate pathway 
is absent in humans, enzymes that comprise the pathway are important anti-infective drug 
targets(3, 4) and in previous work (5, 6) it was shown that fosmidomycin (which inhibits the 
second enzyme in the pathway) gave very promising results in treating malaria. The structures 
and mechanisms of action of six of the eight enzymes present in the pathway have been known 
for some time, but deducing the structures (and mechanisms of action) of the last two enzymes 
has been more challenging. The penultimate enzyme is E-4-hydroxy-3-methyl-but-2-enyl 
diphosphate (HMBPP) synthase (IspG, GcpE, EC1.17.7.1) which catalyzes the 2H+/2e- reduction 
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of 2-C-methylerythritol-2,4-cyclo-diphosphate (MEcPP, 1) to HMBPP (2), while the terminal 
enzyme, HMBPP reductase (IspH, LytB, EC1.17.1.2) catalyzes the 2H+/2e- reduction of HMBPP 
to isopentenyl diphosphate (IPP, 3) and dimethylallyl diphosphate (DMAPP, 4), in a ~5:1 ratio. 
The structure of IspG has not yet been reported, but there have been two structures published for 
IspH, one from Aquifex aeolicus,(7) the other from E. coli.(8) Both structures contain Fe3S4 
clusters. However, based on the results of Mössbauer(9),(10) and EPR spectroscopy,(11) and from 
microchemical analyses,9, (11) we and others have concluded that Fe4S4 clusters are responsible 
for catalysis. The Fe4S4 cluster, while catalytically active, is thus relatively labile, as also found 
for example in aconitase and in pyruvate-formate lyase activating enzyme.(12) To date, there has 
been only one report of IspH inhibitors,(13) with IC50 values of ~1-2 mM having been obtained. 
Here, we report progress aimed at obtaining more potent inhibitors.  
    Based on the crystallographic, mutagenesis, catalytic activity and spectroscopic results 
described previously,(7-11) we reasoned that there might be two distinct approaches to 
developing IspH inhibitors.  In the first, it might be possible to develop “conventional” inhibitors 
which bind to amino-acids involved in catalysis. In previous work(7) we proposed that a key 
residue involved in delivering H+ to HMBPP was the totally conserved E126, and the essential 
nature of this residue in catalysis has now been confirmed by site-directed mutagenesis.8 We 
reasoned that basic or cationic inhibitors might interact with this key residue, inhibiting the 
enzyme. The second hypothesis to test is that “unconventional” inhibitors, compounds that bind 
to the Fe/S cluster, might be developed.  If the cluster is Fe3S4, this would be unprecedented and 
would thus, of course, not suggest what inhibitor structures to make.  On the other hand, if the 
active species is Fe4S4 (as deduced from the IspH Mössbauer,(9, 10) EPR(11) and catalytic 
activity(9, 11) results), there is in fact precedent for the formation of organometallic species (i.e. 
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containing Fe-C bonds) between Fe4S4 clusters and alkynes, which would be expected to act as 
IspH inhibitors.  For example, in the early literature, McMillan et al.(14) investigated the 
reduction of acetylene (C2H2) to ethylene (C2H4) by reduced Fe4S4 synthetic clusters, in 
particular [Fe4S4(SPh)4]3-, 5. These workers proposed that an acetato complex reacted initially 
with C2H2 to form an organometallic species, 6: 
[Fe4S4(SPh)4]3- [Fe4S4(SPh)3(OAc)]3-+SPh- [Fe4S4(SPh)3(C2H2)]2- + OAc-
OAc- C2H2
5 6  
most likely containing a side-on (π/σ) acetylene unit, which was then cis-reduced to ethylene. 
Basically the same reduction, of diphenylacetylene (7) to cis-stilbene (8), was reported by 
Itoh.(15) 
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In these systems, the alkyne complex was not observed directly, but under controlled potential 
(electrochemical reduction) conditions, Tanaka et al.(16) found evidence for a π complex of 
acetylene bound to [Fe4S4(SPh)4]3- and [Mo2Fe6S8(SPh)9]3- clusters, as evidenced by quite large 
shifts in the C≡C vibrational Raman spectra. These workers also demonstrated that acetylene 
bound most strongly to reduced ([Fe4S4]+) clusters, and resulted in release of 1 SPh-. These 
results suggested to us that acetylenes might likewise bind to reduced IspH, forming 
organometallic (Fe-C) bonds. Interestingly, with low valent (FeI) complexes, alkynes have also 
been found to bind far more strongly than do alkenes,(17) leading again to the possibility that 
alkynes could bind to Fe and be good IspH inhibitors, displacing the olefinic substrate, HMBPP.     
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     This formation of a π (or π/σ) “metallacycle” complex would be very similar to that 
deduced for the binding of the HMBPP parent molecule, allyl alcohol (which lacks the Me and 
CH2OPP substituents ) to the FeMo cofactor in nitrogenase,(18) illustrated  schematically above 
(9) as the Fe3MoS3X cubane-like fragment. It also seemed possible that aromatic residues might 
interact with the Fe4S4 cluster, just as the cyclopentadienide ion does in model Fe4S4 clusters,(19) 
such as 10 (as an η6 as opposed to an η5 species). Although the structures of complexes such as 6  
have not been confirmed crystallographically, the structure proposed by McMillan et al.(14) (6) 
is likely to involve the same type of bonding as found in many other organometallic 
complexes,(20) being described(18) as a resonance hybrid of  a pure π complex and a σ complex, 
the latter corresponding to a metallacycle. 
 
5.3 Results and Discussion 
In an effort to learn more about just what types of compound might bind to the Fe4S4 cluster in 
IspH, we first screened a series of small molecules, using EPR spectroscopy. The 9 GHz EPR 
spectrum of A. aeolicus IspH in the g ~ 2 region exhibits a broad spectrum (Figure 5.1a), very 
similar to that of the E. coli protein (Figure 5.1b) and is characteristic of an S=1/2 [Fe4S4]+ 
species.(11) The unliganded A. aeolicus IspH also has two small signals at g~5 (Figure 5.2a), 
which likely indicate the presence of higher spin species. For purpose of comparison, the g-
values for the systems studied here are presented in Table 5.1, together with g-values for related 
systems such as aconitase, and IspG (GcpE).  
           We first tested a series of small molecules and ions: CO, N3-, MeCN and CN-, for cluster-
binding in A. aeolicus IspH, but only CN- was found to have any effect on the EPR spectrum, 
Figure 5.1c (Figure 5.2b).The g-values observed were 2.08/2.05 and 1.94, Figure 5.1c, close to 
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those  observed previously with CN- binding to the Pyrococcus furiosus 4Fe ferredoxin (g1 = 
2.09, g2 = 1.95, and g3 = 1.92), another 4Fe-4S cluster with 3 Cys ligands and a unique 4th Fe 
position,(21) due we propose to end-on binding to the 4th Fe in IspH. There was also an increase 
in signal intensity in the g~2 region (from ~20% to ~60% spin/protein), due to conversion of the 
higher spin state species to S=1/2.  
           We then tested a series of other small molecules that might be anticipated to bind in a 
sideways-on mode (as with proposed for acetylene in the model systems): propargyl alcohol, 
propargylamine and propiolic acid. All species resulted in large spectral changes, and by way of 
example the IspH + propiolic acid (HC≡CCO2H) spectrum is shown in Figure 5.1d. These results 
indicated to us that, as with the Fe4S4 containing small molecules, acetylenes bind to IspH, 
forming π or π/σ complexes. With both CN- as well as propiolic acid binding there also appear 
to be two bound ligand conformations or binding modes (e.g. hydrogen bonded or not), as 
evidenced by the splitting of the g1 signals.  
However, propiolic acid had poor activity in IspH inhibition, and we reasoned that 
acetylenic diphosphates (or the isoelectronic, cyano diphosphates) might interact more strongly 
with IspH, since there would be an increase in binding affinity due to their diphosphate moieties 
docking into the (inorganic) PPi site seen crystallographically.(8) We thus synthesized four 
acetylenic diphosphates (11 - 14, Figure 5.3) and two cyanoalkyl diphosphates (15, 16) and 
tested them for their activity in IspH inhibition.  IC50 results are shown in Figure 5.3. The most 
active compound was 12 with an IC50 = 0.45 µM (Ki ~ 60 nM; Figure 5.4a).  As shown in Figure 
5.4b, this compound can bind with its diphosphate group in the inorganic “PPi” site seen 
crystallographically,(8) with the alkyne fragment interacting with the unique 4th Fe (identified 
from  EPR, Mössbauer and catalytic activity results, and added computationally here as 
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described previously(7)), with Fe-C bond lengths of ~2.4 Å, suggesting π-complex formation. 
There was a large change in the EPR spectrum of IspH in the presence of 12 (Figure 5.1e, Figure 
5.2c) indicating a major change in the cluster’s electronic structure, consistent with these 
docking results. Moreover, there was evidence for only a single bound species. The shorter chain 
analog 11 was less active than was 12, as was the longer chain analog 13, and conversion of the 
bridging O to CH2 (17) reduced the activity of 11 even more (Figure 5.3), due presumably to a 
disruption in H-bonding to the SXN motif.  Likewise, the addition of a terminal CH2OH (14) 
reduced activity, consistent with the known stronger binding of terminal versus substituted 
alkynes to low valent Fe complexes.(17) The changes in g-values on addition of the acetylenes 
were generally similar, as expected, and as with CN- there was a ~3x increase in signal intensity 
in the g~2 region (due to a high-to-low spin state conversion).We also tested the effects of the 
isoelectronic analogs (15, 16) of the acetylenes (-C≡C-H → -C≡N), cyanides, on IspH inhibition, 
but both compounds were far less active than their acetylenic counterparts.  
      These results clearly indicate that alkyne diphosphates can be good IspH inhibitors, with 
the most active species being > 1,000 x more potent than previously reported IspH inhibitors.(13) 
Since PPi itself and other diphosphates are only weak (~1 mM) IspH inhibitors,(8) we conclude 
that ligand binding is driven by  π (or π/σ) or η2-alkynyl complex formation with the Fe4S4   
cluster,  the same type of complex formation as suggested by Raman spectroscopy,(16) for 
acetylene binding to an  [Fe4S4(SPh)4]3- cluster. Moreover, the results of density functional 
theory calculations show that there is indeed Fe-C metal ligand bonding present in an 
[Fe4S4(SMe)3(HC≡CCH2OH)]2- model system. We show in Figures 5.4 c,d some typical MO 
results. The αHOMO-1 shows the interaction of an Fe d orbital with the C≡C π orbital, in the 
plane of the Fe…C≡C fragment. The βHOMO-1 illustrates the interaction between an Fe d 
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orbital with another type of C≡C π orbital, this time perpendicular to the plane of Fe…C≡C. If 
IspH, under these reducing conditions, contained an Fe3S4 cluster, there would be no obvious 
way in which acetylenes would bind tightly to the cluster (or the protein), while η2-alkynyl (i.e. π 
or π/σ) complex formation is predicted, based on previous work, and is supported by the DFT 
results. 
We next investigated a series of cationic (or basic) diphosphates and (cationic) 
bisphosphonates, which are isosteres of the diphosphate group. In previous work(22) we found 
that aromatic, cationic bisphosphonates (such as 18) were potent (Ki ~ 20 nM) inhibitors of the 
enzyme farnesyl diphosphate synthase since, as shown below:  
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their charge distribution mimics that expected  for the allylic cation / diphosphate anion ion- 
pair.(23) In the case of IspH, similar allylic cations (shown above) have been proposed(24) to be 
involved in catalysis, so we tested both 18 and 19 for their activities in IspH inhibition. Neither 
had potent activity (18, IC50 = 540 µM; 19, IC50 > 1mM, Figure 5.3). We then tested six 
additional bisphosphonates (20 - 25, Figure 5.3) with 1-H, 1-Me or 1-OH backbone groups and 
pyridine, pyridinium or amino-pyridine side-chains.  The most active compound (IC50 = 67 µM) 
was 21, an amino-pyridine, expected to contain an amidinium-like (protonated) side-chain. 
Overall, however, the activity of these bisphosphonates was only modest, and based on Glide 
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docking results using the “closed” IspH structure (PDB File #3F7T) it appeared that this might 
be due to the “branched” nature of the bisphosphonate backbone. We thus next synthesized a 
series of pyridinium diphosphates, 26 - 29, which based on computational docking results using 
Glide(25) appeared to better fit the IspH active site. The most active compound in the series 
(Figures 5.3, 5a) was 26, a meta pyridinium diphosphate having an IC50 = 38 µM, slightly more 
potent than the best bisphosphonate, 21. When docked into the IspH active site, we find (Figures 
5.5b, c) that when the diphosphate backbone binds to the “PPi” site seen crystallographically, the 
pyridinium HN is only ~1.9 Å from the E126 O (modeled as CO2-), indicating the possibility of 
an H-bond or electrostatic interaction with this active site residue. The para-pyridinium analog 
(27) was less active (IC50 = 149 µM), and the ortho-pyridinium analog (28) was far less active 
(IC50 = 1.2 mM), correlating with the increased NH-O (CO2-) distances of 3.47 Å and 4.28 Å, 
Figure 5.5c. Interestingly, all three aromatic rings also locate close to the 4th Fe, but the major 
decrease in activity seen as the ring nitrogens move away from the E126 carboxyl indicates the 
dominance of a Coulombic interaction, consistent with the lack of activity of the chloropyridine 
analog, 29, which is expected to be far less basic than is 26. These activity and docking results 
are consistent, then, with the pyridinium diphosphates binding to IspH with their PPi groups 
binding to the inorganic PPi site, while their aromatic rings interact with E126, as illustrated in 
Figures 5.4b, c. There was no major change in the EPR spectrum of 26 bound to the protein, 
Figure 5.2d, consistent with the lack of any π-complex interaction. We then sought to improve 
activity by varying the length of the CH2 spacer in the side-chain: addition of 1 CH2 group (30) 
resulted in an IC50 = 9.1 µM (Ki ~ 1.2 µM), but addition of 2 CH2 groups reduced activity  (31, 
IC50 = 463 µM; Figure 5.3), with the pyridinium nitrogen in 30 again docking close to E126, 
while 31 did not. Taken together, these results argue against formation of a carbocation 
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mechanism since for this, we would anticipate good activity for 28 (with maximum charge 
density separated by two carbons from the PPi backbone), while experimentally, maximum 
activity is found with 30 (with its NH+ located four carbons from the PPi backbone). That is, 
none of the cationic (18, 19) or pyridine/pyridinium analogs of the putative carbocation transition 
states (or reactive intermediates) act as inhibitors, while the longer chain species that can bind to 
both the PPi site as well as E126, are the most potent inhibitors among the whole series of 
compounds (18-31)  investigated. Notably, with both the alkyne as well as the cationic inhibitors, 
the side-chains are located (Figure 5.5d) close to the Fe4S4 cluster blocking, we propose, HMBPP 
access. 
These results lead to the proposals for IspH inhibition shown in Figure 5.6. We propose 
that both alkyne as well as alkene diphosphates (i.e. HMBPP) bind to the Fe4S4 cluster at the 
unique 4th Fe, forming π (or π/σ) “metallacycles”, as shown in Figures 5.6a, b, the same type of 
binding reported previously for the HMBPP parent molecule (allyl alcohol) bound to the FeMo 
cofactor in nitrogenase.(18) As shown in Figure 5.6b, the presence of such a metallacycle also 
immediately leads to a proposal for the IspH catalytic mechanism in which in a first H+/e- step, 
the HMBPP 4-OH is protonated and an η1-allyl intermediate and water form. This intermediate is 
then cleaved in a second H+/e- step, forming the DMAPP product, Figure 5.6b. IPP forms in the 
same way, after an η1-allyl (or η3-allyl) isomerization. This model is described in more detail 
elsewhere(26) and is supported by electron nuclear double resonance spectroscopy using [u-13C] 
and [2H]-labeled HMBPP, which strongly suggest metal-ligand interaction. We thus propose that 
the alkyne as well as the cationic inhibitors block or displace HMBPP from binding to the Fe4S4 
cluster: the alkynes form π (or π/σ) “η2-alkynyl” metallacycles, while the cationic inhibitors 
interact with the active site E126 carboxylate, again effectively blocking HMBPP binding.   
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Validation of the Mechanism of IspH Inhibition, and Catalysis.  
Finally, after review of this article, Grawert et al.(27) reported the results of new crystallographic 
structures of HMBPP, PPi, IPP and DMAPP bound to IspH(27) which help us validate the 
inhibition models proposed here. These workers now report that HMBPP binds as an alkoxide to 
the unique 4th iron (to the oxidized [Fe4S4]2+ cluster), the same binding mechanism we proposed 
earlier.(7) On irradiation in the x-ray beam, HMBPP is reduced, forming a deoxy species (bound 
to the Fe4S4 cluster), basically as we proposed based on EPR/ENDOR and docking results.(26) 
These x-ray results are of interest since they enable us to make a direct comparison between the 
x-ray and EPR/ENDOR/docking based methods,(26, 27) helping us validate the use of inhibitor 
docking. We show in Figure 5.7a an alignment of the x-ray structure of HMBPP bound to IspH 
with that we proposed (Figure 5.1G in ref (26)) for the initial HMBPP binding pose in which the 
O-4 can interact with the unique 4th Fe. There is a 0.32 Å rmsd between the heavy atoms (C, O, P) 
in the HMBPP ligand between the x-ray and our docking/EPR based structures, ~ 0.43 Å if we 
include the Fe, S atoms in the cluster, Figure 5.7a. On reduction, we proposed(26) that the 4-OH 
is removed from the ligand and the σ/π metallacycle is reduced, resulting in loss of water and 
formation of a η1/η3-allyl complexes and thence, IPP and DMAPP. 
 The new crystallographic results are thus in good accord with those we proposed from 
our EPR, ENDOR and computational work, which gives confidence in the proposed ligand 
geometries we describe here for the bound inhibitors. As can be seen in Figure 5.7b, the alkyne 
group in propargyl diphosphate (11) bound to IspH(26) is located in  essentially the same 
position as the deoxy product species seen crystallographocally, where it can interact with the 
unique, 4th iron, forming a π or π/σ complex. The alkynes are much stronger inhibitors of IspH 
than are the alkenes (IPP, DMAPP),(8) and indeed the ENDOR spectrum of 11 bound to IspH 
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exhibits an ~6 MHz 13C hyperfine interaction,(26) 2-3 times larger than the 13C hyperfine 
interactions found for either allyl alcohol bound to nitrogenase,(28) or HMBPP bound to 
IspH.(26)  
 
5.4 Conclusions 
Taken together, these results are of interest for several reasons. First, we find that cationic 
diphosphates are IspH inhibitors. However, rather than mimicking transition states /reactive 
intermediates, we propose that they interact with the active site E126, preventing HMBPP 
binding to the Fe4S4 cluster. Second, we find that alkyne diphosphates are quite potent (IC50 ~ 
0.45 µM; Ki ~ 60 nM) IspH inhibitors. This activity was predicted based on previous Raman and 
catalytic activity results with model systems, which have been interpreted as indicating π (or 
π/σ) “metallacycle” formation between Fe4S4 clusters and acetylene. That alkynes are, in fact, 
IspH inhibitors, also supports the idea that catalytically active IspH contains active-site Fe4S4 and 
not Fe3S4 clusters, since there is no obvious way in which an alkyne group would bind to the 
three exposed S2- in such clusters.  On the other hand, there is good literature precedent for 
alkynes binding to Fe4S4 clusters, supporting formation in IspH of π (or π/σ) complex formation. 
Third, the results of quantum chemical calculations indicate Fe-C metal ligand bonding with the 
acetylene group (in a [Fe4S4(SMe)3(HC!CCH2OH)]2- model. Fourth, the formation of acetylene 
metallacycles is consistent with the observation that the HMBPP parent molecule, allyl alcohol, 
forms a metallacycle with the nitrogenase FeMo cofactor, which contains a related Fe/S (Mo, 
“X”) cluster and where the ligand forms Fe – C bonds with a single Fe.  The observation that the 
IC50 for the most potent IspH alkyne inhibitor (IC50 = 0.45 µM; Ki ~ 60 nM) is much smaller than 
the KM for HMBPP binding (KM = 5 µM) is also expected based on organometallic precedent in 
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which alkynes bind much more strongly (to low valent Fe complexes) than do alkenes.(17) Fifth, 
we find that CN- binds to IspH with the resulting spectrum quite strongly resembling that found 
with P. furiosus Fd, another protein with an unique 4th Fe. And finally, the recent revision of the 
earlier 3 Fe IspH structural/mechanistic models is in accord with our earlier mechanistic proposal 
of initial binding of the HMBPP 4-OH (as an alkoxide) to an [Fe4S4]2+ cluster which, on 
reduction, forms an allyl complex which is then cleaved to form the IPP and DMAPP 
products.(26) This gives confidence in the models we propose here for alkyne inhibition. These 
results also open up the intriguing possibility that metallacycle complexes may act as reactive 
intermediates (or transition states) in both IspG as well as IspH catalysis, and that alkynes can be 
expected to be good inhibitors of other Fe4S4 cluster-containing enzymes which contains 
“unique” 4th Fe atoms. 
 
5.5 Materials and Methods 
A. aeolicus IspH protein purification.  
BL-21(DE3) cells expressing IspH from A. aeolicus were grown in LB media supplemented with 
150 mg/mL ampicillin at 37 °C until the OD600 reached 0.6. Cells were then induced with 200 µg 
/ L anhydrotetracycline, then grown at 20 °C for 15 hours. Cells were harvested by centrifugation 
(9000 rpm, 8 min, 4 °C) and were kept at -80 °C until use. Cell pellets were resuspended and 
lysed in B-PER (Thermo Scientific, Rockford, IL) protein extraction reagent for one hour at 4°C, 
then centrifuged at 200,000 rpm at 4 °C for 15 min. The supernatant was applied to a Ni-NTA 
column equilibrated with 5 mM imidazole in pH 8.0 buffer containing 50 mM  Tris·HCl and 150 
mM NaCl. After washing with 20 mM imidazole, protein was eluted with 100 mM imidazole. 
Fractions were collected and dialyzed in pH 8.0 buffer containing 50 mM Tris·HCl, 150 mM 
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NaCl, 5% glycerol, and 1 mM DTT, 4 times. The purified protein was flash-frozen in liquid 
nitrogen and stored at -80 °C until use.  
E. coli IspH Protein Purification.  
BL21 DE3 (Invitrogen) cells harboring an E. coli IspH construct were grown in LB media at 
37°C until the OD600 reached 0.6.  Induction was performed with 200 ng/ml anhydrotetracycline 
at 20°C for 15 hours. Cells were harvested by centrifugation at 9000 rpm for 8 mins and stored at 
-80 °C. Cell pellets were resuspended and lysed in B-PER (Thermo Scientific, Rockford, IL) 
protein extraction reagent for about one hour at 4°C, then the lysate was centrifuged at 250,000 
rpm for 30 mins. The supernatant was collected and loaded onto an IBA Strep-tag column 
equilibrated with buffer W (100 mM Tris·HCl, 150 mM NaCl, pH 8.0). After washing with 
buffer W, protein was eluted using buffer E (buffer W containing 2.5 mM desthiobiotin). 
Fractions were collected and dialyzed in pH 8.0 buffer containing 50 mM Tris·HCl, 150 mM 
NaCl, 5% glycerol, and 1mM DTT, twice. The purified protein was flash-frozen in liquid 
nitrogen and stored at -80 °C until use. 
Protein reconstitution.  
Both A. aeolicus and E. coli IspH proteins as isolated had a very small peak at 410 nm (A280/A410 
< 0.02), so were reconstituted for further studies. Before reconstitution, protein was transferred 
into a Coy Vinyl Anaerobic Chamber after being degassed on a Schlenk line.  The following 
steps were performed inside the anaerobic chamber with an oxygen level < 2 ppm. In a typical 
reconstitution experiment, 10 mM DTT and ~ 0.5 mg of elemental sulfur were added to 3 mL 0.6 
mM protein solution in a pH 8.0 buffer containing 50 mM Tris·HCl, 150 mM NaCl and 5% 
glycerol. After stirring for 1.5 hours, FeCl3 was slowly added from a 30 mM stock solution to 6 
equivalents. After 3 hours, an aliquot of the solution was centrifuged and a UV-VIS spectrum 
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recorded. If the A410nm / A280nm ratio was ≥ 0.38, the protein was then desalted by passing through 
a PD10 column. If the ratio was < 0.38, more DTT, elemental sulfur and FeCl3 were added and 
the sample incubated with stirring (for typically ~ 2 hours) until the 410 nm / 280 nm absorption 
ratio was ~ 0.38. The reconstituted protein was then concentrated by ultrafiltration, and the 
protein concentration determined by using a Bio-Rad (Hercules, CA) Protein Assay kit.  
Enzyme inhibition assays.  
All assays were performed anaerobically at room temperature according to Altincicek et. al.(24) 
with minor modification. To a pH 8.0 buffer solution containing 50 mM Tris·HCl, 150 mM 
NaCl, and 5% glycerol, sodium dithionite was added to 0.4 mM, methyl viologen was added to 2 
mM, and IspH was added to 72 nM. For enzyme assays, various amounts HMBPP were added 
and the reactions were monitored at 732 nm. The initial velocities were fitted by using the 
Michaelis-Menten equation with OriginPro 8 (OriginLab Corporation, Northampton, MA) 
software. The activity of reconstituted A. aeolicus IspH tested under the conditions described 
above was 1.2 µmol min-1 mg−1 with a KM=7 µM. For inhibition assays, various concentrations 
of inhibitor were added and incubated for 10 min, prior to addition of 34 µM HMBPP. Initial 
velocities at different inhibitor concentrations were then plotted as dose-response curves, and 
were fitted to the following equation, from which IC50 values were determined:  
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where x is the inhibitor concentration and y is the fraction inhibition. Ki values were then 
deduced from the IC50 value by using the Cheng-Prusoff equation:(29)  
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where [S] is the HMBPP concentration, and KM is the Michaelis constant. 
EPR spectroscopy.  
Samples for EPR spectroscopy were typically 0.3 mM in IspH, and were reduced by adding 20 
equivalents of sodium dithionite followed by incubating for 5 min. Glycerol was added to 42.5 % 
(v/v). EPR samples were frozen in liquid nitrogen after reduction. EPR spectra were collected at 
X-band using a Varian E-122 spectrometer together with an Air Products (Allentown, PA) 
helium cryostat. Data acquisition parameters were typically: field center = 3250 G; field sweep = 
800 G; modulation = 100 kHz; modulation amplitude = 5 G; time constant = 32 ms; 60 sec per 
scan; 8 sec between each scan; and temperature = 15K. EPR spectral simulations were carried 
out by using the EasySpin program.(30) 
Docking calculations.  
For docking calculations, the IspH target protein (PDB: 3F7T) was prepared using the protein 
preparation wizard in Maestro 8.0.(31) Water from the active site region was removed, as was 
the diphosphate ligand. The Fe3S4 cluster was reconstituted computationally to form the Fe4S4 
species as described previously(7) and hydrogen atoms were added to the protein. Hydrogen 
bonds were optimized to default values and an energy minimization in Macro-Model 9.5(32) 
performed only on the protein hydrogens, using default parameters. A receptor grid large enough 
to encompass all crystallographically-observed binding sites was then generated from the 
prepared target protein. Geometry optimized ligands were docked using Glide(25) extra-
precision (XP) mode, and no other constraints were applied. In some instances, we also used the 
MMFF94 force-field(33) to effect further geometry optimization. 
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Density functional theory calculations.  
In order to gain a better understanding of the interaction between the propargyl diphosphate 
inhibitors and the Fe-S cluster, we used the published structure of the lowest energy form of allyl 
alcohol bound to the nitrogenase FeMo cofactor (structure 3 in ref.18), converting Mo → Fe, X 
→ S and allyl → alkynyl as the initial structure. Geometry optimization was performed by using 
the pure density functional theory (DFT) method with a BPW91 functional,(34, 35) a Wachter’s 
basis (62111111/3311111/3111) for Fe,(36) 6-311G* for all the other heavy atoms, and 6-31G* 
for the hydrogens, using the Gaussian 09 program.(37) This method is similar to that used in the 
calculations of the ligand-bound nitrogenase structures(18) and is the same as that we used 
previously to make accurate predictions of NMR hyperfine shifts, ESR hyperfine couplings, as 
well as Mössbauer quadrupole splittings and isomer shifts, in various iron-containing proteins 
and model systems.(38-43) 
Synthetic aspects.  
General methods All reagents used were purchased from Aldrich (Milwaukee, WI). The purities 
of all compounds investigated were confirmed either via combustion analysis (for solid samples) 
or by using 1H and 31P NMR spectroscopy at 400 or 500 MHz on Varian (Palo Alto, CA) Unity 
spectrometers. Cellulose TLC plates were visualized by using iodine or a sulfosalicylic acid-
ferric chloride stain.(44) Propargyl methanesulfonate and but-3-ynyl methanesulfonate were 
synthesized according to a literature method.(45, 46) The syntheses and characterization of 
compounds 18 - 25 have been described previously.(22, 47-51) and the samples used here were 
from the same batches as described.  
General procedure for preparation of diphosphates Diphosphates were prepared using 
modified literature procedures.(52) Typically,  0.5-1 mmol of halide or mesylate in a minimum 
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amount of CH3CN (0.4-0.6 mL) was added dropwise to a stirred solution of 2-3 equiv of 
tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (3-6 mL) at 0°C,  then the 
reaction mixture was allowed to stir for 2-24 h at room temperature and solvent removed under 
reduced pressure. The residue was dissolved in cation-exchange buffer (49:1 (v/v) 25mM 
NH4HCO3/2-propanol) and slowly passed over 60-100 mequiv  Dowex AG50W-X8 (100-200 
mesh, ammonium form) cation-exchange resin, pre-equilibrated with two column volumes of the 
same buffer. The product was eluted with two column volumes of the same buffer, flash frozen, 
then lyophilized. The resulting powder was dissolved in 50 mM NH4HCO3. 2-Propanol/CH3CN 
(1: l (v/v)) was added, and the mixture vortexed, then centrifuged for 5 min at 2000 rpm. The 
supernatant was decanted. This procedure was repeated three times, and the supernatants were 
combined. After removal of the solvent, lyophilization, then flash chromatography on a cellulose 
column, a white solid was obtained. 
Synthesis of individual compounds 
Prop-2-ynyl diphosphate (11).  Propargyl methanesulfonate (134 mg, 1 mmol) in CH3CN (0.5 
mL) was added dropwise to a stirred solution of  2.70 g (3.0 mmol) tris(tetra-n-butylammonium) 
hydrogen diphosphate in CH3CN (4 mL) at -20°C.  The reaction mixture was then slowly 
warmed to room temperature over 2 h and solvent removed under reduced pressure. Flash 
chromatography on a cellulose column (4:1:2.4 (v/v/v) 2-propanol/CH3CN/50 mM NH4HCO3) 
yielded 47 mg (18 %) of a white solid. 1H NMR (400 MHz, D2O) δ 2.68 (s, 1H), 4.38 (d, J H,P = 
9.2 Hz, 2H); 31P NMR (162 MHz, D2O) δ -10.10 (d, J = 20.7 Hz), -7.67 (d, J = 20.7 Hz). 
But-3-ynyl diphosphate (12).  But-3-ynyl methanesulfonate (148 mg, 1 mmol) in CH3CN (0.5 
mL) was added dropwise to a stirred solution of 2.70 g (3.0 mmol) tris(tetra-n-butylammonium) 
hydrogen diphosphate in CH3CN (4 mL) at 0°C.  The reaction mixture was allowed to warm to 
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room temperature over 24 h and solvent removed under reduced pressure. Flash chromatography 
on a cellulose column (2:1:1 (v/v/v) 2-propanol/CH3CN/50 mM NH4HCO3) yielded 28 mg 
(10%) of a white solid. 1H NMR (400 MHz, D2O): δ 2.16-2.17 (m, 1H), 2.35-2.40 (m, 2H), 3.81-
3.84 (m, 2H); 31P NMR (162 MHz, D2O): δ -9.83 (d, J = 17.0 Hz), -7.82 (d, J = 15.9 Hz).  
Pent-4-ynyl diphosphate (13).  Pent-4-ynyl methanesulfonate (162 mg, 1 mmol) was treated 
with 2.70 g (3 mmol) tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (4 mL). 
Flash chromatography on a cellulose column (2:1:1 (v/v/v) 2-propanol/CH3CN/50 mM 
NH4HCO3) yielded 103 mg (35%) of a white solid. 1H NMR (400 MHz, D2O): δ 1.65-1.70 (m, 
2H), 2.13-2.17 (m, 3H), 3.83 (q, J = 6.8Hz, 2H). 31P NMR (162 MHz, D2O): δ -9.64 (d, J = 20.9 
Hz), -7.76 (d, J = 20.7 Hz). 
4-Hydroxybut-2-ynyl diphosphate (14).  4-Chlorobut-2-yn-1-ol (104 mg, 1 mmol) was treated 
with 2.70g (3 mmol) tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (4 mL). 
Flash chromatography on a cellulose column (2:1:1 (v/v/v) 2-propanol/CH3CN/50 mM 
NH4HCO3) yielded a white solid. 1H NMR (400 MHz, D2O): δ 4.07(s, 2H), 4.31(d, J H, P = 6.8Hz, 
2H); 31P NMR (162 MHz, D2O): δ -10.11(d, J = 20.8 Hz), -8.85 (d, J = 20.7 Hz). 
Cyanomethyl diphosphate (15).  2-Chloroacetonitrile (76 mg, 1 mmol) was treated with 2.70 g 
(3 mmol) tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (4 mL). Flash 
chromatography on a cellulose column (2:1:1 (v/v/v) 2-propanol/CH3CN/50 mM NH4HCO3) 
yielded  45 mg (17%) of a white solid. 1H NMR (400 MHz, D2O): δ 4.56 (d, J = 10.4 Hz, 2H); 
31P NMR (162 MHz, D2O): δ -10.25 (d, J = 22.0 Hz), -7.37 (d, J = 20.7 Hz). 
2-Cyanoethyl diphosphate (16).  3-Bromopropanenitrile (134 mg, 1 mmol) was treated with 
1.80 g (2 mmol) tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (4 mL). Flash 
chromatography on a cellulose column (2:1:1 (v/v/v) 2-propanol/CH3CN/50 mM NH4HCO3) 
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yielded 31 mg ( 11 %) of a white solid. 1H NMR (400 MHz, D2O): δ 2.68 (t, J = 6.4 Hz, 2H), 
3.96 (q, J = 6.4 Hz, 2H). 31P NMR(162 MHz, D2O): δ -10.24 (d, J = 20.7 Hz), -6.21 (d, J = 20.7 
Hz). 
[[(Prop-2-ynyl) phosphinyl] methyl] phosphonic acid (17). Propargyl methanesulfonate (134 
mg, 1 mmol)  was treated with 2.70 g (3 mmol) tris(tetra-n-butylammonium) hydrogen 
methanediphosphonate in CH3CN (4 mL).  Flash chromatography on a cellulose column (2:1:1 
(v/v/v) 2-propanol/CH3CN/50 mM NH4HCO3) yielded 93 mg (35 %) of a white solid. 1H NMR 
(500 MHz, D2O): δ 2.00 (t, JH,P = 12.0 Hz, 2H), 2.70 (t, J = 2.0 Hz, 1H), 4.37 (dd,   JH,P = 9.2 Hz, 
J = 2.0 Hz, 2H); 31P NMR (202 MHz, D2O): δ 15.59 (d, J = 9.3 Hz), 20.06 (d, J = 10.7 Hz). 
(Pyridin-3-yl)-methyl-diphosphate (26).  3-(Bromomethyl)pyridine (86 mg, 0.5 mmol) was 
treated with 1.35 g (1.5 mmol) tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (3 
mL). Flash chromatography on a cellulose column (3:2 (v/v) 2-propanol/50mM NH4HCO3) 
yielded 73 mg (45 %) of a white solid. 1H NMR (400 MHz, D2O): δ 4.80 (d, JH,P = 7.2 Hz, 2H), 
7.31(dd, J = 7.6 Hz, J = 4.8 Hz, 1H), 7.81 (d, J = 7.6 Hz, 1H), 8.30 (d, J = 4.8 Hz, 1H), 8.42 (s, 
1H); 31P NMR (162 MHz, D2O): δ -9.74 (d, J = 22.0 Hz), -5.95 (d, J = 22.0 Hz). 
(Pyridin-4-yl)-methyl-diphosphate (27).  4-(Bromomethyl)pyridine (86 mg, 0.5 mmol) was 
treated with 1.35 g (1.5 mmol) tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (3 
mL). Flash chromatography on a cellulose column (3:2 (v/v) 2-propanol/50mM NH4HCO3) 
yielded 65 mg (40 %) of a white solid. 1H NMR (400 MHz, D2O): δ 4.92 (d, JH,P = 8.0 Hz, 2H), 
7.41 (d, J = 6.0 Hz, 2H), 8.34 (d, J = 5.6 Hz, 2H); 31P NMR (162 MHz, D2O): δ -9.66 (d, J = 20.7 
Hz), -6.49 (d, J = 20.7 Hz). 
(Pyridin-2-yl)-methyl-diphosphate (28).  2-(Bromomethyl)pyridine (86 mg, 0.5 mmol) was 
treated with 1.35 g (1.5 mmol) tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (3 
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mL). Flash chromatography on a cellulose column (3:2 (v/v) 2-propanol/50 mM NH4HCO3) 
yielded 56 mg (35%) of a white solid. 1H NMR(400 MHz, D2O): δ 4.91 (d, JH,P = 7.2 Hz, 2H), 
7.28 (t, J = 4.8 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.80 (t, J = 8.0 Hz, 1H), 8.28 (d, J = 4 Hz, 1H); 
31P NMR (162 MHz, D2O): δ -9.55 ( d, J = 22.0 Hz), -6.02 ( d, J = 19.4 Hz).  
(6-Chloropyridin-3-yl)-methyl-diphosphate (29). 5-(Bromomethyl)-2-chloropyridine (103 mg, 
0.5 mmol) was treated with 1.35 g (1.5 mmol) tris(tetra-n-butylammonium) hydrogen 
diphosphate in CH3CN (3 mL). Flash chromatography on a cellulose column (3:2 (v/v) 2-
propanol/50 mM NH4HCO3) yielded  70 mg (40 %) of a white solid. 1H NMR (400 MHz, D2O): 
δ 4.82 (d, JH,P = 7.6 Hz, 2H), 7.29 (d, J = 8.4 Hz, 1H), 7.74 (dd, J = 8.4 Hz, J = 2.4 Hz, 1H), 8.20 
(d, J = 2.4 Hz, 1H). 31P NMR (162 MHz, D2O) : δ -9.73 (d, J = 22.0 Hz),  -5.81 (d, J = 22.0 Hz). 
Pyridin-3-yl-ethyl-diphosphate (30). 3-(2-Bromoethyl) pyridine (93 mg, 0.5 mmol) was treated 
with 1.35 g (1.5 mmol) tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (3 mL). 
Flash chromatography on a cellulose column (2:1:1 (v/v/v) 2-propanol/CH3CN/50 mM 
NH4HCO3) yielded  42 mg (25 %) of a white solid. 1H NMR (400 MHz, D2O): δ 2.87 (t, J = 6.4 
Hz, 2H), 4.00 (q, J = 6.4 Hz, 2H), 7.33 (t, J = 6.4 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 8.24 (s, 1H), 
8.36 (s, 1H); 31P NMR (162 MHz, D2O): δ -9.78 (1 d, J = 20.6 Hz), -7.07 (d, J = 20.6 Hz). 
Pyridin-3-yl-propyl-diphosphate (31).  3-(3-Bromopropyl) pyridine ( 100 mg, 0.5 mmol) was 
treated with 1.35 g (1.5 mmol) tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (3 
mL).  Flash chromatography on a cellulose column (4.5:2.5:3.0 (v/v/v) 2-propanol/CH3CN/50 
mM NH4HCO3) yielded 57 mg (33 %) of a white solid. 1H NMR (400 MHz, D2O): δ 1.75-1.89 
(m, 2H), 2.65-2.73 (m, 2H), 3.84 (t, J = 6.0 Hz, 2H), 7.34-7.36 (m, 1H), 7.74 (d, J = 8.0 Hz, 1H), 
8.26 (s, 1H), 8.35 (s, 1H). 31P NMR (162 MHz, D2O): δ -9.49 (d, J = 20.7 Hz),  -6.87 (d, J = 21.9 
Hz). 
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5.6 Tables and Figures 
Table 5.1. g-values reported for Fe4S4 proteins and those observed in this study.  
 
 
 g1 g2 g3 
E. coli LytB Fe4S4(11)  2.038 1.927 1.889 
E. coli GcpE Fe4S4(53) 2.04 1.90 - 
Bovine heart aconitase (active 
form, Fe4S4)( 54) 
2.06 1.93 1.86 
Bovine heart aconitase (inactive 
form, Fe3S4)( 54) 
- 2.016 - 
E. coli GcpE Fe3S4(55) 2.032 2.003 - 
Unliganded A. aeolicus LytB (Fig. 
1a; only g values in the g=2 
region are listed) 
2.04 1.94; 1.92 1.87 
Unliganded E. coli LytB  
(Fig. 1b). 
g value obtained by simulation. 
2.043 1.915 1.901 
A. aeolicus LytB with KCN (Fig. 
1a) 
2.08; 2.05 1.94; 1.93 - 
A. aeolicus LytB with 12 (Fig. 1a). 
g value obtained by simulation. 
2.087 2.012 1.992 
P. furiosus ferredoxin (21) 2.12 1.86 1.79 
P. furiosus ferredoxin with KCN 
(21) 
2.09 1.95 1.92 
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Figure 5.1. 9 GHz EPR spectra of IspH at 15K reduced with Na2S2O4. a) A. aeolicus IspH, no 
added ligands, microwave power = 1 mW. b) E. coli IspH, no added ligands, microwave power = 
1 mW; c) A. aeolicus IspH + KCN, 10 equivalents, microwave power = 1 mW; d) A. aeolicus 
IspH + propiolic acid, 10 equivalents, microwave power = 0.2 mW; e) A. aeolicus IspH + but-3-
ynyl diphosphate (12), 20 equivalents, microwave power = 0.05 mW. Spectral simulations are 
shown by the dashed lines (g-values are compiled in Table 5.1, together with g-values for Fe3S4 
proteins). 
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Figure 5.2. Wide scan X-band GHz EPR spectra of IspH at 15K, reduced with Na2S2O4. a) 
A. aeolicus IspH, no added ligands, microwave power = 1 mW. b) A. aeolicus IspH + KCN, 10 
equivalents, microwave power = 1 mW; c) A. aeolicus IspH + 12, 20 equivalents, microwave 
power = 0.05 mW; d) A. aeolicus IspH + 26, 20 equivalents, microwave power = 1 mW. 
 
 
 
 
157 
Figure 5.3. Structures of the 21 compounds investigated as A. aeolicus IspH inhibitors together 
with (below the structures) their IC50 values.      
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Figure 5.4. IspH inhibition by alkyne diphosphates. a) Dose-response curves for IspH inhibition 
by 12 (IC50 = 450 nM) and 13 (IC50 = 6.5 µM). b) Proposed docking model for 12 bound to the 
IspH active site: the diphosphate binds to the PPi site while the alkyne group forms a π (or π/σ) 
“metallacycle” complex with the unique 4th Fe in the Fe4S4 cluster, similar to that proposed for 
acetylene binding to model Fe4S4 clusters and allyl alcohol binding to a nitrogenase FeMo 
cofactor.  c) αHOMO-1 for propargyl alcohol bound to a model Fe4S4 cluster, illustrating metal 
ligand interaction. d) as c) but βHOMO-1. The contour values are ± 0.02 au. 
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Figure 5.5. IspH inhibition by pyridinium diphosphates. a) Dose-response curves for IspH 
inhibition by 26, 27, 28 and 30. The IC50 for the most potent inhibitor (30) is IC50 = 9.1 µM; Ki ~ 
1.2 µM.  b) Glide docking pose for 26 bound to the IspH active site: the diphosphate binds to the 
PPi site while the pyridinium sidechain interacts with E126. c) View of the ortho, meta and para-
pyridinium diphosphates (26-28) docked to IspH: the most potent inhibitor has the shortest 
HN…E126 CO2- distance; the worst inhibitor has the longest distance. d) Superimposed docking 
poses for 12 and 26 showing that they both bind in the same region (preventing HMBPP 
binding). 
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Figure 5.6. Mechanistic proposals for IspH catalysis and inhibition. a) π (or π/σ) metallacycle 
complex formation by alkyne inhibitors. b) IspH catalysis is which an η2-alkenyl metallacycle is 
reduced and protonated then dehydrates to form an allyl complex, which is then cleaved to form 
the DMAPP and IPP products. c) IspH inhibition by pyridinium diphosphates which block 
HMBPP binding to the 4th Fe. 
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Figure 5.7. Comparisons between x-ray structures and docking /EPR/ENDOR deduced 
structures for a), HMBPP initial docking (PDB code 3KE8 and Ref. 25, Fig 1G). b) propargyl 
diphosphate (docking) superimposed on deoxy complex (PDB ID code 3KE9 and Ref. 25, Fig.  
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